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ABSTRACT 
Poly(lactide-co-glycolide) (PLG) biodegradable microparticles were evaluated as an oral 
delivery system for immunisation against equine influenza virus. Model particulates 
(fluorescent polystyrene and gold labelled polystyrene) were used to characterise the route and 
mechanism of intestinal uptake. Peyer's patches were found to be the site of particulate 
intestinal absorption characterised by phagocytosis at the M cell surface. Microparticles were 
found within intercellular compartments indicating a paracellular route for the transit of 
microparticles from lumen to lymph. A quantitative method of counting the number of 
microparticles passing into the lymph in both the superior mesenteric and thoracic lymph 
ducts indicated levels of intestinal uptake high enough to deliver vaccines via this route. 
PLG microparticles encapsulating equine influenza virus were prepared by the process of 
solvent evaporation. The immune responses were evaluated in mice after either systemic or 
oral immunisation of Balb\c mice using formalin treated equine influenza (Prague 56 H7N7) 
either encapsulated in PLG biodegradable microparticles or free in solution. Using the single- 
radial-immunodiffusion test, the haemagglutinin integrity of the microencapsulated influenza 
was found to be preserved during the microencapsulation process. When administered 
systemically the microencapsulated virus induced raised levels of anti-influenza IgG antibody 
in serum that were comparable with those obtained with the virus in solution. Oral 
administration of the microencapsulated virus induced raised levels of anti-influenza IgA 
antibody in saliva as well as levels of anti-influenza IgG comparable to those obtained after 
parenteral injection. Raised levels (compared to preimmune levels) of anti-influenza antibodies 
in both the systemic circulation and mucosal secretions indicates that orally administered 
microencapsulalated equine influenza virus represents a practical method of immunisation 
against influenza. 
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CHAPTER 1 
Introduction 
Since the development of the first vaccine against smallpox in the 18' century 
(Jenner, 1796) the impact of vaccination on world health has been enormous. 
Smallpox is now a disease of historical interest only, following the declaration by the 
World Health Assembly on May 8' 1980 of its eradication (World Health 1980, 
Figure 1). In developed countries in particular, the widespread use of vaccines has 
led to a dramatic decrease in the incidence of such diseases as diphtheria, pertussis, 
tetanus (DPT), poliomyelitis, measles and tuberculosis (Hinman and Orenstein, 1990). 
In the third world over 60 million children are immunised each year against the 
common childhood diseases, preventing over 2.2 million infant deaths annually 
(Bloom, 1989). Despite this success, the majority of human diseases still requires a 
vaccine (Woodrow, 1990) and many of the presently available vaccines give 
inadequate protection. One of the reasons for this is that the traditional approach to 
vaccine development fail to address the initial invasive sites of the pathogen into the 
host. Most pathogens enter the host at the mucosal surfaces which are protected by 
a separate immune system termed the mucosal or local immune system. The 
traditional vaccines are ineffective at inducing local immunity and give little 
protection against pathogens whose initial portal of entry is the mucosa, for example 
the enteric pathogens that cause diarrhoea! diseases. Diarrhoeal diseases are thought 
to result in up to 15 million deaths each year (Woodrow, 1990). As a consequence 
there is a great need for new or improved vaccines that induce local immunity at 
mucosal surfaces. 
1 
Figure 1 
WHO poster proclaiming the eradication of smallpox 
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1.1 IMMUNOLOGICAL BASIS FOR VACCINES 
It is the responsibility of the body's immune system to provide a defence against 
pathogenic microorganisms or substances. Exploitation of the natural protection 
provided by the cells and humoral factors of the immune system provides the 
immunological basis for vaccines. A vaccine can be defined as an artificial stimulus 
used to activate these defence mechanisms in providing protection (or immunity) 
against a invasive natural form of that stimulus. The immune system is divided into 
two categories the specific and non-specific; it is the specific which provides the 
memory and specificity required for vaccines (For a general text on the immune 
system refer to Riott, 1991). 
Specific immunity is developed in response to previously encountered antigen and is 
specific to that antigen. The specific response can either provide humoral or cell 
mediated immunity. Humoral immunity is provided by antibodies originating from the 
antigenic stimulation of B-lymphocytes. On the surface of the B-lymphocyte are 
immunoglobulin (antibody) receptors. The receptor only recognise a specific sequence 
(epitope) on the surface of the antigen, therefore, each lymphocyte is specific to only 
one antigen. The B-lymphocyte clonally proliferates (under the control of helper T- 
lymphocytes) to form mature plasma cells which secrete antibody (primary response), 
whilst a proportion of the B-lymphocytes mature into memory cells. The antibody will 
only recognise the specific antigen which caused stimulation. Memory cells remain 
dormant in the body until that specific antigen is encountered again, at which time, 
they are activated to form antibody producing plasma cells. The secondary response 
is far greater and more rapid because the cells are already primed. Vaccines provide 
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a non-virulent form of the antigen to achieve the same responses. The boosters in an 
immunisation schedule provide the secondary stimulus for an enhanced response. 
Circulating antibodies provide protection such as neutralisation of the invasive 
pathogen by binding to epitopes important for pathogenesis, thus, preventing the onset 
of disease (Ada, 1990 and 1991). Depending on the pathogen, antibodies may not 
provide complete protection. 
Viral pathogens which reside within cells can evade humoral immunity. Vaccines 
against such pathogens, must evoke cell-mediated immunity of which T-lymphocyte 
stimulation is required. T-lymphocytes only recognise antigen when it is presented on 
the surface of cells in association with a cellular marker, the major histocompatibility 
complex (MHC). Antigen presentation to the lymphocyte is provided by macrophages 
(non-specific cells which phagocytose and remove foreign material in the body). 
Macrophages present either peptides (in association with MHC class II), or infectious 
viral material (in association with MHC class I) on their surface. Each T-lymphocyte 
is specific to each antigen, but in contrast to B-lymphocytes, they respond to many 
epitopes from a microorganism. The macrophages secrete interleukins which provide 
chemical stimuli for the differentiation of the T-lymphocytes into effector helper or 
cytotoxic T-cells. Memory T-cells are also produced which provide a reservoir of 
cells mobilised to respond to a repeated attack from the antigen. Cytotoxic T-cells are 
able to destroy the invaded cell by mechanisms involving interferons. For this reason 
cell-mediated immunity is required to clear infection. Humoral and cell mediated 
immunity are intimately linked for example the stimulus for the differentiation of B- 
cells into antibody producing cells is provided by helper T-cells (formed in response 
to the same antigen). The specificity and memory are the essential components of the 
4 
specific immune system that can be exploited to produce vaccines, but antigen 
presentation (provided by non-specific antigen presenting cells) is equally important. 
1.2 THE TRADITIONAL VACCINES 
Before considering developing new or improved vaccines, it is important to outline 
the types of vaccine presently in use, in order to draw a baseline. Termed traditional 
because they have been developed using long-standing approaches, they can be 
divided into two catorgories: 1) live attenuated vaccines and 2) killed vaccines. 
For a comprehensive text describing the scope of traditional vaccines the reader is 
referred to an overview by Ada (1990) and a general immunisation text such as that 
by Dudgeon and Cutting (1991). 
The principle of attenuation is to reduce the virulence of the microorganism so that 
it is safe to the host but at the same time allowing replication. This can be achieved, 
for example, by changing the conditions in which the microorganism grows. A 
sustained dose of the antigen is presented to the immune system ensuring long lasting 
protection whilst the natural infection ensures cell-mediated as well as humoral 
immunity. 
The approach to killed vaccines is to reduce the virulence of the microorganism by 
preventing replication (inactivation) without losing its immunogenicity. The 
microorganism can be inactivated by heat or chemical treatment. If the whole 
microorganism is used many antigens are available which means immunity is induced 
in most individuals. As a result of non-replication these vaccines need to be 
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administered repeatedly over time. Using the same approach, toxins (toxic products 
liberated from certain microorganisms) can be rendered harmless by chemical 
treatment to give toxoids which can induce protection. 
Most of the vaccines approved for use in humans represent the above (refer to Table 
1), there is another type of vaccine, the subunit vaccine which only consist of the 
important epitopes needed to confer immunity. Advances in genetic engineering and 
biotechnology have enabled these epitopes to be produced synthetically. 
1.2.1 Limitations of the traditional vaccines 
The types of vaccine described have advantages and inherent limitations. Killed 
vaccines and toxoids are considered safer because a non-replicating microorganism 
carries less virulence potential than a live vaccine containing a replicating 
microorganism. Live vaccines have been known to revert to a virulent form, for 
example the live poliomyelitis Sabin type 3 vaccine, this has resulted in some 
countries, such as Holland, replacing the OPV oral poliomyelitis vaccine with a new 
enhanced-potency killed parenteral IPV vaccine as a measure to overcome this 
problem (Hinman and Orenstein, 1990). The use of live vaccines in 
immunosuppressed individuals, the elderly and the young, is of special concern. Some 
killed vaccines, however, may also give adverse reactions such as the parenteral 
whole cell vaccines for typhoid (Levine et al. 1990) and pertussis (Ada, 1990). In the 
case of pertussis, the whole cell vaccine has been replaced in Japan by an acellular 
vaccine (Kimura and Kuno-Saki, 1988). Most vaccines in use today carry some risk 
to the host but the overall benefit to the whole community is the major objective in 
6 
vaccination programmes. Due to their safety, there is now a trend towards 
development of subunit vaccines, however, a problem remains, one of poor 
immunogenicity (Woodrow, 1990). 
Live attenuated vaccines need to be stored in a cold chain to remain viable. Most of 
the presently available live and killed vaccines need to be stored between 2-8°C to 
remain active for any length of time (Dudgeon and Cutting, 1991). This is not only 
expensive, but poses several logistical problems for supply in isolated areas of the 
third world. The relative low cost of producing live attenuated and killed vaccines is 
counteracted by the need for cold storage and concomitant cost. 
The major drawback in the use of killed and subunit vaccines is the necessity for 
multiple doses for adequate protection. Up to 5 injections of tetanus toxoid may be 
required for life long immunity. A typical immunisation schedule given to children 
in developed countries requires multiple contacts, four in the first year of life 
(Dungeon and Cutting, 1991). The BCG vaccine for tuberculosis and the measles 
vaccine (both attenuated and live) are the only presently available vaccines that 
require one dose. The dropout rate for boosters is high in the third world (Bektimirov 
et al. 1990). It is important to be immunised as soon as possible after birth, but 
because of the maternal antibodies circulating in the infant the Diptheria, Pertussis 
and Tetanus (DPT) vaccine cannot be given until 6 weeks of age. This is not such a 
major problem in the developed world because good sanitation ensures the mass 
population are protected from the onset of the disease. In the third world, however. 
poor sanitation results in a prevalence of disease in these areas and children are at 
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great risk as soon as they are born. Presently only two vaccines can be given at birth: 
the BCG vaccine for tuberculosis and the oral polio OPV vaccine (Bloom, 1990). 
Most vaccines currently available are administered via the parenteral route; only the 
oral poliomyelitis vaccine is given orally (refer to Table 1). The oral route offers a 
number of advantages over parenteral administration: acceptability, convenience, and 
cost effectiveness (saving the need for trained personnel to administer injections and 
use of specialised equipment such as needles and syringes). The development of an 
oral route of administration as opposed to the parenteral is a major directive of the 
WHO transdisease vaccination programme initiated in 1987 (Bektimirov et al. 1990). 
In order to develop improved vaccines the pathogenesis of the microorganism must 
be addressed. The route of invasion and subsequent dissemination of the pathogen 
within the host is important when devising protective strategies. Traditional vaccines, 
administered parenterally induce protective immunity in the serum of the host giving 
good protection against pathogens which directly invade the serum of the host such 
as Clostridium tetani (Tetanus) and viral hepatitis B, or have a stage during 
pathogenesis in which they infect systemic organs by passage through the bloodstream 
(viraemia and bacteraemic) such as poliomyelitis. Traditional vaccines provide poor 
protection at the mucosal surfaces which line the respiratory, gastrointestinal and 
genito-urinary tracts. For the majority of invasive pathogens these are the initial sites 
of entry into the host (refer to Table 2). The traditional vaccines were developed 
without consideration that a separate immunity exists to protect the mucosa - local 
immunity or the mucosal immune response. Vaccines that fail to induce immunity at 
the mucosa, fail to give adequate protection against pathogens that colonise or 
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TABLE 1 
PRESENTLY AVAILABLE VACCINES FOR HUMAN USE 
BACTERIAL VACCINES ROUTE 
Live attenuated Killed inactivated 
BCG Parenteral 
Diptheria Parenteral 
Tetanus Parenteral 
Anthrax Parenteral 
Pertussis Parenteral 
Typhoid Parenteral 
Cholera Parenteral 
Plague Parenteral 
Pneumoccocal (subunit) Parenteral 
Meningcoccal (subunit) Parenteral 
H. influenza B (subunit) Parenteral 
VIRAL VACCINES 
Live attenuated Killed vaccines 
Oral vaccine (OPV) Oral 
Yellow fever Parenteral 
Measles Parenteral 
Mumps Parenteral 
Polio vaccine (IPV) Parenteral 
Rabies Parenteral 
Influenza A, B Parenteral 
Japanese B encephalitis Parenteral 
Influenza A, B (subunit) Parenteral 
Hepatitis B (subunit) Parenteral 
TABLE 2 
Infectious microorganisms whose initial portal of entry 
are the mucosal surfaces. 
Invasive microrganisms 
initial site of infection 
Mucosal surface of the lower and Mucosal surface of the Mucosal surface of 
upper respiratory tract Gastrointestinal tract the Genito-rinary tract 
Herpes simplex 1 Vibrio cholerae HIV-1 
Escherichia coli 
Bordetella pertussis (ETEC) Herpes simplex 2 
measles Escherichia coli 
(EPEC) Eschericheria coli 
Influenza viruses Shigella species Neisseria gonorrhea 
Parainfluenza viruses 
Syncytial virus Salmonella typhi 
Rhinoviruses Rotavirus 
Adenoviruses 
Coronaviruses Reovirus 
Coxsackieviruses 
Echoviruses Poliomyelitis 
Mycobacteria 
Neisseria meningitidis 
Streptococcus pneumoniae 
Haemophilus influenzae 
Group A Streptoccocus 
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penetrate via these surfaces. Vibrio cholerae for example, colonises the mucosal 
surface of the small intestine (Gillinghan and Po, 1991). The present parenteral killed 
vaccines give low and short lived protection (Holmgren et al. 1989). The fact that 
enteric diseases are estimated to account for up to a quarter of infant deaths in 
developing countries (Black, 1993) and the majority of the diseases included in Table 
2 still require a vaccine, highlights the great need for new vaccines capable of 
inducing mucosal immunity. In order to evoke mucosal immunity the vaccine must 
first reach the mucosa. Substantial evidence suggests that a disseminated mucosal 
response can be initiated by orally administered antigens reaching the subepithelial 
lymphoid tissue of the gastrointestinal tract (refer to section 1.3). It is possible, 
therefore, to exploit for example the oral route to induce mucosal protection and 
overcome some of the inherent problems associated with parenteral delivery; 
inadequate protection at mucosal surfaces, inconvenience, poor patient acceptability 
and cost. However, other limitations associated with presently available vaccines also 
need to be considered, such as the need for cold storage and repeated dosage. In 
order to develop oral vaccines, the properties of the mucosal immune system must 
first be considered. 
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1.3 THE MUCOSAL EVNIUNE SYSTEM 
The mucosal membranes that line the respiratory, gastrointestinal and genito-urinary 
tracts cover a enormous surface area, over 400m2 in the Human (McGee and Kiyono, 
1993). By inhalation, ingestion and sexual contact this vast area is a potential entry 
site for infectious microorganisms (refer to Table 2) and harmful environmental 
materials. A separate immune system, termed the mucosal immune system, 
comprising the mucosal tissue of these tracts as well as exocrine secretory glands 
(lacrimal, salivary and mammary) protects these surfaces against invasive pathogens 
and environmental materials. 
The predominant antibody found in the external secretions that bathe the mucosa is 
secretory immunoglobulin A (sIgA) (Tomasi and Zigelbaum, 1963). Initially, it was 
thought that antibodies found in the mucosal secretions were a result of serum derived 
antibodies spilling over into the secretions and resulting in mucosal immunity- 
described as the spillover concept (Bergmann and Waldman, 1988). This was rejected 
in favour of local production at the mucosa, when Hanson (1961) demonstrated 
structural differences existed between serum and milk immunoglobulin A and later, 
Tomasi and Zegelbaum (1963), found that immunoglobulin A was the predominant 
antibody found in secretions. 
Secretory IgA is composed of two or more IgA monomeric units as opposed to serum 
IgA which is monomeric (Hanson, 1961 and 1993). Secretory IgA also contains two 
additional components; the secretory component and the J chain. The secretory 
component is thought to facilitate the transport of polymeric IgA from plasma cells 
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within the submucosa to the mucosal surface where invasive pathogens are 
encountered (Russell and Mestecky, 1988), it is also thought to protect the heavy 
chains of the molecule from proteolysis by digestive enzymes (Rossen and Butler, 
1973). Secretory IgA protects primarily by inhibiting the adherence of pathogens to 
the mucosal surface and stops invasion of the host. S-IgA can bind to bacterial toxins 
and viral surface epitopes important for cell attachment as well as specific and non- 
specific inhibitory effects on the adherence of bacteria to the mucosal surface (McGee 
and Mestecky, 1990). 
1.3.1 The Common Mucosal Immune Response 
The mucosal immune response is initiated when antigen is encountered by the 
subepithelial lymphoid tissue present throughout the mucosa 
- 
termed the mucosal 
associated lymphoid tissue (MALT). This can be divided into the bronchus associated 
lymphoid tissue (BALT) (Bienenstock and Johnson, 1973), found within the mucosa 
of the respiratory tract and the gut associated lymphoid tissue (GALT, O'Hagan, 
1990), found within the mucosa of the gastrointestinal tract. These are thought to be 
strategically situated to respond to foreign antigens entering the host by inhalation and 
ingestion. Craig and Cebra (1971) were the first group to directly demonstrate that 
lymphoid tissue was the source of precursors for IgA producing plasma cells. When 
GALT (Peyer's patch) cells were transferred into irradiated allogenic rabbits there 
was a repopulation in the lamina propria of recipient small intestine by donor cells 
producing IgA. In contrast only small numbers of donor lymph node cells (peripheral 
lymphoid tissue) were found in the recipient intestine, the majority of which were 
producing IgG. They concluded that the GALT was the foci from which IgA 
producing plasma cells in the gut were derived. In a similar experiment, Rudzik et 
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al. (1975) demonstrated that BALT and GALT cells transferred to irradiated rabbits 
were able to repopulate both the lamina propria of lung and intestine with donor IgA 
containing cells. This study demonstrated that the production of precursor IgA 
secreting plasma cells was an inherent property of mucosal lymphoid tissue whether 
BALT or GALT. Rudzik et al. (1975) described the BALT and GALT as: "Lymphoid 
aggregates at sentinel sites guarding the portals of entry of potential pathogens". They 
also suggested the existence of a common mucosal immune system whereupon 
different mucosal sites are linked by migrating IgA committed lymphocytes. This 
hypothesis was supported by Roux et al. (1977) who demonstrated that mesenteric 
node (MLN) IgA lymphoblasts "home" to recipient mice mammary gland during late 
pregnancy and lactation. They proposed a system in which precursors of IgA derived 
from GALT enter mesenteric lymph nodes, differentiate, enter the general circulation 
via the thoracic duct and home to distant secretory sites. Jackson et al. (1981) 
confirmed these findings. Donor MLN cells (IgA lymphoblasts) were found to 
preferentially home to mammary glands (lactating) as well as the intestine, MLN and 
salivary glands in recipient mice. This was supported by McDermott and Bienenstock 
(1979) who demonstrated donor mesenteric lymph node lymphoblast cells, the 
majority of which were of the IgA isotype, repopulated intestine, respiratory and 
genital tracts in recipient mice. However, they suggested a preferential homing of 
MLN to the gut and bronchial lymph cells to the lungs indicating an element of organ 
preference in the mucosal response. 
In humans, the evidence for a common mucosal system has been derived from clinical 
studies in which specific antibodies have found in mucosal secretions distant from the 
site of antigen encounter. In a study conducted by Waldman et al. (1982) an oral 
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administration of killed influenza vaccine (enterically coated) resulted in the presence 
of specific antibody in the nasal secretions. In a later study, IgA specific influenza 
antibodies were simultaneously found in tears, saliva and nasal secretions after oral 
administration of killed influenza (Bergmann et al. 1986). 
Substantial evidence suggests that a common mucosal immune system does exist in 
which migratory IgA lymphoblasts derived from the MALT home to distant sites 
within the mucosal tissue, whereupon, secretory IgA is produced to protect mucosal 
surfaces (refer to Figure 2). Exploitation of the common mucosal immune response 
forms the basis for oral vaccine development. Orally delivered antigens encountered 
by subepithelial lymphoid tissue within the gastrointestinal tract evoke a disseminated 
mucosal response capable of evoking protection against pathogens invasive of distant 
mucosal sites, as well as the gastrointestinal tract for example an oral delivered 
vaccine against influenza virus that invades the mucosa of the respiratory tract. 
Oral delivered antigens must first cross the intestinal epithelium and enter the 
subepithelial lymphoid tissue (GALT). The GALT is composed of organised lymphoid 
tissue and diffuse lymphoid tissue (O'Hagan, 1990). The organised tissue is composed 
of lymphoid follicles occurring as isolated follicles or in aggregates known as Peyer's 
patches. The diffuse tissue occurs as lymphocytes within the lamina propria (LPL) or 
between mucosal epithelial cells (IEL). Evidence suggests that the Peyer's patch are 
the source of the immune response (Craig and Cebra, 1971 and Rudzik et al. 1975) 
and numerous studies demonstrate that the main site of antigen uptake in the gut is 
the Peyer's patches (see following sections). 
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Figure 2 The common mucosal immune response 
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1.3.2 Morphology of the Peyer's Patch 
Peyer's patches are collections of lymphoid follicles distributed throughout the small 
intestine, from the pylorus to the ileocecal valve, but they predominate in the ileum. 
They occur in a wide variety of species including man (Rubas and Grass, 1991). The 
primary difference between the species being the number follicles clustered together 
and the relationship of the folds and crypts to the lymphoid aggregate. The Peyer's 
patch contains a dome region consisting of one or two germinal centres (B-cell zone) 
situated towards the base of the follicle and parafollicular areas (T-cell zone) (refer 
to Figure 3). The adult Peyer's patch consists of 40-70% B lymphocytes found 
primarily within the germinal centre and 11-40% T lymphocytes predominantly found 
in the dome and interfollicular areas. Isotype switching of B cells bearing IgM isotype 
to IgA isotype is thought to occur in the dome as a result of switch T cells 
(Kawanishi et al. 1983). The dome region is also populated by macrophages and 
dendritic cells (LeFevre et al. 1985, Carlson and Owen 1987). 
The epithelium overlying the dome of the follicles is termed the follicle associated 
epithelium (FAE) and allows the transport of luminal material into the dome. 
Specialised cells 
-M cells within the FAE are thought to facilitate this. This was 
demonstrated by Bockman and Cooper (1973), who compared the uptake of luminal 
carbon and ferritin into lymphoid follicle epithelial cells (in mouse Peyer's patch, 
rabbit appendix and chicken bursa of Fabricius) with that of neighbouring non- 
lymphoid epithelial cells. Ferritin and carbon were taken into the follicle associated 
epithelial cells but not the non-lymphoid epithelial cells. Bockman and Cooper (1973) 
demonstrated that the epithelium overlying lymphoid follicles contained specialised 
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Figure 3 
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cells capable of transporting luminal material to the domes and that this specialised 
cell was unique to lymphoid follicles, independent of species. Bienenstock (1976) 
described cells similar in appearance in the epithelium overlying the bronchus 
associated lymphoid tissue of rabbits, and reported the preferential uptake of luminal 
ferritin into the FAE 
- 
evidence that these specialised cells are found in all mucosa 
lymphoid tissue and share a common function. At this time the specialised cells were 
referred to as follicle associated epithelial cells which was confusing terminology as 
it implied all the cells in the FAE were specialised and did not take into account the 
normal columnar epithelial cells found in the FAE. These specialised cells were later 
named membranous cell or M cell due to the thin apical cytoplasm that separates the 
lymphocytes within the FAE from the lumen (Owen 1977). 
1.3.3 Morphology of the Membranous Cell (M Cell) 
The FAE consists of both M cells and absorptive columnar cells. The number of M 
cells vary between species but typically they occur as single cells scattered among the 
normal absorptive cells, separated by tight junctions. They possess a number of 
features which distinguish them from neighbouring absorptive cells (Owen and Jones 
1974), refer to Figure 4. On their luminal surface they have a poorly defined 
glycocalyx which overlies stumpy microvilli. Unlike the microvilli of enterocytes, the 
microvilli of M cells are not aligned so as to form a brush border. The M cell 
organelles occur predominately just below the apical cytoplasm of the cells with an 
high occurrence of mitochondria but few lysozymes (Owen et al. 1986, Trier 1991). 
a basally located nucleus occurs within the cell. The lateral plasma membrane deeply 
invaginates its cytoplasm forming an intercellular compartment containing 
19 
My 
Aýý 
-. 
7, X
1Q, Mc 
Eýýtl ýý' 4+q. .. y r 1L"n 
4 P. Y 
fýüC1 r'r 
44 
y-5- 
^ : ý" 
I`% Iý a 
.^ 
. 
-+J''_ 
A` 'ti: 
ilk" 
Mir 
Figure 4 
Electron micrograph showing an M cell (M) of a rat. Characteristic features 
distinguishing these cells from normal enterocytes (E) are the shorter, fewer 
microvilli (Mv), an apical cytoplasm (AC) containing numerous mitochondria 
(Mc) and invading lymphocytes. Magnification x 9,620 
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lymphocytes, lymphoblasts and macrophages. This compartment has been referred to 
as the central hollow (Wolf and Bye 1984). These features suggest that if material is 
transported through the M cell, it will not be subject to lysosomal attack and so will 
be transported essentially unaltered, termed transcytosis (Rubas and Grass 1991) to 
an area rich in immunocompetent cells. 
The immune response is initiated when antigen is presented to the B and T cells in 
the Peyer's patch dome by antigen presenting macrophage and dendritic cells. Antigen 
is presented in association with MHC II molecules to helper T cells. Antigen specific 
B cells are activated by antigen to form primed lymphoblasts. These primed 
lymphoblasts and antigen specific T blasts pass from the Peyer's patch via the 
lymphatics into the mesenteric lymph nodes and then the thoracic duct and into the 
blood. The primed B helper T cells "home" to mucosal sites at which differentiation 
into antibody producing plasma cells occurs under the influence of helper T cells. For 
viral pathogens it is important to induce cell mediated immunity as well as humoral 
immunity. CD8 phenotypic T lymphocytes, the precursors to cytotoxic T 
lymphocytes, are also present within Peyer's patches. Oral immunisation with viral 
antigens is known to induce specific cytotoxic T lymphocytes in distant mucosal and 
systemic sites (McGee et al. 1992). For a comprehensive review of the mucosal 
immune response it is suggested the reader refers to ; Russell and Mestecky 1987, 
Mestecky 1987, McGee et al. 1992 and McGee and Kiyono 1993. 
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1.3.4 M Cell Uptake 
The M cell has been described as an "antigen sampling" cell allowing the entry of 
luminal material into the Peyer's patch so an immune response can be mounted. 
Studies have been conducted to characterise the mechanism of M cell uptake and 
subsequent passage of material through the cell. Bockman and Cooper (1973) 
described a "pinocytotic" mechanism of entry of luminal ferritin and carbon into M 
cells of lymphoid tissue resulting in material filled vesicles and vacuoles within the 
apical cytoplasm. A pinocytotic entry of horse radish peroxidase into mouse M cells 
was also described by Owen (1977). Within 30 minutes HRP filled vesicles were 
observed within the M cell cytoplasm and after 60 minutes in the extracellular space 
being engulfed by lymphocytes. There was a retention of HRP enzymatic activity 
after uptake indicating no lysosomal attack. 
The possible role of receptor mediated endocytosis in M cell uptake, uptake into the 
cell after initial binding to a specific marker on the cell surface (Rubas and Grass 
1991), was investigated by Neutra et al. (1987). M cell apical surfaces contains 
anionic surfaces and membrane associated glycoconjugates shown by polycation and 
lectin binding sites (Owen and Bhalla 1983). Neutra et al. (1987) found in vitro that 
lectin-ferritin conjugates bound equally to M cells and absorptive cells. In vivo, 
however, the lectin-ferritin conjugates bound to M cells in greater numbers and were 
subsequently endocytosed and found in vesicles within the M cell. It was found that 
a simultaneous administration of an adherent conjugate (wheat germ agglutinin- 
ferritin) with that of a nonadherent BSA-colloidal gold conjugate resulted in a 50 
times greater uptake of the adherent probe. 
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The unique features of M cells which allows entry of luminal material to pass 
unaltered to immunocompetent cells can also be exploited by pathogens as a means 
of escaping lysosomal breakdown. For example, intestinal lymphoid follicles are 
major sites for initial multiplication of Salmonella typhi before dissemination to 
distant systemic tissue (Gaines et al. 1967, Hohmann et al. 1978). Various studies 
investigating the involvement of M cells in the pathogenesis of microorganisms has 
further characterised the features of M cell uptake. 
1.3.4.1 The Uptake of Microorganisms into M Cells 
The uptake of Vibrio cholerae into rabbit Peyer's patches was documented by Owen 
et al. (1986). A mechanism in which pseudopodia extending from the M cell 
microvilli engulfing the bacteria was described. Similar to the transport of HRP 
(Owen, 1977) the bacteria was taken into vesicles within the M cell, transported 
through the cell and released into the extracellular space and taken up into 
macrophages. No invasion into the normal epithelial cells was seen. Only viable 
cholerae entered the M cell. This study demonstrated that a microorganism usually 
non invasive of the mucosa is actively taken into M cells indicating M cell sampling. 
It also indicates that components on the pathogen are necessary for uptake into M 
cells. 
The role of specific ligands on microorganism adherence to M cells was investigated 
by Inman and Cantey (1984). The adherence of Eschericheria coli RDEC-1 strain to 
rabbit M cells was due to the possession of a pilus proteins. The transfer of the 
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plasmid that codes for the pili caused the specific adherence of a strain of Shigella 
flexneri to M cells. Controls lacking this plasmid did not adhere to the lymphoid 
follicles. The Shigella strain was seen deep within the cytoplasm of M cells and in 
association with dendritic cells resulted in an acute inflammatory response. In 
contrast, the RDEC-1 strain remained on the surface. After 14 days the RDEC-1 
strain continued to colonise the lymphoid epithelium whilst the Shigella strain did not 
survive after 4 hours. Inman concluded the resistance to endocytosis of the RDEC-1 
strain to the possession of "additional virulence factors" a possible escape mechanism 
from the induction of a mucosal immune response. This study showed that adherence 
alone does not ensure uptake into the M cell. 
Wolf et al. (1981) investigated the entry of reovirus from the gastrointestinal tract to 
the systemic tissues. Using the murine model, reovirus type 1 was found 
preferentially to adhere and be taken up into M cells. No viruses were detected 
adhering to or inside normal absorptive cells. The virus was enveloped by vesicles 
within the cytoplasm of the cell and found in the extracellular space beneath the M 
cell close to lymphocytes. In a later study, reovirus type 3 was found adhering and 
inside lysosome bodies within the normal absorptive cells (Wolf, Kauffman, Finberg 
et al. 1983). No transport across these cells were observed. They were, however, 
transported across M cells in a similar manner described for type 1. The ability of the 
reovirus to adhere to the normal absorptive cells was attributed to the nature of the 
outer capsid protein haemagglutinin. Wolf et al. (1983), concluded that the surface 
characteristics of M cell and normal absorptive cells differ. 
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Sicinski et al. (1990) reported the specific adherence and endocytotic uptake of 
poliovirus type 1 into human epithelial M cells in vitro. The poliovirus was contained 
in vesicles within the apical cytoplasm of the M cell. No poliovirus was detected 
adhering or endocytosed by normal absorptive cells. It was concluded that the M cell 
route was being exploited by the virus to enter systemic tissue. A similar conclusion 
was made of Human Immunodeficiency Virus type 1 (HIV-1), in a study carried out 
by Amergen et al. (1991). HIV-1 selectively adhered and was endocytosed by mice 
and rabbit intestinal M cells in vitro. The virus was found within "endosomes" in the 
apical cytoplasm and next to lymphocytes in the extracellular space. The presence of 
M cells within human rectal mucosa suggests a possible invasive route in humans. 
Virus was not found adhering to or within the normal absorptive cells, within the 
lymphoid tissue or villous regions. They attributed this to specific surface markers on 
the apical surface of the M cell or to the lack of accessability to enterocytes due to 
their well defined glycocalyx. 
A phagocytotic mechanism of uptake into rabbit M cells was observed for 
mycobacteria (Fujimura, 1986). At the apical surface pseudopodia extensions were 
close to the bacterium and subsequently contained in vesicles within the cytoplasm. 
The bacteria adhered specifically to the M cell with none detected inside normal 
absorptive cells. Bacteria were found within macrophages in the extracellular space 
indicating that an immune response to the pathogen was mounted. 
In summary, luminal antigens are transported into M cells by a mechanism of 
endocytosis (pinocytosis or phagocytosis depending on the size of the material). This 
process is enhanced after prior adherence to the apical surface. Some pathogens can, 
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however, resist uptake by possessing additional virulence factors. Pathogen uptake 
into the M cell, in some cases, may be exploitation of the host to escape lysosomal 
breakdown but as these are the sites which initiate an immune response, this route is 
advantageous to the host. 
1.4 APPROACHES TO ENHANCE MUCOSAL IMMUNITY 
1.4.1. Antigen Degradation Within the Gastrointestinal Tract 
The major drawback with oral immunisation is the problem of antigen breakdown 
within the gastrointestinal tract. The function of the gastrointestinal tract is to 
breakdown food and extract the nutrients needed to sustain life. To carry out this 
task, the tract has a system of mechanical, chemical and enzymatic components. 
These components are also capable of degrading orally administered antigens. For a 
general text on the digestive system refer to Sanford (1982). 
In reaching the GALT (primarily the Peyer's patches within the small intestine) the 
antigen encounters numerous enzymes throughout the tract. Saliva in the oral cavity 
and oesophagus contains salivary amylase, lipase and lysozymes which breakdown 
polysaccharides, triglycerides and bacterial cell walls respectively. After transit 
through the oesophagus, the antigen must pass through the stomach. It is here that the 
food is processed to a semi-solid chyme and held until it passes into the small 
intestine. The environment within the stomach is extremely acidic with a pH in the 
range 1-2 resulting from the secretion of hydrochloric acid. This acidity can 
breakdown antigens. The stomach contains enzymes such as pepsin which breakdown 
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proteins to polypeptides by hydrolysis of the peptide bonds. The length of time the 
antigen would have to withstand these conditions before passing into the small 
intestine depends on a number of factors such as the fed state, but it could be up to 
3 hours (Wilson and Washington, 1989). The small intestine contains enzymes 
potentially capable of destroying antigens, of particular concern are the enzyme 
components of the pancreatic secretions including amylase (which breakdowns 
polysaccharides), trypsin and chymotrypsin (which breakdowns polypeptides). 
ribonucleases and deoxyribonucleases are also contained in the pancreatic secretions 
which breakdown nucleic acids. A function of the small intestine is to facilitate 
nutrient absorption, therefore, food is held at the ileocecal junction until digestion is 
almost complete. The time varies but it may held here for 3-5 hours. This may be 
advantageous, in that antigen is retained in the area of maximum uptake (ileum) but 
it also means the antigen is subject to excessive enzymic attack. Possible ways to 
overcome the problem of antigen degradation in the gut are to (a) increase the amount 
of antigen administered or (b) enhancing (potentiating) the immunogenicity of the 
antigen by the use of mucosal adjuvants. 
1.4.2 Mucosal Adjuvants 
An adjuvant is defined as a substance, which when administered with an antigen 
enhances the immune response to the antigen (latin adjuvare - to help Riott, 1991). 
Adjuvants which work by acting directly on the cells involved in immunity are termed 
immunostimulants. Others increase antigen localisation in an area rich in 
immunocompetent cells and release antigen over a length of time to give continual 
stimulation of the immune system (this is termed the depot effect). The first adjuvants 
1ý 
were described by Ramon (1925), and since then a number of adjuvants have been 
developed, primarily for enhancing the immune responses to parenteral delivered 
antigens (reviews: Edelman, 1980, Warren et al. 1986 and Altman and Dixon, 1989). 
The problem with many of the currently available adjuvants is their toxicity; for 
instance, mineral oil adjuvants (Freund's adjuvants) are not licenced for human use 
because of the carcinogenesis associated with the mineral oils (Warren et al. 1986). 
The need for a new range of safer adjuvants is highlighted by the fact that Alum 
(aluminium salt) is the only presently available adjuvant licensed for use in humans 
(Edelman, 1980). 
Mucosal adjuvants are adjuvants that enhance the immunogenicity of orally delivered 
antigens. Several approaches are currently being investigated (Lycke and Svennerholm 
1990, O'Hagan, 1992) (refer to Table 3). Although some of the adjuvants listed in 
Table 3 act as immunostimulants, for example Muramyl dipeptidase (MDP) which 
acts directly on antigen presenting cells (Morisaki et al. 1983), most of the adjuvants 
act as antigen delivery vehicles with the aim of increasing the amount of antigen 
delivered to the mucosa. The live bacterial and viral vectors which express foreign 
antigens (review: O'Hagan, 1992) are able to replicate at the mucosa surface giving 
a prolonged delivery of antigen which is capable of acting as a secondary stimulus. 
The vector has to express non-virulence but at the same time retain the ability to 
colonise the mucosa, therefore, there is concern over safety (refer to section 1.2). 
Preexisting immunity to the carrier may also limit repeated doses. Ethical concerns 
over foreign gene insertion into humans seems limiting to live vector use in humans. 
Non-replicating delivery systems seem to offer a more likely option (O'Hagan, 1990). 
Adjuvants such as lectins (Pusztai et al. 1991) and cholera toxin and subunits 
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(Holmgren et al. 1989) which bind to intestinal epithelium, have the drawback that 
conjugation to the antigen may effect the antigenic epitopes on the surface of the 
antigen. There also remains doubts over the toxicity of cholera toxin and some lectins 
(O' Hagan 1990). 
A second type of non-replicating delivery system is those which aim to protect the 
antigen from the conditions encountered within the gut (refer to previous section). 
Liposomes are spheres of phospholipid bilayers containing an aqueous compartment 
in which antigen can be incorporated (Allison and Gregoriadis, 1976). Oral 
immunisation with liposomes containing purified Streptococcus mutans resulted in 
raised levels of salivary IgA in rats (Michalek et al. 1989). In a study conducted by 
Childers et al. (1990) liposomes were found to be taken into M cells of rats after 
administration via in situ intestinal loops. This indicated the adjuvant effect of 
liposomes may be due to delivery of antigen to the sites where a mucosal immune 
response is initiated. The drawback to the use of liposomes as mucosal adjuvants, 
however, is the possible instability of liposomes in the gut (O'Hagan, 1990). The use 
of ISCOMs (immunostimulating complexes) is another possible approach to enhance 
mucosal immunity. These are composed of Quil A, and membrane antigens of viruses 
incorporated into a micelles by hydrophobic interactions (Morein et al. 1984). 
Influenza virus ISCOMs (Sunquist et al. 1988) are licenced in Sweeden for parenteral 
use in horses. However, there is limited data at present on the stability of ISCOMs 
within the gastrointestinal tract. 
30 
There is, therefore, a need for more effective and safer delivery systems for orally 
administered antigens. The use of microparticulate antigen delivery systems composed 
of antigen incorporated into a polymer matrix is an approach gaining much interest. 
1.4.3 Microparticulate Antigen Delivery Systems 
The antigen is incorporated into a polymer matrix by the process of 
microencapsulation to form spherical microparticles (refer to section 5.1). The 
internalised antigen is, therefore, protected from the conditions encountered in the 
gastrointestinal tract. Microparticles can be monolithic in which the antigen is 
dispersed throughout the polymer matrix or a reservoir capsule in which the antigen 
lies in the centre surrounded by a core wall of polymer (Tice and Cowsar 1984). 
The adjuvant effect of microparticulates was first recognised for parenterally delivered 
antigens. Kreuter et al. (1976) and Kreuter and Liehl (1978) demonstrated that split 
(1976) or whole influenza virus (1978) either adsorbed or encapsulated into 
polymethacylate particles was able to elicit an higher antibody response than soluble 
vaccines. The proposed mechanism of adjuvancy of the microparticulate was 
considered to be a result of a sustained release of the antigen from the microparticle 
resulting in antigen localisation in an area rich in immunocompetent cells (the depot 
theory first described by Glenny 1926). Kreuter et al. 1988, later found the immune 
response correlated with the hydrophobicity of the microparticulate (increase in 
hydrophobicity increased the response). This was supported by Tabata and Ikada 
(1987), who showed that an increase in hydophohicity increases macrophage 
phagocytosis. The adjuvant effect of microparticles administered parenterally seems 
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to be a combination of a depot effect and an increase in macrophage phagocytosis, 
both of which lead to greater antigen presentation and an increase in T cell dependent 
immune responses (Riott, 1991, refer to section 1.1) 
. 
Preis and Langer (1979) demonstrated that a pellet composed of ethylene-vinyl acetate 
copolymer implanted subcutaneously released antigen in a controlled manner into the 
surrounding tissues and evoked an enhanced antibody formation in serum over a 
period of six months comparable to the secondary response from antigen emulsified 
in Freund's complete adjuvant. This response was due to antigen, released over a 
prolonged period, acting as a secondary stimulus. The polymer used in this study was 
non-biodegradable and had to be removed surgically. 
One of the major directives of the WHO programme for vaccine development 
(Bektimirov et al. 1990) is to develop methods to incorporate multiple vaccines into 
controlled release microparticles, made from biodegradable polymers, to release the 
vaccine at set times to mimic the booster immunisations by delivering a number of 
pulses of vaccine spaced over a number of months 
- 
the one shot vaccine. 
The polymer used for microencapsulation needs to be both biodegradable (to avoid 
surgical removal) and bioresorbable (broken down into metabolites) to be considered 
safe for human use. The polyester, poly(lactide-co-glycolide) meets both these 
requirements and considerable research into their use as a polymer for sustained 
release antigen delivery vehicles has been carried out. 
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1.4.4 Poly(lactide-co-glycolide) (PLG) Microparticles as Controlled Release 
Vaccines 
PLG is a polyester composed of lactic and glycolic acids (Tice and Cower 1984). 
PLG is non-toxic and has been used in humans as suture material (Wise et al. 1979), 
because of its biodegradability, biocompatability and low inflammatory reaction to 
tissue (Maulding 1987, Visscher et al. 1985 and Vissscher et al. 1987). 
PLG has been used as microparticle drug delivery systems (Tice et al. 1989) and has 
been used to encapsulate peptides (Challacombe et al. 1992 and Eldridge et al. 1991), 
bacterial components (M`Queen et al. 1993, Reid et al. 1993 and Edelman et al. 
1993), whole viruses (Moldoveanu et al. 1993 and Ray et al. 1993) using various 
formulation techniques (refer to Chapter 5). The microparticle formulations can be 
lyophilised enabling storage at room temperature. 
The release of antigen from PLG microparticles is dependent on the degradation of 
the polymer (caused by the hydrolytic cleavage of the ester bonds) and the diffusion 
of the antigen through the polymer matrix (Tice and Cowsar 1984). PLG polymers 
composed of different molecular weights and lactide to glycolide ratios can be 
produced which degrade at different rates (refer to section 5.6.1). By using different 
polymers the microparticulate delivery system can be tailored to release antigen at 
specific rates. In theory, by using a mixed population of microparticles composed of 
different PLG polymers one can deliver booster doses within a single immunisation. 
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PLG microparticles have been investigated as antigen delivery systems for parenteral 
immunisation. Eldridge et al. (1991) demonstrated that size was a crucial factor in 
the type of response elicited. Microparticles in the range 1-10µm were readily 
phagocytosed and transported to the draining lymph nodes. Therefore, a high 
concentration of antigen was available to lymphocytes, resulting in rapid and 
enhanced immune responses. The larger microparticles only elicited a response after 
sufficient degradation and subsequent phagocytosis. Using a combination of sizes they 
evoked a prolonged and enhanced immunity. Gander et al. (1993) investigated PLG 
degradation rates on the release of Tetanus toxoid in an attempt to mimic conventional 
immunisation schemes. A combination of fast and slow degrading polymers in a 
single administration gave enhanced responses at 4 weeks and 16 weeks and a 
persistent response after 8 months. 
A series of experiments using particulate antigens has suggested that a particulate 
form of the antigen given orally elicits a greater mucosal immune response than a 
soluble form. Initial investigations conducted by Cox and Taubman (1984) reported 
that oral administration of a particulate form of dinitrophenylated bovine y-globulin 
(DNP-BCG) (by conjugating with Streptococcus mutans) was able to give greater 
secretory immune responses than the soluble form of the antigen. This effect was 
further investigated by O'Hagan et al. (1989). Ovalbumin adsorbed to microparticles 
(size 100nm) composed of a biodegradable polymer poly(butyl-2-cyanoacrylate) 
administered orally, elicited a greater IgA response in the saliva of rats than the 
soluble antigen. The same effect was obtained with ovalbumin encapsulated within 
microparticles composed of polyacrylamide (size 2.55µm) (O'Hagan et al., 1989). In 
all these studies the effect was attributed to the greater uptake of the particulates into 
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the gut associated lymphoid tissue, although there was no direct experimental 
demonstration of this effect. This outlines the need for detailed investigations into 
both the immune response to an oral microencapsulated antigen and the 
characterisation of the mechanism of uptake. 
In summary, PLG microparticles have great potential as antigen delivery vehicles for 
oral vaccines. Microparticles have inherent adjuvant properties relating to 
phagocytosis by antigen presenting cells. PLG microparticles, which have already 
been used as parenteral antigen delivery systems, should give protection to the antigen 
in the environment found within the gastrointestinal tract. It has also been shown that 
a greater mucosal immune response can be evoked by a particulate form of the 
antigen. To elicit an oral immune response the microparticles must first cross the 
intestinal barrier and enter the GALT. 
1.5 THE UPTAKE OF PARTICULATES ACROSS THE INTESTINAL 
EPITHELIUM 
The intestinal epithelium is composed of normal absorptive enterocytes and the 
specialised cells of the follicle associated epithelium overlying lymphoid tissue. 
Particulate uptake across the intestinal epithelium has important implications for the 
possible toxic effects of ingested material, and the feasibility of the oral delivery of 
drugs and vaccines. To initiate a mucosal immune response the antigen delivery 
vehicles, discussed in the previous section, must breach the epithelium overlying the 
lymphoid tissue. Before discussing this, it is pertinent to review the evidence for 
particulate uptake across non-lymphoid tissue. 
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1.5.1 Particulate Uptake Across Non-Lymphoid Tissue 
Sanders and Ashworth (1961) investigated the intestinal uptake of latex particles, 
0.22µm in diameter, after intragastric administration in rats. Within 1 hour the 
particles were detected within cytoplasmic vesicles in the jejunal epithelial cells. The 
particles were later found in lymphatics. Uptake across normal absorptive cells was 
confirmed in a study conducted by Matsumo et al. (1983). Percoll particles, 20-30nm 
in diameter, orally administered to mice for 7 days were detected in vacuoles within 
enterocytes of the ileum. These particles were invariably associated with lysozymes. 
The low amount of uptake confirmed by the low level found within the subepithelial 
tissue of the villus mucosa was suggested by the authors as a consequence of 
discharge back into the lumen. Some particles, however, did reach the mesenteric 
lymph nodes and the liver. 
Some authors have suggested a route in which particulates pass between enterocytes, 
rather than through them 
- 
the paracellular route. Polyalkylcyanoacrylate 
nanocapsules, 165nm in diameter, were administered to dogs using an in situ gut loop 
(Aprahamian et al. 1987). Scanning electron microscopy revealed the presence of the 
nanoparticles in the intercellular spaces between the enterocytes of the jejunum but 
not the cytoplasm of the enterocytes. The particles were especially prevalent in the 
intercellular spaces at the tips of villi where defects in the mucosa occurred as a result 
of cell dequamation. At these sites the particles reached the villus core and entered 
capillaries. The paracellular route of uptake has also been suggested for a series of 
controversial findings by Volkheimer (review, 1983) reporting the uptake of 
particulates in the size range 5 to 110µm. PVC particles and potato starch granules 
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with a diameter between 5-110µm were reported to cross the intestinal epithelium 
between enterocytes, especially at the tips of villi which showed mucosal defects. 
PVC particles were transported from the site of intestinal uptake either within portal 
blood or lymph and were later found in the cerebro-spinal fluid. These findings have 
been viewed with extreme scepticism: first, the entry of such large particles into the 
portal system seems unlikely considering the particles must cross the wall of the 
capillaries through fenestral channels of diameter 5-100nm (Aprahamian et al. 1987). 
Second, it is thought that only the smallest water soluble molecules are able to breach 
the blood/brain barrier, let alone particles in the micrometer range (Davis and Ilium 
1988). 
In summary there are two routes by which luminal particulates cross non-lymphoid 
epithelium one, through the absorptive enterocytes and two, the paracellular route, 
between the absorptive enterocytes. Transport through the enterocytes takes place by 
a endocytotic mechanism and is restricted to small particulates, less than 200nm. 
After uptake, the particulate is prone to lysosomal breakdown within the enterocyte. 
The second route, the paracellular is proposed despite the tight junctions (occluding 
junctions) between the cells, although Phillips et al. (1987) reported the transport of 
horseradish peroxidase within occluding junctions but this macromolecule is only 5nm 
in size. It is therefore, not surprising that for large particulates the main site of 
reported paracellular transport is at the sites of defects in the mucosa such as the tips 
of villi. 
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1.5.2 Particulate Uptake Across Lymphoid Tissue 
Evidence of particulates uptake into the GALT can divided into those studies which 
demonstrate 1) uptake into whole Peyer's patches and 2) uptake across the follicle 
associated epithelium (FAE) at the ultrastructural level. 
In reviewing particulate uptake across the GALT, a number of points need to be 
considered: 
1) The mechanism of uptake at the M cell surface. 
2) The properties of particulates which determine uptake, for example, size and 
surface charge. 
3) The mechanism and transit time for particulate transport through M cells. 
4) The amount of particulates which cross the GALT and 
5) The fate of particulates after uptake. 
1.5.2.1 Particulate Uptake into Peyer's Patches 
The first evidence of particulate uptake at the Peyer's patches was reported by groups 
investigating the potential toxic effects of ingested environmental particulates. An 
investigation into the uptake of carbon in mice was carried out by Joel et al. (1978). 
Carbon (20-50 nm) administered in drinking water was visible in the Peyer's patches 
after 2 days. The amount observed correlated with the length of feeding; after 2 
months more carbon was found in the subepithelial dome regions of the patches the 
majority of which were within macrophages. No particles were present in the villi 
distant from the patch but a few particles were observed within villi adjacent to 
patches. After 6 months feeding black dots along the length of the small intestine 
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were visible. These were found to be isolated lymphoid follicles containing carbon. 
This indicated that the epithelium over lymphoid follicles was specialised for 
particulate uptake. LeFevre et al. (1978) extended these findings to investigated the 
intestinal uptake and migratory pathway of latex microparticles after chronic feeding. 
Latex microparticles were chosen for their uniform size and resistance to gastric 
breakdown. The microparticles (2µm) were given in drinking water for a period of 
3 or 61 days. Sections of intestine, containing Peyer's patches, and mesenteric lymph 
nodes were taken and analysed using light microscopy for the presence of the 
microparticles. Microparticles were found within the domes of Peyer's patches in 
those mice which received high concentrations of microparticles, the amount observed 
correlating to the fed dose. Tissue taken 14 days after feeding had terminated 
contained more microparticles than tissue observed 74 days after feeding, indicating 
a migration of microparticles away from the patch over time. In the Peyer's patches 
from the mice fed high concentrations for 61 days, microparticles were present along 
the serosa, some of which were contained within macrophages. Some villi adjacent 
to the patch contained low numbers of microparticles whereas distant villi contained 
none. The presence of latex in the neighbouring villi was thought to result from the 
transfer through: "lymphatic channels". In the mice fed high concentrations over a 
61 day period, microparticles were found in the mesenteric lymph nodes, some of 
which were contained within macrophages. LeFevre et al. (1978) suggested that 
migration of free and intracellular microparticles from the patch through lymphatics 
into the mesenteric lymph nodes had occurred. 
LeFevre et al. (1980) investigated the influence of particulate size on the uptake into 
Peyer's patches. A comparison was made between the uptake and migratory pathway 
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of large (styrene divinylbenzene 15.8µm) and small (carbonised divinylbenzene 
5.7µm) microparticles. The microparticles were administered as a single gavage or 
in drinking water for 30 or 60 days. Tissue sections and blood (heart drainage) were 
taken and analysed by light microscopy or a solubilised tissue technique for the 
presence of microparticles. For the single gavage and low particle concentration 
chronically fed (30 days) mice no microparticles were evident either in the blood or 
tissue sections, using both methods of detection. No accumulation of the 15.81tm 
microparticles were present in the Peyer's patches, blood, liver, spleen and 
mesenteric lymph nodes taken from mice chronically fed with high concentrations of 
microparticles. In contrast, Peyer's patches taken from the mice fed high 
concentrations of 5.7µm microparticles for 60 days contained microparticles, many 
within macrophages. Microparticles were not detected in intestinal non-lymphoid 
tissue, except as previously reported in the villi bordering the domes. Solubilised 
Peyer's patches, lungs and mesenteric lymph nodes contained microparticles, whereas 
the blood and spleen did not. Tissue taken longer periods after feeding showed more 
accumulation of microparticles in the mesenteric lymph nodes. 
The significance of surface properties of microparticles to Peyer's patch uptake was 
investigated by LeFevre et al. (1985). Five crystallite particles, all less than 51Am, 
were orally administered to mice for 3 months. Carbon and iron oxide were found 
within the subepithelial and basal regions of Peyer's patches. In contrast, asbestos, 
quartz and carmine were not detected. This was attributed to the different 
hydrophobicities; carbon and iron oxide are hydrophobic whereas, the other 
crystallites are hydrophilic. LeFevre and Joel (1984) suggested that uptake into the 
Peyer's patch involved a phagocytotic event at the epithelial surface and, therefore, 
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would be influenced by: "factors known to influence phagocytosis". As previously 
discussed, macrophage phagocytosis of particulates is increased if the particulates are 
hydrophobic (Tabata et al. 1987 and Kreuter et al. 1988). The findings of LeFevre 
et al. (1985) were confirmed in studies conducted by Eldridge et al. (1990). This 
group investigated the uptake of fluorescent microparticles 1-10µm (showing various 
degrees of hydrophobicity) into mouse Peyer's patches. The amount of uptake into 
the dome region of the patch after a single gavage correlated with the degree of 
hydrophobicity; the more hydrophobic the greater the uptake. Also in agreement with 
LeFevre et al. (1980), was the finding that microparticles greater than 10µm were not 
taken into the patches. This study was the first to demonstrate the uptake and 
migratory pathway of microparticles composed of poly(DL-lactide-co-glycolide). After 
a single gavage of PLG microparticles the Peyer's patches, mesenteric lymph node 
(MLN) and spleen were taken at various times and analysed for the presence of 
microparticles. Microparticles were detected initially in the patches after time 
however, the maximum numbers decreased and more were found in the MLN and 
spleen. This migratory pattern was found to be size dependent, only microparticles 
less than 51tm were found in the MLN and spleen whilst those greater than 5µm 
remained in the patch. Migratory microparticles were reported to be within 
macrophages. 
The effect of size on uptake was further investigated by Ebel (1990). Mice were 
orally gavaged with two different sizes of fluorescent latex microparticle, 2.65µm and 
9.13µm and the Peyer's patch and spleen removed. The tissues were solubilised and 
the number of microparticles counted using flow cytometry. Both types of 
microparticle were detected in the patches but none of the larger ones were found 
in 
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the spleen. This indicated that the large microparticles had remained in the patch and 
had not reached the general circulation. 
The effect of size and physio-chemical properties of microparticles on uptake was 
reported by Jani, Halbert et al. (1989). Fluorescent carboxylated and non- 
carboxylated latex microparticles (100,500,1000,3000nm) were administered orally 
to rats for 10 days. The 100,500 and 1000nm microparticles were found in the 
serosa of the Peyer's patches, MLN, liver and spleen. Photomicrograph evidence 
showed 500nm non-carboxylated microparticles "transversing" a lymphatic vessel 
supporting the migratory path proposed by Eldridge et al. (1990). The smaller non- 
carboxylated 100 and 500nm microparticles were taken up to a greater extent than the 
1000nm, whilst the 3µm microparticles could not be detected in the patches or MLN. 
Jani et al. (1989) also detected 100nm non-carboxylated microparticles in the villi of 
the small intestine suggesting an "endocytotic uptake" by normal enterocytes. 
Particulate uptake was further investigated by the same group using gel permeation 
chromatography to measure the amount of polystyrene in tissues after oral 
administration of microparticles (50,100,300,500,1000 and 3000nm) to rats for 10 
days (Jani et al., 1990). Jani et al. (1992) attempted to further investigate the 
intestinal uptake of microparticles using histological analysis. All the microparticles 
were present in the serosal layer of the Peyer's patch except the 3µm which were 
thought to adhere to the patch. Jani et al. (1992) conflicts with LeFevre et al. (1980), 
Eldridge et al. (1990) and Ebel (1990), in the claim that the upper limit for 
microparticle uptake across the intestine was 31tm. The localisation of the 50nm in 
the normal enterocytes led the group to suggest particulates 50-100nm may cross the 
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mucosa by endocytosis, which agrees with the findings of Sanders and Ashworth 
(1961) and Matsuno et al. (1983). 
In the studies above, the mechanisms of uptake at the epithelial surface of the Peyer's 
patch or the specific cells in the FAE which facilitate uptake are not described. These 
studies, however, demonstrate that the primary sites of particulate uptake across the 
intestinal epithelium is the Peyer's patch. This phenomenon is influenced by a number 
of factors including the quantity administered and physio-chemical properties of the 
particulate such as hydrophobicity and charge and particulate size. In the studies 
discussed there is general agreement that the particulates leaving the Peyer's patches 
follow the lymphatic pathway (refer to chapter 4) although, hitherto, there is no direct 
evidence of microparticles in the lymph or whether they are transported in the lymph 
intracellularly or intercellularly. The significance of microparticles following the 
lymphatic pathway in respect to oral vaccines is that the antigen delivery vehicle will 
avoid the first pass effect of the liver and be disseminated to the systemic tissues. 
1.5.2.2 Particulate Uptake into M Cells 
The second type of study is where particulate uptake at the follicle epithelial surface 
at the ultrastructural level is investigated. A group of monoclonal antibodies 
specifically labelling M cells in the FAE of rabbits was raised by Pappo (1989); 
previously the M cell was identified by the morphological differences between M cell 
and enterocytes (Owen and Jones 1974). The specificity of these M cells to 
monoclonal antibodies was utilised in a study conducted by Pappo and Ermak (1989) 
investigating the uptake of fluorescent latex microparticles into the FAE overlying 
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rabbit Peyer's patches. Fluorescent latex microparticles (600-750nm) were 
administered into an in situ gut loop, containing Peyer's patches, and left for 90 
minutes. The Peyer's patch was removed, sectioned, and observed using a fluorescent 
microscope for the presence of microparticles. The microparticles adhered to and 
were taken into the cells within the FAE of the patch after 30 minutes but not into the 
cells of the neighbouring villi. After 90 minutes the microparticles were present in 
the subepithelial domes. Monoclonal labelling of the FAE revealed that the actual site 
of microparticule entry into the FAE was at the M cells. The authors described uptake 
as occurring in: "synchronous waves", in which the microparticles are taken 
completely through the patch before more microparticles on the apical surface start 
as a second successive wave. The enhancement of M cell uptake by conjugating a 
monoclonal antibody directed against the M cell apical surface to polystyrene 
microparticles (1.0µm) was demonstrated by Pappo et al. (1991). Monoclonal 
antibody conjugated microparticles were taken up into M cells more than three times 
that of uncoated microparticles with no uptake observed over neighbouring villi. The 
interesting aspect of this study was that the monoclonal used had some specificity for 
enterocytes (Pappo 1989) but uptake of the conjugate was seen over M cells. This 
proved that, as well as the importance of binding to the cell surface, the M cell has 
intrinsic phagocytotic capabilities. 
James et al. (1991) developed a technique to trace the passage of microparticles 
through the FAE of mouse Peyer's patches by optical sectioning using confocal 
microscopy. In vitro incubation of amidine-coated fluorescent latex (0.61tm) resulted 
in selective adherence and uptake into M cells (identified by the lack of alkaline 
phosphatase activity). The same technique for tracing the passage of luminal 
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microparticulates coated with antigens across mouse FAE was performed by Porta et 
al. (1992). Peyer's patches removed from in-situ gut loops injected with native latex 
beads (0.5µm) or coated with either immunoglobulin A (IgA) or bovine serum 
albumin were prepared for scanning electron microscopy or confocal microscopy. The 
IgA coated microparticles were observed selectively adhering to the surface of M 
cells and taken up into these cells. IgA coated microparticles adhered 4 times and 
were taken into the M cell 25 times greater than the BSA coated microparticles. In 
contrast, the native microparticles were not taken up across the FAE, which conflicts 
with previous reports by the other groups discussed. 
In more recent studies using confocal microscopy and SEM, Jepson et al. (1993a) 
demonstrated that fluorescent latex microparticles (0.461tm), administered to rabbit 
in situ gut loops, bound selectively and were taken up by M cells across the FAE 
within 45 minutes of administration. SEM photomicrographs showed that the 
microparticles on the surface of the M cell were surrounded by protruding microvilli 
indicating a phagocytotic mechanism at the M cell surface. Microparticles taken 
across into the FAE were found in close association with lymphocytes occupying the 
central hollow. In agreement with the findings of Porta et al. (1991) binding and 
uptake of microparticles were greater over M cells at the periphery of the Peyer's 
patch dome, indicative of M cell distribution (Savidge et al. 1991). Studies by Jepson 
et al. (1993b), compared the extent of uptake across the follicle associated epithelium, 
between that of poly(lactide-co-glycolide) microparticles (0.5µm) and fluorescent latex 
into rabbit Peyer's patches. Whilst the latex microparticles were selectively adsorbed 
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to M cells, PLG microparticles also adhered to enterocytes within the FAE. The PLG 
microparticles were, however, taken across the M cells. 
To visualise the mechanism of uptake at the M cell surface, the ultrastructure needs 
to be observed for example by the electron microscope. In agreement with the 
phagocytotic mechanism suggested by Jepson et al. (1993), Seifert et al. (1983) and 
Sass et al. (1990) showed the uptake of latex particles (0.5µm) into the M cells of 
rats. Using scanning electron microscopy (SEM), particles were identified on M cells 
surrounded by pseudopodia outpushings protruding from the M cell surface (Sass et 
al., 1990). 
In conclusion, the overwhelming evidence suggests the main sites for particulate 
uptake across the FAE is the M cell. Few studies have actually demonstrated the 
mechanism of uptake at the M cell surface but it is thought to occur as a phagocytotic 
event. The antigenic sites specific to the apical surfaces of the M cell, which would 
help to understand the specificity for uptake, are still largely unknown. Initial 
binding, however, to the apical surface seems to be a prelude to uptake indicative of 
receptor mediated endocytosis. Binding is not the total requirement for uptake. Both 
Neutra et al. (1987) and Pappo et al. (1991) found that conjugates that bind to both 
enterocytes and M cells are only taken into M cells in vivo. This suggests the M cell 
possesses an intrinsic capability for particulate uptake. 
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1.5.3 Quantitation of Microparticulate Uptake Across the Intestinal Epithelium 
Fundamental to the use of microparticle delivery systems for oral vaccines, is the 
quantity which is taken across the intestinal epithelium. Several investigations have 
been conducted to elucidate this phenomenon. Ebel (1990) described a method for 
quantifying absorption of fluorescent particles from the mouse small intestine using 
the technique of flow cytometry. Less than 0.01 % of the 106-108 administered oral 
dose of fluorescent particles (2.15µm) was taken across the intestine, and absorption 
was dependent on particle size, dose level and the fed state of the animal. This level 
of uptake is in agreement with the levels found by LeFevre et al. (1977) who reported 
less than 0.01 % of a single administered dose of radioiodinated latex particles (170- 
227nm) was taken across the intestine of mice. Recent studies using confocal 
microscopy have indicated similar levels of intestine absorption: only 
5x 10-5% of a dose of polystyrene microparticles was taken across rabbit intestinal 
Peyer's patches (Jepson et al. 1993a) after administration via in situ gut loops. Pappo 
and Ermak (1989) investigated the amount of uptake across the FAE of rabbit Peyer's 
patches after an interluminal dose of fluorescent microparticles. Using fluorescent 
microscopy, total uptake was found to be 5% of the administered dose. 
Other workers have reported levels of microparticle absorption several orders of 
magnitude higher. Alpar et al. (1989) claimed extremely high levels of 
microparticulate uptake across the intestine following oral administration; 39% of the 
administered oral dose of latex microparticles (1.1 µm) was detected in the systemic 
circulation of rats 45 minutes after administration. Studies by Jani et al. (1990) also 
reported high levels of uptake following the oral administration of polystyrene 
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microparticles for 10 days to rats. The amount of polystyrene determined in systemic 
and gastrointestinal tissue, using gel permeation analysis, was 34 % of the 
administered dose for 50nm microparticles and 26% for the 100nm microparticles. 
Apart from there being a few claims of high uptake, the majority of evidence suggests 
that particulate uptake across the intestinal epithelium occurs at low levels. The 
possibility of this route for the delivery of therapeutic drugs is doubtful (unless 
extreme measures were taken! refer to Figure 5). The amount of antigen required to 
induce an immune response, however, requires smaller doses and therefore, this route 
may be exploited for delivering oral vaccines. 
1.6 ORAL IMMUNISATION WITH PLG MICROENCAPSULATED 
ANTIGENS 
Recently, for reasons discussed in previous sections (1.4.3), poly(lactide-co-glycolide) 
has been extensively used as a polymer for microparticulate antigen delivery systems. 
Consequently, a number of studies have investigated its use as oral vaccines. Early 
studies using PLG encapsulated antigens were conducted in collaborative work by 
groups at the Southern Research Institute and the University of Alabama U. S. A. 
Microparticles (size 1-5µm) (encapsulating a conjugated form of Hemocyanin) orally 
administered to mice (Tice et al. 1987) induced raised levels of antigen specific IgA 
antibodies in saliva and intestinal secretions. An increased serum response was also 
observed. The response was observed up to 28 days after antigen administration 
indicating that there was a sustained release of the encapsulated antigen as the 
polymer degraded. In studies conducted by the same group (Eldridge et al. 1990) 
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orally administered microparticles were found to selectively target Peyer's patches, 
giving direct evidence that the increased secretory immune responses with 
microparticulated antigens was a result of antigen delivery to the sites which initiate 
a disseminated mucosal response. In the same study (1990) it was demonstrated that 
PLG microparticles less than 51tm entered the general circulation through the 
lymphatic pathway, whereas, those greater than 51Lm remained within the patch. This 
group attempted to exploit this phenomenon in order to evoke both a systemic and 
mucosal responses. Mice were orally dosed with either PLG microparticles (size 1- 
10µm) encapsulating Staphylococcal enterotoxin B (SEB) or soluble SEB. Raised 
levels of anti-toxin antibodies were obtained in the serum and external secretions 
(saliva and intestinal secretions) from the mice given microencapsulated antigen 
whereas, no secretory and very low serum responses were seen in the mice given 
soluble antigen. It was concluded that the small microparticles disseminated to the 
systemic lymphoid tissue to give a systemic response whilst the larger ones remained 
in the patch and, as a result of a sustained release of the antigen, induced a mucosal 
response. 
In a study by Challacombe et al. (1992), PLG microparticles encapsulating ovalbumin 
were evaluated as oral delivery systems. Microparticles (size 31tm) containing antigen 
and soluble antigen were administered orally to mice on 3 consecutive days and 
boosted 4 weeks later. After the booster dose there was a significant increase of anti- 
OVA antibodies in the saliva (IgA isotype) and serum (IgG isotype) of mice 
administered microencapsulated antigen which persisted up to 8 weeks after the 
primary dose. In contrast, significantly lower responses were obtained with the 
soluble form. 
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PLG microparticles have also been used to encapsulate viruses and investigated for 
use as oral vaccines. Ray et al. (1993), encapsulated a purified human parainfluenza 
virus into PLG (50: 50) microparticles (size 1-101tm). After oral administration in 
hamsters the serum and saliva antibody responses slightly increased but were 
significantly lower than the responses both in the saliva and serum of mice given 
microparticles intraperitoneally. Significant was the finding that the antigenic integrity 
of epitopes within the protein coat of the virus was retained after microencapsulation. 
It is against these epitopes that neutralising antibodies are formed to give immunity. 
The oral delivery in mice of PLG microencapsulated inactivated influenza virus was 
studied by Moldoveanu et al. (1993). Mice primed systemically with soluble antigen 
and boosted orally with microencapsulated antigen gave increased levels of anti- 
influenza antibodies in serum (IgG isotype) and saliva (IgA isotype) greater than those 
obtained with mice boosted orally with soluble virus. The responses were high enough 
to give protection in the nose, trachea and lungs when challenged with live influenza. 
In a recent study by O'Hagan et al. (1993), cells secreting specific antibody to 
cholera toxin B subunit (CTB) were found in the spleen and mesenteric lymph node 
after oral administration to mice of PLG microencapsulated CTB. These responses 
were not detected when the mice were orally dosed with soluble CTB. Using SDS- 
PAGE and western blotting techniques, it was shown that the structural integrity of 
CTB was retained after the microencapsulation process. Of considerable significance 
to the development of oral vaccines against viruses, was the finding that OVA 
entrapped PLG microparticles elicited both T-cell and cytotoxic T cell responses after 
intraperitoneal immunisation. 
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Much work is currently being undertaken to develop oral vaccines against enteric 
diseases. One interesting strategy is to raise specific antibodies against the 
components on the pathogen essential for mucosal attachment. M'Queen et al. (1993) 
encapsulated the pilus proteins of rabbit E. coli (RDEC-1), responsible for mucosal 
attachment, into PLG microparticles. Sections of ileum and caecum did not show E. 
coli attachment after challenge in the rabbits given microparticles intraduodenally. In 
contrast, sections from non-immunised rabbits showed bacterial attachment. Following 
this line of thought, oral vaccines against the pilus proteins of enterotoxigenic E. coli 
have been investigated by Edelman et al. (1993) and Reid et al. (1993). 
1.7 INFLUENZA: A CANDIDATE FOR AN ORAL VACCINE 
Influenza is a viral respiratory infection which accounts for an high rate of morbidity 
in both human and animal populations. Outbreaks may occur as epidemics and 
occasionally pandemics, such as the 1918 outbreak which killed 20 million people. 
Death usually occurs as a result of secondary bacterial infections and is particulary 
a risk to the infants, elderly and those with an history of cardiovascular, pulmonary 
or renal disorders (Kilbourne, 1988). 
Influenza is a disease for which the development of an oral vaccine against would be 
particulary applicable. First, the initial route of entry into the host is the mucosal 
surface of the upper and lower respiratory tracts, primarily the ciliated columnar cells 
(Kilbourne, 1988). Therefore, local immunity at these surfaces would seem an 
attractive strategy for protection. As far back as 1940, Francis found that resistance 
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to influenza infections correlated better with specific antibodies found within 
nasopharyngeal secretions than in the sera. This was further supported by Fazekas de 
St Groth and Donnerly (1950) who found that antibodies in bronchial secretions, 
produced after local application, protected against influenza. The presently available 
vaccines are composed of killed inactivated virus administered parenterally. The killed 
vaccines induce specific circulating antibodies in the sera but fail to induce mucosal 
immunity or cytotoxic T-lymphocytes (Maasab et al. 1988) which as discussed earlier 
are important components for clearing a viral infection (refer to section 1.1) 
. 
Influenza does infect systemic organs such as the lungs but there is no viremic stage 
(transit through the blood to other areas) and so circulating antibodies give limited 
protection. Present vaccines give approximately 70% protection and lasts 
approximately 1 year (Kilbourne, 1988). 
Surface antigens on the influenza, to which neutralising antibody are formed, are 
susceptible to antigenic variation and so new variants arise which fail to be recognised 
by previously formed antibody, therefore, there is a need to change vaccines 
seasonally. If new strains are not recognised the vaccines in present use have limited 
effect. Secretory IgA has a broad range of protective functions (McGee and Mestecky 
1990) and is better suited to cope with antigenic variation: " Secretory IgA antibodies 
differ from antibodies in sera in that they have a wide spectrum of reactivity which 
increases their value in protecting against influenza when new antigenic variants of 
the virus appear" (Shvartsman and Zykov 1976). 
In a series of fundamental studies conducted by Waldman and Bergman secretory 
immune responses have repeatedly been induced in the respiratory tracts of humans 
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and animals after oral immunisation with influenza virus (reviews: Bergman and 
Waldman, 1987 and 1988). This demonstrates that the common mucosal immune 
system can be successfully exploited by the oral route. 
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1.8 AIMS AND OBJECTIVES 
Aims: 
The aims of the work described in this thesis were to characterise the uptake of a 
model microparticulate across the intestinal lymphoid tissue and to exploit this route 
for the delivery of a microencapsulated oral vaccine against the equine influenza 
virus. 
Objectives : 
1. To demonstrate and characterise the uptake of microparticles across the 
intestinal lymphoid tissue of the rabbit and rat. 
2. To identify the site and mechanism of uptake from the intestinal lumen. 
3. To quantify microparticulate uptake across the intestinal epithelium. 
4. To formulate PLG microparticles containing equine influenza virus and to 
investigate the structural and antigenic integrity after microencapsulation. 
5. To measure the release of antigen from microparticle systems. 
6. To assess the immunogenicity of the microencapsulated virus in mice. 
7. To investigate the secretory immune response in mice after oral immunisation 
with PLG microparticles containing the equine influenza virus. 
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CHAPTER 2 
The Uptake of Microparticles Across the Intestinal 
Lymphoid Tissue in the Rabbit and Rat 
2.1 INTRODUCTION 
Evidence suggests that Peyer's patches are the major sites for particulate uptake in 
the gastrointestinal tract (refer to section 1.5). The initial aim of this investigation was 
to provide definitive evidence for this phenomenon and to characterise it at the 
ultrastructural level. The experimental approach employed was to deliver a model 
microparticle to the Peyer's patches and trace the passage of particles across the 
follicle associated epithelium, using standard histological and electron microscopic 
techniques. In view of this approach, consideration had to be given to the nature of 
the particle and, depending on this, the histological techniques used for observation. 
Non-biodegradable latex microparticles were selected as the model particulate because 
they would resist both the digestive processes of the gastric environment (Sanders and 
Ashworth 1961, LeFevre et al. 1977. ) and the chemicals used in histological analysis 
(Self et al. 1988). 
Two approaches were employed (a) light and fluorescence microscopy to analyse 
whole Peyer's patch tissue and (b) transmission electron microscopy to observe tissue 
at the ultrastructural level. A critical problem in such studies is the identification of 
the particles within the tissue. Batches of latex microparticles can he made to various 
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sizes and exhibit monodispersity which helps in their identification. The fluorescence 
signal emitted by the fluorescent microparticles was very distinctive and markedly 
different from tissue autofluorescence. Particles were delivered either in a chronic 
feeding regime or by injection into in situ intestinal loops. While the latter is an 
artificial situation, it does ensure that microparticles reach the FAE and also the time 
of exposure is controlled. Chronic feeding limits the control of microparticle delivery 
to the intestine but is more in keeping with the aim to develop an oral vaccine. An 
important consideration was tissue preservation, the exact location of particles could 
only be determined if the structural integrity of the tissue was maintained. 
2.2 MATERIALS AND METHODS 
Animals 
The rat and the rabbit were the animal models used in the uptake studies performed. 
Adult male Wistar rats 
Adult female Netherland Dwarf rabbits 
Adult female New Zealand White rabbits 
200-400 gms 
1000-1200 gms 
1000-1200 gms 
The animals were obtained from the Department of Biomedical Services, University 
of Nottingham. 
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Anaesthesia 
Adult rats were anaesthetised using an intraperitoneal injection of Nembutal 
(pentobarbitone sodium BP 60 mg/ml; 0.1 ml of Nembutal for every 100 gms of body 
weight). 
Adult rabbits were anaesthetised by inhalation of halothane administered using a 
Boyles Apparatus (Flurotec II). Using an open circuit, an induction dose of 1% 
halothane was administered. The amount was then increased slowly to 2.5 % for 
10 minutes and then kept constant throughout the experiment at a maintenance dose 
of 1.5-2.5 %. Oxygen and nitrous oxide were applied at 1 litre/minute each throughout 
the procedure. The level of consciousness, in both the rat and rabbit, was tested by 
the deep tendon reflex. 
Microparticles 
Fluoresbrite TM non-carboxylated 0.94 µm YG (2.5% solids-latex) (Polyscience 
Laboratories, Warrington). 
Fluoresbrite TM non-carboxylated 0.11 µm YG (2.5 % solids-latex) (Polyscience 
Laboratories). 
Fluoresbrite carboxylated 0.093 µm YG (2.5% solids-latex) (Polyscience 
Laboratories). 
Fluoresbrite carboxylated 1.1µm BB (2.5 % solids-latex) (Polyscience Laboratories). 
Polybead-carboxylated 0.19 µm (2.5 % solids-latex) (Polyscience Laboratories). 
Polybead non-carboxylated 0.50 µm (2.5% solids-latex) (Polyscience Laboratories). 
Polybead non-carboxylated 0.57 µm (2.5% solids-latex) (Polyscience Laboratories). 
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Latex microparticles 180 nm (Department of Pharmaceutical Sciences, University of 
Nottingham). 
'OMP' ferromagnetic latex microparticles 3.7 µm (Nycomed, Denmark). 
Buffers and Histological fixatives are described in the Appendix 2 
1) In situ gut loops 
Each animal was fasted overnight to minimize bowel contents. It was anaesthetised 
and placed on a dissecting table heated to 37°C. The abdomen was opened in the 
midline to expose the small intestine. The length of the small intestine (from the 
duodenum to the ileocecal junction) was carefully searched for the presence of 
Peyer's patches. These are located on the antimesenteric surface of the ileum. Once 
located, the intestine was carefully ligated as follows: on either side of a patch the 
closed tips of watchmakers forceps were gently pushed through the mesentery close 
to the gut wall and opened to enlarge the perforation and a thread of damp cotton 
thread was drawn through the perforation. The two ends of the each thread were tied 
to form a ligature around the ileum. With one side loosely tied, the particulate 
suspension was introduced into the lumen using a G25 needle (refer to Figure 6). The 
suspensions were then left in the lumen for a time period. The tissue was then 
removed and processed for histological analysis. 
2) Chronic feeding via a stomach tube 
A piece of wood, free from sharp ridges and with a hole in the centre large enough 
to admit the passage of a rubber catheter, was placed under the incisors, raising the 
upper jaw. This results in the spread of the animal's jaw with the gag resting on the 
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Figure 6 Preparation of an in-situ intestinal loop 
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F Fluid filled lumen of ileum 
tongue with the centre of the gag in line with the centre of the pharynx. The catheter 
was carefully pushed through the hole of the gag and passed into the animal's 
stomach along the pharynx and oesophagus. Care is required to ensure that tube is not 
passed into the lungs of the animal and sufficient length of tubing must be used to 
ensure delivery is to the stomach and not the oesophagus. Oesophagus rupturing may 
occur if any suspensions are delivered here. A syringe, filled with the particulate 
suspensions, was attached to the tubing and the particulates were delivered. Phosphate 
buffered saline was passed after the particles to ensure all the microparticles were 
flushed through the tubing. This procedure was repeated daily (for dosage refer to 
experimental details) On completion, the animal was sacrificed and the tissue 
removed. 
Transmission electron microscopy (TEM) analysis of Peyer's patch tissue. 
1. Fixation. 
A. Immersion fixation. 
Tissue was removed from animal and immediately immersed into primary fixative to 
avoid autolytic changes. 
B. Perfusion fixation. 
The animal was anaesthetised (as previously described) and the thorax opened, 
exposing the heart. The tip of an 18-gauge cannula connected to a perfusion apparatus 
was introduced into the left ventricle of the heart and the inferior vena cava cut. A 
prewash buffer was then forced through the animal at a pressure of 100 mmHg for 
1 minute, after which the primary fixative (3 % glutaraldehyde in 0 .1M phosphate 
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buffer) was flushed through the animal for about 15 minutes or until the animal 
showed complete blanching. The tissue was then removed for further processing. 
2. Microdissection of Peyer's patch material 
Microdissection took place with the tissue still in primary fixative. Using a single 
edge razor blade and aided by a dissecting microscope (Vickers), the area around the 
dome of the follicle was trimmed away. This was achieved by removing the serosal 
muscle layer and the neighbouring villi to give a sample about 1 mm2 (refer to 
Figure 7), which allowed better penetration of fixative and complete infiltration of 
embedding media later in the process. 
3. Infiltration and embedding 
A) The tissue was left in primary fixative for 48 hrs then washed three times with 
5% sucrose buffer (1 hour each). 
B) The tissue blocks were then post Fixed in a secondary fixative, 1% osmium 
tetroxide in Millonig's buffer, for 1 hour. 
C) Tissue was dehydrated in graded alcohols (30,50,70,100,100%) for 15 
minutes each. 
D) Two washes in propylene oxide for 15 minutes each. The tissue was left in 
50: 50 propylene oxide: embedding medium overnight in an open vial. 
E) Tissue was left for 24hrs in embedding medium (araldite) only in a stoppered 
vial. 
F) The tissue was then blotted to remove excess resin and cast into moulds 
containing embedding medium, placed in a 60°C oven and left for 48 
hours 
to polymerise. 
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Figure 7 Microdissection of a Peyer's patch 
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4. Sectioning of polymerised tissue blocks. 
One micron sections (semithins) were cut with a Reichert OMU3 ultra-microtome. 
A fine brush was used to pick the sections off the water in the knife reservoir, and 
placed on a glass slide. The sections were then stained for 2 minutes using toluidine 
blue, washed with absolute alcohol and viewed with a light microscope (Nikon) to 
identify the area being sectioned. When an area relating to the follicle associated 
epithelium (FAE) was found, ultra-thin sections were cut from that area. Gold 
sections with a thickness between 60-90 nm were prepared and mounted on 200 mesh 
copper grids. The grids were blotted dry. 
S. Staining of tissue sections 
The sections were double stained with filtered uranyl acetate (Bio-Rad) and filtered 
Renolds standard lead citrate (Bio-Rad). The copper grids, containing the sections, 
were placed on a drop of uranyl acetate for 15 minutes. The grid was rinsed using 
dropwise additions of double distilled water. The grids were placed on a drop of lead 
citrate and left for 6 minutes after which the grids were rinsed using dropwise 
additions of double distilled water. The grids were blotted dry and then observed 
using a Philips 300 or Philips 410 electron microscope. 
Fluorescent microscopic analysis: 
The fixed tissue samples were immersed in a cryoprotectant solution comprising 10% 
sucrose in 0.1 M phosphate buffer and stored at 4°C. Sections for fluorescent 
microscopic analysis were cut using either the freezing microtome or a cryostat (cold 
microtome). 
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1. Freezing microtome sections 
Frozen sections were produced using a freezing microtome (MSE). A block of tissue 
was placed on the microtome stage with a drop of OCT freezing compound and the 
temperature reduced with a Percoll freezing apparatus. When the tissue was frozen, 
it was allowed to equilibrate prior to being sectioned at a microtome setting of 20 
microns. Using a fine brush the sections were lifted from the knife and placed in a 
petri dish containing 0.2 M phosphate buffer. The sections were then mounted on 
glass slides using 0.2 M phosphate buffer as the mountant. During sectioning, the 
mounted sections were observed under a dissecting microscope until the follicle dome 
of a Peyer's patch was reached, at which time the sections were observed under the 
fluorescent microscope. 
2. Cryostat (cold microtome) sections 
Cryostat sections were produced using an open top cryostat chamber (Bright). The 
tissue sample was frozen to the object holder by adding OCT compound around the 
sample and then using forceps the holder was immersed into a beaker of chilled 
isopentane (brought to a temperature of 
-120°C by immersing in a dewer of liquid 
nitrogen) for about 20 seconds. The frozen sample was then placed in the chilled 
cryostat chamber (-17°C). The tissue block was left for at least 1 hour to equilibrate 
to the temperature of the chamber. The object holder was then clamped in position 
and the feed mechanism set to a thickness of 15 microns. The tissue block face was 
carefully lined up to the knife edge and trimmed until the sections being cut were 
representative of the tissue. The tissue sections were prevented from rolling or curling 
by using an antiroll bar which rests on the knife. A slide (at room temperature) was 
held a fraction over the frozen section on the knife causing the section to 
jump off on 
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to the slide. In between sections, the knife edge was scrupulously cleaned using a 
brush and kleenex tissues. The lid of the chamber was kept closed as much as 
possible to maintain the low temperature inside the cryostat. The slides were mounted 
using 0.2 M phosphate buffer and observed under the fluorescent microscope. 
Fluorescent microscope 
The fluorescent microparticles used in the uptake studies fluoresced either 
yellow/green (Excitation max 458nm, Emission max 540nm) or bright/blue 
(Excitation max 365nm, Emission max 468nm) when excitated with uv light, 
therefore, an excitation filter in the uv range was set on the microscope (Leitz 
Ortholux II) when the frozen and cryostat sections were viewed. Neither the OCT 
compound nor the mountant (0.2 M phosphate buffer, pH 7.2) showed fluorescence 
at these wavelengths. 
Method for transmission electron microscopic processing of frozen sections taken from 
Pet'er's patches 
To investigate further what was observed in fluorescent microscopy, the frozen 
sections were processed for TEM analysis. Frozen sections (thickness of 
20-40 microns) were carefully removed from the slide in which they have been 
mounted for previous fluorescent microscopic analysis and placed in a petri dish of 
0.2 M phosphate buffer pH 7.2. The Peyer's patch sections were microdissected as 
previously described to give a single follicle dome. Due to the small size (lmm2), the 
section was embedded in a block of agar to make processing easier. A small amount 
of 2% agar was poured on to a glass slide to give a film about 2 mm thick. Blocks 
of agar were cut and a small hole made in each for the Peyer's patch tissue to 
he 
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carefully placed. A small drop of warm 2% agar was then placed on top of the tissue 
to seal in the section. The blocks were then lifted from the slide and processed for 
TEM using the following procedure; 
A. The agar block left in osmium tetroxide for 30 minutes. 
B. The tissue was then dehydrated using graded alcohols (50,70,90,100,100%) 
for 10 minutes each. 
C. The block was left in propylene oxide for 10 minutes and repeated. 
D. It is then immersed in a 50: 50 propylene oxide : embedding medium in an 
unstoppered vial overnight. 
E. The block was immersed in embedding medium (araldite) for a further 
24 hours. 
F. The block was then cast into BEEM capsules containing embedding medium 
(araldite), ensuring the tissue lay flat, and placed in a 60°C oven for 48 hours. 
For paraffin wax tissue processing and staining methods, and Prussian blue iron test 
on TEM sections, refer to Appendix 3 
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2.3 UPTAKE STUDIES IN THE RAT 
2.3.1 Acute Studies 
Presentation of latex and fluorescent latex microparticles to rat Peyer's patches 
via closed intestinal loops 
2.3.1.1 Materials and Methods 
Male Wistar rats were fasted overnight. They were anaesthetised and microparticles 
injected into either an in situ intestinal loop performed around the Peyer's patches 
(refer to section 2.2. ) or the whole length of the ileum (ligature made at the ileocecal 
junction). For the dosage and times refer to Table 4. At the end of this period Peyer's 
patch tissue was either perfusion fixed (study 1 and 3, fixative 3% glutaraldehyde in 
0.1 M phosphate buffer and study 4, fixative 4% paraformaldehyde in 0.1 M 
phosphate buffer) or immersion fixed (study 2, fixative 3% glutaraldehyde in 0.1 M 
phosphate buffer) and the tissue processed for either TEM or fluorescent analysis. 
Control tissue (gut epithelium containing no Peyer's patch or microparticles) was also 
taken. 
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Table 4 Acute uptake studies in the rat 
TRANSMISSION ELECTRON MICROSCOPY 
Animals Microparticles 
Rats Dose Time 
in loop 
STUDY 1 
1 0.5 ml 30 min 0.19 µm carboxylated microparticles 
2 0.8 ml 30 min 0.50 µm non-carboxylated microparticles 
3 0.5 ml 30 min 0.57 µm non-carboxylated microparticles 
FLUORESCENCE MICROSCOPY 
Animals Microparticles 
Rats Dose Time 
in loop 
STUDY 2 
4 1.0 ml 15 min 0.94 µm Fluoresbrite non-carboxylated 
5 1.0 ml 15 min 0.11 µm Fluoresbrite non-carboxylated 
STUDY 3 
6 2.0 ml 30 min 0.11 µm Fluoresbrite non-carboxylated 
7 2.0 ml 30 min 0.94 µm Fluoresbrite non-carboxylated 
Whole length of ileum 
STUDY 4 
8 2.5 ml 15 min 0.11 µm Fluoresbrite non-carboxylated 
9 3.0 ml 15 min 0.94 pm Fluoresbrite non-carboxylated 
Whole length of ileum 
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2.3.1.2 Rat acute uptake study results 
(a) Transmission electron microscopy analysis. 
In study 1, poor fixation of Peyer's patch material was evident in a number of tissue 
blocks, causing problems when cutting ultrathin sections for TEM analysis. The mass 
of lymphoid tissue lying below the epithelium of the follicle was difficult to fix 
leading to poor infiltration and poor cutting properties. Few M cells were detected. 
Tissue taken from rat 3, (0.57 µm latex microparticles administered) revealed the 
presence of microparticles lining the luminal surface of the intestinal epithelium (refer 
to Figure 8). Further observation of the tissue from rat 3 revealed what appeared to 
be a latex microparticle inside a epithelial cell (refer to Figures 9-10) 
. 
The dense\tight 
prominent borders of the latex microparticle distinguished it from the cellular material 
of the cell. This cell seemed to be a normal enterocyte and not an M cell. Pseudopod 
formations were evident at the cell surface overlying the microparticle. Sections taken 
from rat 1, (0.19 µm latex microparticles administered) showed luminal 
microparticles; no microparticles however, were found intracellularly. No 
microparticles were found in the sections taken from rat 2. 
(b) Fluorescent microscopy analysis. 
In study 2, frozen sections (40µm) taken from rats 4 and 5 showed a distinctive dome 
arrangement of the lymphoid follicles of the Peyer's patch when viewed under the 
fluorescent microscope. Some sections from rat 4 and 5 showed a distinct bright 
yellow fluorescence relating to the microparticles within the dome regions and the tips 
of the neighbouring villi. It was difficult to determine, however, if the microparticles 
observed were intracellular. In an attempt to resolve this problem thinner sections 
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Figure 8 
Electron micrograph showing latex microparticles (Mp, 0.57µm) in contact with 
the luminal surface of an enterocyte within the follicle associated epithelium of 
a rat Peyer's patch. Also labelled the microvilli (Mv) of the cell forming a brush 
border. Magnification x 12,850 
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Figure 9 
Electron micrograph showing a enterocyte within the follicle associated 
epithelium of a rat Peyer's patch. A latex microparticle (Mp, 0.571Am) is shown 
within the cell, different from multivesicular bodies (Mvb) present. Pseudopodia 
formations (Pp) arising from the epithelium of the cell are apparent. 
Magnification x 22,680 
Figure 10 
High power electron micrograph of the latex microparticle in the above figure. 
Magnification x 39,310 
Figure 9 
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using the cryostat were obtained. Cryostat sections (151tm) showed poor dome 
preservation, leaving in most cases only intact villi. One section showing an intact 
follicle dome from rat 4 did reveal the presence of the 0.94µm microparticles within 
the dome. Clusters were abundant at the apex, centre and serosal surface of the 
follicle (refer to Figures 11 and 12). It was difficult, however, to determine if these 
microparticles were intracellular or on surface of the section. Too few intact 
structures were obtained to allow firm conclusions to be drawn. Similar results were 
obtained in study 3, cryostat sections showing poor preservation. In study 4, the use 
of paraformaldehyde as the fixative and buffered sucrose employed as a 
cryoprotectant used instead of glutaraldehyde resulted in better cutting properties 
giving more intact cryostat sections. Microparticles were evident in the dome regions 
of the patch but not to the same extent as the one section from rat 4. The problem 
remained as to whether these were intracellular or a luminal contaminant. Frozen 
sections that had already been viewed under the fluorescent microscope, were further 
processed for TEM analysis and viewed under the electron microscope. The semithins 
showed good preservation (considering the tissue had already been frozen and 
sectioned for fluorescent microscopy) when viewed under the electron microscope, 
however, no evidence of microparticles although no M cells were found. 
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Figure 11 
Photomicrograph of a rat Peyer's patch showing the presence of fluorescent 
microparticles (0.941tm) within the apex of a follicle dome. Magnification x 100 
Figure 12 
Photomicrograph of a rat Peyer's patch showing the presence of fluorescent 
microparticles (0.94µm) within the serosa underlying a lymphoid follicle. 
Magnification x 100 
Figure 11 
Figure 12 
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2.3.2 Chronic Feeding Studies 
Presentation of microparticles to rat Peyer's patches using chronic feeding studies 
2.3.2.1 Materials and Methods 
Two chronic feeding studies were conducted in the rat. In the first, four male rats 
were dosed orally with 0.5 ml suspensions of microparticles for 7 weeks. At the end 
of this period, the animals were anaesthetised and the Peyer's patches removed. The 
tissue was immersion fixed in 3% glutaraldehyde in 0.1 M phosphate buffer and 
processed for TEM analysis. 
In the second study, two groups of male Wistar rats (4 rats in each group) were dosed 
orally with a 0.2 ml suspension of fluorescent latex microparticles (diluted 1 in 18 
with PBS) for 5 consecutive days. 0.2m1 of a diluted suspension contained either 
approximately 6.1 x 101 (0.94µm) or 3.7 x 1011 (0.11µm). The same volume of PBS 
was administered to a group of controls (2 rats) simultaneously. On days 6 and 7 no 
microparticles were administered. The animals were fasted overnight on the evening 
of day 7. On day 8, they were anaesthetised and the Peyer's patches, mesenteric 
lymph nodes and liver tissue removed from each animal and immersion fixed (4 % 
paraformaldehyde in 0.1 M phosphate buffer) overnight. The tissue was then 
transferred to 10 % buffered sucrose solution. Frozen and cryostat sections were taken 
for fluorescent microscopic analysis. 
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Table 5 Chronic uptake studies in the rat 
Animals Microparticles 
Rats Length of Feeding 
STUDY 1 
1,2 7 weeks 180 nm Latex microparticles 
3,4 7 weeks 3.7 µm Ferro-magnetic microparticles 
STUDY 2 
Group A 5 days 0.94 µm Fluoresbrite non-carboxylated 
Group B 5 days 0.11 µm Fluoresbrite non-carboxylated 
Group C 5 days PBS 
Fluorescent microparticlVBWiluted 1 in 18 with 
2.3.2.2 Rat chronic uptake study results 
(a) Transmission electron microscopy analysis. 
Samples taken from the animals dosed for 7 weeks with latex microparticles (study 1) 
showed good fixation which resulted in good cutting properties when sectioned for 
TEM analysis. Semithin sections (1µm) viewed under the light microscope, showed 
numerous follicles with an intact follicle associated epithelium containing M cells. 
These were characterised by a dip in the brush border, the presence of 
lymphocytes 
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and lighter staining with toluidine blue stain. Ultrathin sections (60-90nm) viewed 
under the electron microscope, revealed excellent preservation of tissue and the 
presence of M cells (refer to Figures 13-14). No latex microparticles were evident. 
either inside the cells or on the luminal surface. Tissue taken from rats 3 and 4 (study 
1) was viewed under the light microscope for the presence of microparticles 
exhibiting the iron label. A microparticle smear on a glass slide gave a positive 
Prussian blue iron test. The Prussian blue iron test was then performed on wax (15 
Am) and semithin (1 µm epoxy resin) tissue sections after the wax and resin had been 
removed, revealing a negative result for the presence of iron when viewed under the 
light microscope. 
(b) Fluorescent microscopy analysis. 
Only tissue from the group given 0.94 µm microparticles (group A) showed discrete 
microparticles in the Peyer's patches (refer to Figure 15), liver (refer to Figure 16) 
and mesenteric lymph nodes (refer to Figure 17). The numbers, however, were very 
low with the appearance of only 1 or 2 microparticles in any one slide. Out of 30 
slides analysed under the fluorescent microscope, only 4/5 microparticles in total 
were observed. Group B tissue did not yield any microparticles from approximately 
100 slides analysed. 
2.3.3 Discussion of Microparticle Uptake in the Rat 
A limited amount of evidence for uptake was obtained from the acute study when 
analysed under TEM (study 1). Fixation was generally poor which led to difficulties 
when cutting ultrathin sections. Latex microparticles (0.57µm) «'ere found lining the 
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Figure 13 
Electron micrograph of the follicle associated epithelium of a rat Peyer's patch. 
M cells (M) are clearly identifiable from normal enterocytes (E), having shorter, 
stumpy microvilli (Mv) and invading lymphocytes (L). No microparticles are 
present inside the cells or on their luminal surface. Magnification x 5,390 
Figure 14 
Higher power of the M cell in the above micrograph showing a close up of the 
apical cytoplasm (Ac). Magnification x 11,930 
Figure 13 
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Figure 15 
Photomicrograph of Peyer's patch tissue taken from a rat showing the presence 
of a fluorescent microparticle (0.94µm). Magnification x 250 
Figure 16 
Photomicrograph of liver tissue taken from a rat showing the presence of a 
fluorescent microparticle (0.9414m). Magnification x 250 
Figure 15 
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Figure 17 
Photomicrograph of mesenteric lymph node tissue taken from a rat showing the 
presence of a fluorescent microparticle (0.941m). Magnification x 250 
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luminal surface of the intestinal epithelium of Peyer's patches. This is a significant 
finding because it conflicts with various published accounts that the chemicals used 
in TEM processing destroyed latex (LeFevre et al. 1977, Lentzen 1984 and Jani et 
al. 1989). A microparticle was found inside an enterocyte within the FAE, just below 
pseudopodia formations arising from the epithelium. This result suggests a mechanism 
of phagocytotic uptake similar to that reported by Landsverk (1988); using TEM 
analysis, latex microparticles (610nm) were shown to be phagocytosed by 
pseudopodia before entry into the ileal Peyer's patches of calves. The cells involved 
in uptake were not M cells but epithelial cells. Calves have two types of M cells 
(Lansverk 1988). An interesting observation by Lansverk (1987) was that the M cells 
common to all mammalian species, found in calve jejunal Peyer's patches, did not 
show uptake. 
The problem with using TEM to investigate microparticle uptake is (a) that latex 
microparticles are not electron dense, therefore, their identification in tissue is 
difficult and (b) semithin sections, viewed under the TEM, are less than 1 mm in 
diameter and 90 nm thick 
-a minute sample of the entire Peyer's patch. Due to the 
low number of intracellular microparticles observed and the difficulty in identifying 
latex under TEM, the whole patch was analysed at the light microscopic level, using 
fluorescence microscopy (studies 2-4). Fluorescent latex microparticles employed in 
these studies emitted a clear distinct single, easily recognisable within tissue. Frozen 
sections (40µm) and one cryostat section of tissue from study 2 revealed the presence 
microparticles in the areas relating to the follicle dome and the tips of the villi when 
viewed under the fluorescence microscope. The main problem, however, was 
determining if these microparticles were intracellular or surface contamination due to 
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the cutting action of the knife sweeping luminal fluorescence across the section. In 
an attempt to resolve this fluorescent sections were processed for TEM, when viewed 
under the electron microscope, however, no evidence of uptake was found, indicating 
that the fluorescence may have been due to surface microparticles. It was envisaged 
that cryostat sections less than 15µm in thickness would enable better identification 
of intracellular microparticles. Considerable problems were initially encountered in 
preserving the domes of the Peyer's patch when sections less than 151tm in thickness 
were taken. This was thought to be a result of using glutaraldehyde as the primary 
fixative. Subsequent studies (3 and 4) were conducted to try and improve tissue 
preservation and obtain intact cryostat sections of the follicle dome less than 15µm. 
In these studies luminal fluorescence was flushed out prior to sectioning to limit 
luminal contamination. It was found that a primary fixative of 4% paraformaldehyde 
in conjunction with a post wash of 10% sucrose in phosphate buffer, acting as a 
cryoprotectant, improved tissue preservation when cryostat section were taken. 
Although tissue preservation was improved, obtaining intact sections less than 151im 
was still a problem. Microparticles were apparent at the tips of villi and the limited 
numbers found in the domes were restricted to the 0.941tm microparticles. The results 
were inconclusive as the problem remained as to whether these microparticles were 
intracellular or arose from surface contamination from luminal fluorescent 
microparticles. 
A combination of techniques was employed to detect latex and ferromagnetic 
microparticles in the Peyer's patches after chronic feeding for 7 weeks. Tissue taken 
from chronic study 1, showed fine structural preservation when ultrathins were 
viewed under the TEM. Despite numerous M cells being found, no structures 
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resembling latex microparticles were detected. Structures were observed which 
seemed similar in appearance to microparticles but the lack of tight borders, such as 
that seen in Figures 9-10, indicated these were intracellular vesicles already present 
within the cell. Lefevre et al. (1978,1980 and 1984), in a series of chronic feeding 
studies in mice, have described the uptake of particulates into Peyer's patches as a 
cumulative effect, uptake being dependent on the quantity and the length of feeding. 
with maximum uptake being shown after 60 days feeding. The lack of microparticles 
detected in study 1 may be a result of an insufficient length of feeding. It may also 
be a result of the difficulty in detecting latex microparticles under TEM. The 
difficulty in distinguishing latex microparticles from intracellular vesicles was the 
rationale behind using the ferro-magnetic microparticles in this study. Prussian blue 
iron tests were performed on wax sections (151tm) and epoxy semithins (1µm) in 
which the epoxy resin was removed. These sections gave a negative result for iron 
which could be possibly due to the sensitivity of the test rather than the absence of 
the ferromagnetic microparticles. 
In the fluorescent microparticle feeding study (study 2) the mesenteric lymph nodes 
and liver were taken in addition to the Peyer's patches in order to follow the 
migratory pathway of the microparticles. A substantial amount of tissue was sampled 
and the signal emitted by the microparticles was very distinct, eliminating the any 
possibility that microparticles could be missed. Extremely low numbers of fluorescent 
microparticles were detected in the tissues and these were restricted to the 0.94µm 
microparticles. In similar experiments Jani et al. (1989,1992) reported far greater 
numbers of fluorescent microparticles in the tissues of rats (Sprague Dawley) fed 
microparticles (50,100,500,1000 and 3000nm) for 10 days. However, the total 
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numbers of microparticles administered in our study over the feeding period of 5 days 
was 5% of the total administered dose given over 10 days in the studies conducted 
by Jani et al. (1989,1992). In our studies only discrete individual microparticles were 
recorded. Whilst, because of their difficulty in resolving microparticles of 50nm and 
100nm, Jani et al. (1989 and 1992), relied on general tissue fluorescence as an 
indication of microparticle prescence. This may account for the different levels of 
microparticle uptake found. 
In contrast to the results presented in this thesis, no evidence of microparticles found 
within the FAE of the Peyer's patches is given in the work of Jani et al. (1989 and 
1990); all evidence is restricted to the serosal layer. After such a feeding regime you 
would have expected to have found some evidence of microparticles within the dome 
region of the patch (LeFevre et al. 1978). 
In chronic feeding studies the presentation of the administered microparticles to the 
Peyer's patches cannot be guaranteed, therefore the possibility exists that the 
microparticles administered in our studies were not reaching the sites in the numbers 
required for identifiable evidence of uptake. Considering the limited evidence for 
uptake using in situ delivery of microparticles it is not surprising that little evidence 
was achieved using chronic delivery of microparticles. 
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2.4 UPTAKE STUDIES IN THE RABBIT 
2.4.1 Acute Studies 
Presentation of latex and fluorescent latex microparticles to rabbit Peyer's 
patches via intestinal closed loops 
2.4.1.1 Materials and Methods 
Two strains of rabbit, the Netherland Dwarf and New Zealand White were used. The 
rabbits were fasted overnight. They were anaesthetised and in situ gut loops formed 
around two different Peyer's patches in the same animal (refer to section 2.2. ). The 
microparticles were injected into the loop (for dosage and time refer to Table 6). 
Fixative (study 1,3 % gluteraldehyde in 0.1 M phosphate buffer and study 2-5,4 % 
paraformaldehyde in 0.1 M phosphate buffer) was flushed through the lumen of the 
gut to remove residual particles in the lumen and then the Peyer's patches were 
removed, immersion fixed and processed for either TEM (study 1) or fluorescent 
analysis (study 2-5). 
To compare the uptake of carboxylated microparticles of different size a mixed 
population of different coloured fluorescent microparticles were injected into the same 
loop (study 4). 
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Table 6 Acute uptake studies in the rabbit 
TRANSMISSION ELECTRON MICROSCOPY 
Animals Microparticles 
Rabbit Dose Time in 
Peyer's patch loop 
STUDY 1 ND Y 
A 1.0 ml 20 min 0.19 µm carboxylated microparticles 
B 1.0 ml 20 min 0.57 µm non-carboxylated microparticles 
FLUORESCENCE MICROSCOPY 
Animals Microparticles 
Rabbit Dose Time in 
Peyer's patch loop 
STUDY 2 NDd 
A 1.0 ml 40 min 0.94 µm Fluoresbrite non-carboxylated YG 
B 1.0 ml 40 min 0.11 µm Fluoresbrite non-carboxylated YG 
STUDY 3 NZW Y 
A 1.0 ml 15 min 0.94 µm Fluoresbrite non-carboxylated YG 
B 1.0 ml 15 min 0.11 µm Fluoresbrite non-carboxylated YG 
STUDY 4 XNZWd 
A 1.0 ml 30 min 0.093 µm Fluoresbrite carboxylated YG 
1.1 µm Fluoresbrite carboxylated BB 
Particles dil. 1 in 5 then mixed 
*YG-yellow green fluorescence 
*BB-brilliant blue fluorescence 
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2.4.1.2 Rabbit Acute Uptake Study Results 
(a) Transmission electron microscopy analysis. 
When microdissecting the Peyer's patch tissue a multiple dome arrangement. 
surrounded by villi could be seen in the rabbit, as opposed to the characteristic single 
dome observed in the rat Peyer's patch. A well preserved follicle associated 
epithelium containing numerous intact M cells was observed in the semithin sections 
(1µm) taken from a Peyer's patch obtained in from study 1 when viewed under the 
light microscope. Ultrathins taken from these sections, viewed under the transmission 
electron microscope, revealed a remarkable feature. Pseudopod formations arising 
from the epithelium of an M cell were seemingly engulfing latex microparticles from 
the lumen. Structures relating to latex microparticles could be seen within the apical 
cytoplasm below the epithelium which were comparable in size to the administered 
microparticles (refer to Figures 18-20). However, without the presence of an electron 
dense marker on the microparticles it was impossible to conclude if these were 
actually microparticles or vesicles already present within the cell. No evidence of 
uptake was found within the patches from the tissue that received 0.57µm 
microparticles. 
(b) Fluorescent microscopy analysis 
Frozen sections taken of sample A from study 2, showed excellent tissue 
preservation. Multiple follicle arrangements were observed containing a well 
preserved follicle associated epithelium (FAE)(refer to Figure 21). Fluorescence 
relating to discrete 0.94µm microparticles was present in the domes of the 
follicles 
whilst absent in the neighbouring villi. Microparticles were present at the 
dome apices 
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Figure 18 
Electron micrograph of an M cell lying within the follicle associated epithelium 
of a rabbit Peyer's patch. Latex microparticles (0.19Ecm, Mp) are in the process 
of being engulfed by pseudopodia (Pp) arising from the epithelium of the cell. 
Within the apical cytoplasm is a possible latex microparticle (Mp). Magnification 
x 26,160 
Figure 19 
High power of epithelial surface of the Al cell in Figure 18. This shows 
pseudopodia (Pp) arising from the epithelium surrounding the latex 
microparticles. Magnification x 54,980 
Figure 18 
Figure 19 
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Figure 20 
High power of the epithelium of the M cell in Figure 18. Latex microparticles 
(Mp) are clearly in contact with the epithelial surface of the cell. Magnification 
x 88,430 
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Figure 21 
Photomicrograph of a rabbit Peyer's patch showing the follicle dome (FD) 
arrangement and the neighbouring villi (v). Magnification X 25 
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(refer to Figures 22-25) but absent at the serosal layer. This result was seen in every 
section observed. In frozen sections of sample B from study 2,0.11µm microparticles 
were observed along the whole length of the serosa (refer to Figures 26-27) 
, 
even 
within the serosa underlying villi (refer to Figures 28-29). The microparticles were 
present as discrete particles and in clusters. Cryostat sections taken from Peyer's 
patch B, study 2, showed less dome preservation than the frozen sections. The serosal 
layers were, however, intact and mimicked the results found in the frozen sections; 
the presence of 0.11µm fluorescent microparticles lining the whole length of the 
serosa. To investigate whether the 0.11µm microparticles observed were a result of 
adherence to the serosa rather than transport through the patch to the serosa, frozen 
sections from sample B were processed for TEM analysis and the ultrastructure of the 
serosal observed. Microparticles were present when viewed under the TEM, however, 
due to the poor preservation of tissue it was inconclusive as to whether these 
microparticles were intra or intercellular (refer to Figure 30). 
Frozen sections of the sample A from a New Zealand white in study 3, showed 
similar results to the Netherland model. Discrete microparticles were present within 
the dome apices (refer to Figures 31-33). A few microparticles were seen transversing 
the dome but very few were present in the serosa. Frozen sections taken from Peyer's 
patch B, study 3 showed the presence of luminal microparticles trapped between the 
villi and domes. In agreement with the Netherland model, 0.11µm microparticles 
were present in the serosa with very little observed in the domes. 
In study 4, cryostat sections were cut and viewed under the fluorescence microscope. 
The preservation of tissue was good enabling intact follicle domes to 
be viewed. Both 
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Figure 22 
Photomicrograph of a follicle dome (FD) bordered by two villi (V) of a rabbit 
Peyer's patch. Fluorescent microparticles (FMp, 0.94µm) are present within the 
apex of the dome but absent from the villi. Magnification x 100 
Figure 23 
Photomicrograph of two follicle domes (FD) bordering a villus (V) of a rabbit 
Peyer's patch. Fluorescent microparticles (FMp, 0.941Lm) are present within the 
domes but absent from the villus. Magnification x 100 
Figure 22 
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Figure 24 
Photomicrograph of a follicle dome (FD) next to a villus (V) of a rabbit Peyer's 
patch. Fluorescent microparticles (0.94µm) are almost totally restricted to the 
follicle associated epithelium. Magnification x 100 
Figure 25 
Photomicrograph of a follicle dome (FD) of a rabbit Peyer's patch showing the 
presence of fluorescent microparticles (0.94µm). Magnification x 100 
Figure 24 
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Figure 26 
Photomicrograph of the serosal layer (S) of a follicle dome of a rabbit Peyer's 
patch showing the presence of fluorescent microparticles (FMp, 0.111im), 
Magnification x 100 
Figure 27 
Photomimicrograph of the serosal layer of a follicle dome of a rabbit Peyer's 
patch showing the presence of fluorescent microparticles (FMp)) (different area 
from shown in figure 26). Magnification x 250 
Figure 26 
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Figure 28 
Photomicrograph showing villi (V) of a rabbit Peyer's patch. Also labelled: the 
serosal layer (S). Magnification x 250 
Figure 29 
Photomicrograph of the serosal layer in Figure 26. The fluorescent microparticles 
(FMp, 0.111m) within this area are clearly visible. Magnification x 250 
Figure 28 
Figure 29 
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Figure 30 
(A) Photomicrograph of the serosal layer (s) of a follicle dome of a rabbit Peyer's 
patch showing the presence of fluorescent microparticles (FMp, 0.111tm). 
Magnification x 100. (B) Electron micrograph of the serosal layer of the frozen 
tissue section shown in (A). Latex microparticles (Mp) are evident. Magnification 
x 14,000. 
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Figure 31 
Photomicrograph of a rabbit Peyer's patch showing the follicle dome (FD) 
arrangement and the surrounding villi (V). Magnification x 25 
Figure 32 
Photomicrograph of the above structure in which the image has been turned 
down to emphasise the fluorescence emitted by the fluorescent microparticles 
(0.941Am). The fluorescence is almost totally restricted to the areas relating to the 
follicle domes. Magnification x 25 
Figure 31 
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Figure 33 
Photomicrograph of a follicle dome apex (FD) next to a villus (V) of a rabbit 
Peyer's patch. Fluorescent microparticles (0.94µm) are almost entirely present 
in the area relating to the follicle associated epithelium. Magnification x 250 
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the 0.093µm (yellow/green) and the 1. lµm (brilliant/blue) carboxylated microparticles 
were present at the serosa but were absent from the domes of the patch. Some luminal 
fluorescence was seen between the villi showing that luminal washing, prior to tissue 
harvest, was an inefficient method to ensure complete removal of all luminal 
contaminants. Frozen sections showed a mass of green and blue microparticles at the 
serosa but were absent from the domes. Some fluorescent sections were further 
processed for TEM (LR White resin) to investigate further if the microparticles were 
intracellular. Semithin sections (1µm) observed under the fluorescent microscope 
showed no evidence of microparticles. 
2.4.2 Chronic Feeding Studies 
Presentation of Fluorescent latex microparticles to rabbit Peyer's patches using 
a chronic feeding study 
2.4.2.1 Materials and Methods 
Two Netherland Dwarf rabbits were dosed orally with a 0.5 ml suspension of 
microparticles for 5 consecutive days. The same volume of PBS was administered to 
a control at the same time. On days 6 and 7, either no microparticles or PBS was 
administered. The animals were fasted overnight on the evening of day 7. On day 8, 
Peyer's patches, mesenteric lymph nodes and liver tissue was removed from each 
animal and immersion fixed (4% paraformaldehyde in 0.1 M phosphate buffer) 
overnight. The tissue was then transferred to 10% buffered sucrose solution. Frozen 
and cryostat sections were taken for fluorescence microscope analysis. 
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Table 7 Rabbit chronic feeding study 
Animals Microparticles 
Rabbit Length of 
Feeding 
Group A 5 days 0.94 µm Fluoresbrite TM non-carboxylated 
Group B 5 days 0.11 pm Fluoresbrite TM non-carboxylated 
Group C 5 days PBS 
Microparticles diluted 1 in 18 with PBS 
2.4.2.2 Rabbit Chronic Uptake Results 
Peyer's patches, mesenteric lymph nodes and liver from group A revealed no 
microparticles in any of the sections. A substantial amount of autofluorescence was 
present, especially in the liver samples but this was markedly different from the 
fluorescence signal emitted by the microparticles in previous experiments. Only 1 
microparticle was observed in a liver section from a rabbit in group B, no 
microparticles were found in any of the Peyer's patch material nor within the 
mesenteric lymph node sections from this group. 
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2.4.3 Discussion of Microparticle Uptake in the Rabbit 
In situ gut loops were performed on different Peyer's patches within the same animal 
to gain the maximum information from the least number of rabbits. In study 1, fine 
tissue preservation enabled intact M cells along the length of the FAE to be viewed 
under the TEM. Evidence of a phagocytotic mechanism of uptake was found at the 
site of an M cell; pseudopodia arising from the epithelium of an M cell were found 
surrounding microparticles at the epithelial surface. No such phenomenon was 
observed at the site of the normal enterocytes. This was a direct demonstration of the 
actual site and mechanism of microparticle uptake across the rabbit intestine. 
Structures thought to be microparticles were in the apical cytoplasm of the cell. In a 
comparable study using TEM, Fugimura (1986) reported a phagocytotic mechanism 
of particulate uptake in rabbits after in situ loop administration of mycobacteria 
(BCG). this study (Fugimura, 1986) highlights the problems encountered using TEM 
analysis; the electron micrographs clearly show extensions of the M cell epithelium 
surrounding the BCG outside the cell, but intracellular identification of the BCG is 
unconvincing. A phagocytotic mechanism of uptake of latex microparticles into rat 
Peyer's patches was described by Sass et al. (1990). Using scanning electron 
microscopy (SEM) microfolds on the surface of M cells were shown engulfing latex 
microparticles (0.5µm and 1.01tm) 10 minutes after administration into an in situ gut 
loop. This phenomenon was restricted to the M cells. A phagocytotic mechanism of 
uptake of latex microparticles (0.461tm) at the M cell surface was confirmed in rabbits 
by Jepson et al. (1993a) using SEM analysis. SEM enables a more rapid scan of the 
total Peyer's patch but has the disadvantage of not showing intracellular mechanisms. 
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In studies 2 and 3 two different strains of rabbit were used, the Netherland Dwarf 
(study 2) and the New Zealand White (study 3) to investigate fluorescent 
microparticle uptake after acute delivery. In both strains the 0.94µm microparticles 
were present along the apices of the follicle domes and the 0.11µm microparticles 
along the total length of the serosa from frozen sections. The localisation of the 
microparticles in the follicle domes and the absence in the villous regions indicates 
that this phenomenon was not due to luminal fluorescence swept over the tissue by 
the cutting action of the microtome knife. The frozen sections observed in these 
studies were 40µm, therefore, it was difficult to determine if the microparticles 
observed were intracellular or adhering to the surface of the follicle domes. Using the 
focus of the microscope, they did appear to lie in the plane of the section, indicating 
uptake. 
Even if the microparticles observed at the apices of the follicle domes were due to 
adherence rather than uptake, it remains a significant finding. It suggests evidence for 
receptor mediated endocytosis into Peyer's patches where initial binding to the apical 
surface is a prelude to uptake. There were very few microparticles found transversing 
the dome; this may indicate that uptake occurs in synchronous waves, after the 
completion of which the process of uptake starts again. This process seems similar 
to the one described in rabbits by Pappo and Ermak (1989). 
The presence of 0.11µm in the serosa underlying neighbouring villi seemed a curious 
finding, although, it agrees with those of LeFevre et al. (1978), who reported the 
transport of latex microparticles (2µm) to villi adjacent to the domes after uptake into 
the Peyer's patches of mice. TEM processing of frozen sections (0.11µm 
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microparticles administered) carried out to distinguish if the fluorescence observed 
at the serosa was intracellular or a string of luminal fluorescence adhering to the 
serosal layer was inconclusive due to the poor preservation of tissue after TEM, but 
microparticles were certainly present within the area relating to the serosa. 
The results presented in this thesis indicate that uptake across the FAE and through 
the patch is an extremely rapid process, In study 2 and 3 the microparticles were left 
in the loop 40 minutes and 15 minutes respectively. Pappo and Ermak (1989) reported 
the uptake of fluorescent microparticles (600-750nm) across the FAE of rabbits within 
10 minutes. Similar rates were reported by Jepson et al. (1993a) in rabbits and in a 
study by Sass et al. (1990) latex microparticles were found in the basal regions of the 
Peyer's patches and lymphatic capillaries within 10 minutes in rats. 
Study 4 was conducted to investigate the effect of microparticulate charge on uptake. 
LeFevre et al. (1978), Herzog et al. (1983) and Jani et al. (1989) reported that 
chemical solvents (xylene, propylene oxide and ethanol respectively) may dissolve 
latex, therefore, to eliminate completely its possibility, half of the Peyer's patch 
material taken from study 4, was immediately placed in liquid nitrogen and cryostat 
sections were taken. The same extent of microparticle uptake was observed. Both the 
0.0931tm and 1.1µm carboxylated latex microparticles were found at the serosal layer 
of the Peyer's patches. The microparticles were virtually absent from the dome areas. 
This contrasts with the findings of study 2 and 3, where 0.941, tm non-carboxylated 
microparticles were restricted to the dome. This indicates that charge is a factor in 
microparticle uptake. Jani et al. (1989) reported that carboxylated microparticles were 
taken into rat Peyer's patches to a lesser extent than non-carbo xylated. 
In studies 
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presented in this thesis, it seems that carboxylated microparticles are taken into rabbit 
patches and transported to the serosal in greater numbers, although, the results are 
not unequivocal because of the difficulty in determining if the microparticles found 
at the serosa were the result of uptake through the patch or contamination by luminal 
overflow when the Peyer's patch was removed from the intestine. Some frozen 
sections were further processed for TEM. LR White embedding medium was used as 
this avoids the use of propylene oxide. Preservation in the LR White tissue was not 
as good as the epoxy resin as previously; the tissue easily fragmented when cutting 
ultrathins. Semithins viewed under the fluorescent microscope showed no presence 
of microparticles. This may be a limitation in the technique (poor preservation of 
tissue) rather than lack of uptake. 
The lack of microparticles found in the rabbit chronic feeding study was surprising; 
only one, 0.11µm microparticle was found in a liver section. Peyer's patches, 
mesenteric lymph node and liver tissue were extensively analysed for the presence of 
microparticles. The lack of microparticles may have been a result of the short feeding 
regime, namely 5 days. The possibility also exists that the microparticles were not 
reaching the patches in the numbers required for uptake, the majority being flushed 
out with the luminal contents. 
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2.5 GENERAL DISCUSSION OF MICROPARTICLE UPTAKE IN THE 
RABBIT AND RAT 
Considering the results gained from the two animal models, more evidence of 
microparticle uptake was achieved in the rabbit. This may be a result of the amount 
of Peyer's patch tissue in the two species. The size of the patch in rabbits may reach 
10mm2 whilst that of the rat measures approximately 5mm2, therefore, considerably 
more follicle-associated epithelium is available in the rabbit. Under the light 
microscope, the arrangement of the follicles differ. In the rabbit the lymphoid follicles 
consist of a multiple array of domes whilst in the rat one dome is characteristic. The 
number of M cells in the FAE of rabbit is far greater than in the rat. Pappo (1988), 
reported over 50% of the FAE of the rabbit being made up of M cells; in the rat, 
only about 5- 10% of the FAE consists of M cells (Smith et al. 1980). If M cells are 
the site for microparticulate uptake, and our results would suggest this, then a greater 
uptake will occur in rabbits. The appearance of pseudopodia above intracellular 
microparticles in both species indicates a phagocytotic mechanism of uptake common 
to both species. The main problem using TEM for analysis of latex microparticles is 
the similarity between the particles and structures already present within the cell. For 
this reason, the mechanism of microparticle transit through the cells could not be fully 
determined. 
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CHAPTER 3 
ELECTRON DENSE MARKERS FOR THE 
IDENTIFICATION OF MICROPARTICLE UPTAKE 
USING TEM ANALYSIS 
3.1 INTRODUCTION 
When an electron beam is fired at a heavy metallic element in a transmission electron 
microscope, the electrons are deflected or stopped due to the electron dense cloud 
surrounding the metal. This phenomenon causes the heavy metal to appear dark when 
viewed under the TEM. This has been exploited for use TEM staining. Particulate 
gold is an electron dense material which has been used extensively in TEM as a 
cytochemical marker (Beesley 1985, Herzog and Farquhar 1983). Latex is electron 
lucid making its identification in tissue difficult under TEM, with an appearance 
similar to structures in the cell. This was the major difficulty when using latex 
microparticles to characterise uptake across lymphoid tissue (refer to Chapter 2). To 
trace clearly microparticle uptake through the cells of Peyer's patches an electron 
dense particulate or marker was required. For this reason particulate gold was used 
in uptake studies performed in rabbits. 
Two strategies were employed; either (a) native colloidal gold particulates 100-150nm 
or (b) colloidal gold (10nm) labelled latex microparticles. 
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3.2 MATERIALS AND METHODS 
Microparticles 
Polybead amino microspheres 0.50µm (2.5 % solids-latex) (Polyscience Laboratories). 
Covospheres FX fluorescent microparticles 0.51tm (Duke Laboratories UK). 
Biotinylation of latex microparticles (Hnatowich et al. method, 1987) 
25 mg of amino latex microspheres was resuspended in 1 ml of bicarbonate buffer 
(50mM, p. H. 8.5). 0.4 mg NHS-LC-Biotin (Pierce, USA) was added and placed on 
ice for 2 hours. To remove unwanted biotin the mixture was centrifuged at 1000g for 
15-30 minutes. After centrifugation the sample was diluted with 0.1M phosphate 
buffer p. H. 7.0. This was repeated two more times. 
Biotinylation of latex microparticles (Sytowski method, 1990) 
Briefly, 100 µl of Covosphere microparticles were washed twice with phosphate 
buffered saline (PBS pH 7.2), centrifuged at 10,000 g for 6 minutes and sonicated for 
5 minutes. NHS-LC-biotin (Pierce USA) (750 Al in PBS) was added to the 
microparticles and the mixture was gently rotated for 60 minutes at room 
temperature. The biotinylated microparticles were then washed 3 times with PBS and 
dialysed against PBS overnight to remove excess NHS-LC-biotin. 
Conjugation of streptavidin-gold (10nm) to biotinylated microparticles 
30ul of biotinylated microparticles was added to 30u1 of streptavidin-gold (diluted 1 
in 100 with dilution buffer) and left 1 hour at room temperature. This was spun at 
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10,000 R. P. M. for 5 minutes. The pellet was resuspended in 30u1 PBS. This was 
repeated 3 times. The pellet was finally resuspended in 30ul of PBS. 
Anti-biotin-Colloidal gold labelling of biotinylated microparticles 
To label the biotinylated microparticles with colloidal gold, the method of Sytowski 
(1990) was used. The biotinylated microparticles were sonicated for 10 minutes, 10 
µl of anti-biotin-colloidal gold (Biorad)(10 nm) was then added to 100 µl of the 
microparticles and rotated gently for 25 minutes at room temperature. The preparation 
was centrifuged at 10,000 rpm for 6 minutes, the supernatant was removed and the 
microparticle pellet was resuspended in 200 µl of PBS (pH 7.2). 
3.3 COLLOIDAL GOLD PARTICULATES 
3.3.1 Preparation 
Colloidal gold particulates were prepared using a method adapted from Frens (1973). 
The objective was to prepare gold particulates large enough (100-150nm) to use as 
an electron dense microparticulate in uptake studies. The method involved two stages 
(1) the formation of a gold sol by the chemical reduction of gold chloride by sodium 
citrate and (2) stabilisation of the gold sol by protein adsorption. 
Protocol for the preparation of gold particles 100-150nm in size: 
(u) 50 mis of gold chloride (AuC14,0.01 % by weight) was heated to 60°C 
(boiling point). 
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(b) 0.16 mis of sodium citrate (Nacitrate, 1% by weight) was added to the gold 
chloride, a reflux condenser applied and the mixture kept boiling for 30-40 
minutes (the colour of the mixture at this stage was red/pink which indicated 
the completion of gold particulate formation) 
(c) The gold sol is allowed to cool. 
(d) 1 ml of PEG 20,000 was added to 40 mis of the gold sol (1 % v/v) and the 
mixture centrifuged at 10,000rpm for 10 minutes (or until there is no colour 
in the supernatant). 
(e) The supernant is discarded and the pellet resuspended in 1 ml of phosphate 
buffer (10mM p. H. 7.2). 
3.3.1.1 Results 
The gold particulates were placed on a coated grid and observed under the 
transmission electron microscope (refer to Figure 34-35). In accordance with the 
method described by Frens (1973) large particulates up to 100nm were produced by 
reducing the volume of sodium citrate. The particulates were polydispersed with 
respect to size, ranging from 30-100nm, and very electron dense. The gold sol must 
be stabilised in order to avoid flocculation when electrolytes are added, this is 
maintained by electrostatic attractions between the gold and proteins adsorbed to their 
surface to give a gold-protein complex (Park 1989). In this experiment PEG (20,000) 
was used. If the gold is not stabilised the colour changes from a claret red to blue 
showing flocculation has taken place. These particulates were used to investigate 
particulate uptake into Peyer's patches. 
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Figure 34 
Electron micrograph of a colloidal gold particulate. Magnification x 219,394 
Figure 35 
Electron micrograph of colloidal gold particulates. Magnification x 127,980 
Figure 34 
Figure 35 
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3.3.2 Presentation of Colloidal Gold Particulates to Rabbit Peyer's Patches via 
Closed Intestinal Loops 
3.3.2.1 Materials and Methods 
Male New Zealand White rabbits were fasted overnight. They were anaesthetised and 
in situ intestinal loops formed around the Peyer's patches. The gold particulates were 
injected into the loop and left for 30 minutes. In rabbit 2, the lumen of the gut was 
rinsed with 1% bovine serum albumin prior to the injection of the gold. The Peyer's 
patches were then removed and immersion fixed in 3% gluteraldehyde in 0.1 M 
phosphate buffer and processed for TEM analysis. 
Table 8 Colloidal gold particulate uptake studies 
Animals Microparticulates 
Rabbit Dose Time in 
NZW loop 
STUDY 1 1.0 ml 30 min Colloidal gold particulates stabilised with 
PEG 20 000 
Resuspended in PBS 
STUDY 2 1.0 ml 30 min Colloidal gold particulates stabilised with 
1% bovine serum albumin 
Resuspended in PBS 
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3.3.2.2 Results of Colloidal Gold Uptake 
The structure of the Peyer's patches from both studies showed good preservation 
when viewed under the TEM. Ultrathin sections of M cells were isolated and viewed 
under the TEM. No evidence of colloidal gold particulates inside the cells was found. 
Luminal colloidal gold was, however, evident at the luminal surface (refer to Figure 
36-37). 
The problem with the colloidal gold particulate was that of polydispersity with respect 
to size. The range was 30-100nm, therefore, difficulties were encountered in clearly 
identifying the particulate even though they were electron dense under the TEM. A 
more monodispersed population would have been more advantageous for identification 
purposes. 
In study 2, the rational behind stabilising the gold particles with bovine serum 
albumin was to enhance uptake by making the particulate more antigenic. Other 
workers have documented that antigenicity can enhance uptake. Rinsing the lumen 
with BSA before particulate administration was to prime the M cells antigenically, 
however, there was no difference between the evidence gained from study 1 and 2, 
although, the reason may be the small size and administered dose of the particulate. 
For exact identification, a monodispersed electron dense particulate was required. It 
was decided to combine the electron density exhibited by colloidal gold and the 11 
monodispersity shown by latex microparticles, by labelling the surface of latex 
microparticle with colloidal gold. 
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Figure 36 
Electron micrograph showing a colloidal gold particulate (CGP) on the luminal 
surface of an enterocyte within the follicle associated epithelium of a rabbit 
Peyer's patch. Magnification x 12,852 
Figure 37 
High power of the enterocyte shown in figure 36. The colloidal gold particulate 
(CGP) is clearly visable. Magnification x 54,978 
Figure 36 
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3.4 COLLOIDAL GOLD LABELLING OF LATEX MICROPARTICLES 
3.4.1 Preparation 
(a) Hnatowich et al. method. 
The initial approach used was a two step method using the avidin (streptavidin) 
- 
biotin system: 
i) Conjugation of biotin to the surface of latex amino microparticles (0.50µm) 
(modified from that of Hnatowich et al. (1987) for biotinylating immunoglobulins). 
A substitution reaction occurs between the amine groups on the microparticles and the 
NHS-LC-biotin ester to link biotin through an amide bond to the surface of the 
microparticles and ii) formation of a complex between biotin (on the surface of the 
microparticles) and streptavidin (conjugated to a colloidal-gold probe, 10nm) to label 
the surface of the microparticles with colloidal gold. (refer to Figure 38). 
(for full details refer to materials and methods section) 
Viewed under the TEM, there appeared to be no gold attached to the latex 
microparticles (refer to Figure 39). This may have been due to a low level of biotin 
conjugated to the microparticles. Little information concerning the amino groups on 
the microparticles were disclosed by Polyscience, therefore there may have been a 
lack of available amino groups on the microparticles for adequate biotinylation. For 
this reason a different method of biotinylating latex microparticles was used; 
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Cross section 
(b) Sytowski method. 
Adapting the method of Sytowski (1990), biotin was conjugated via amino groups on 
the surface of fluorescent latex microparticles (0.5µm, obtained from Duke Scientific) 
using NHS-LC-Biotin. 
Streptavidin-colloidal gold (10nm) conjugation was carried out as before. 
(refer to materials and methods section). 
The gold labelled microparticles were placed on a coated grid and viewed under the 
TEM. Colloidal gold (10mu) was clearly attached to the latex microparticles (refer 
to Figure 40). These microparticles also emitted a strong fluorescence when viewed 
under the fluorescence microscope, therefore, confirming the availability of a double 
label for use in fluorescence and electron microscopy. The amount of colloidal gold, 
however, was not as much as expected. The density of the gold was fainter than 
before; an indication that the reagents were losing their potency in storage. The use 
of antibiotin-colloidal gold instead of streptavidin-colloidal gold was a possible 
remedy for this. The low amount of gold on the microparticles may have been due 
to gold conjugation when suspending in PBS of high molarity (500mM). The 
incubation time of the streptavidin-gold with the biotinylated microparticles may also 
have been too short. 
All these parameters were investigated by changing the conditions described; 
(a) Fluorescent latex Covasphere + anti-biotin gold (10nm, washed and 
resuspended in 500mM PBS) 
(b) Fluorescent latex Covasphere + anti-biotin gold (l0nm, washed and 
resuspended in 10mM PBS) 
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Figure 39 
Electron micrograph showing latex microparticles (unsectioned) with no colloidal 
gold label (Hnatowich method). Magnification x 18,650 
Figure 40 
Electron micrograph showing latex microparticles (unsectioned) with colloidal 
gold (CG, 10nm) associated with the surface (Sytowski method). Magnification 
x 88,430 
Figure 39 
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(c) Fluorescent latex Covasphere + streptavidin gold (10mu, washed and 
resuspended in 10mM PBS) 
All samples were incubated for 1 hr 15 min. 
The greatest amount of labelled gold was found in (b), using anti-biotin-gold and 
10mM PBS (refer to Figures 41). In (c) the amount of gold label increased by using 
10mM PBS and 1 hr incubation but not as much as for the anti-biotin gold. It was 
decided to conduct an acute study in the rabbit using gold labelled microparticles 
prepared with the conditions described in (b). 
3.4.2 Presentation of Colloidal Gold Labelled Latex Microparticles to Rabbit 
Peyer's Patches via Closed Intestinal Loops 
3.4.2.1 Materials and Methods 
A New Zealand White rabbit was fasted overnight. It was anaesthetised and in situ 
gut loops formed around two Peyer's patches. The lumen of the rabbit was rinsed 
extensively with PBS (10mM) prior to injecting the microparticles into the loop. The 
microparticles were left in the loop for 15 minutes. The Peyer's patches were then 
removed and immersion fixed either in 3% glutaraldehyde in 0.1 M phosphate 
buffer 
and processed for TEM analysis or 4% paraformaldehyde and processed 
for 
fluorescence analysis. 
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Table 9 Colloidal gold labelled latex microparticle uptake studies 
Animals Microparticles 
Rabbit Dose Time in 
Peyer's loop 
patch 
A 2.0 ml 15 min gold-labelled Covaspheres 0.51tm 
diluted 1 in 30 with PBS 
B 2.0 ml 15 min Covaspheres 0.51tm 
diluted 1 in 30 with PBS 
2.4.2.2 Results of Gold Labelled Microparticle Uptake 
Frozen sections of sample A and B showed a fine follicle dome arrangement; 
microparticles were restricted to the domes of the patches but absent from the villi 
when viewed under the fluorescence microscope. Sample A tissue was processed for 
TEM. Ultrathin sections were taken from areas populated by M cells. Within one M 
cell was a microparticle which clearly showed the colloidal gold label (refer to Figure 
42). The microparticle was intercellular, indicative of a paracellular pathway of 
transport through the cell. Other similar structures were also found (refer to Figure 
43) but these were not as well defined as those found in Figure 42. 
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Figure 41 
Electron micrograph showing colloidal gold labelling of latex microparticles 
(0.51tm Covaspheres) using the biotin/antibiotin bridge. (A) Unlabelled latex 
microparticles (0.5µm Covaspheres). (B) Colloidal gold particulates (10nm). (C) 
Latex microparticles (shown in A) labelled with colloidal gold, 10nm (shown in 
B), unsectioned. (Magnification A-C x 56,400). (D) Higher power of the labelled 
microparticle shown in C. (Magnification x 100,000). 
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Labelling of latex microparticles for visualisation in tissue under TEM. (A) 
Electron micrograph showing latex-biotinylated/antibiotin-colloidal gold 
microparticles (0.50µm) used in this study, unsectioned (Magnification x 30,300). 
(B) Electron micrograph showing an M cell (M) of a rabbit containing a latex- 
biotinylated/antibiotin-colloidal gold microparticle (Mp, 0.50µm) (Magnification 
x 5632). (C) Higher power of the latex microparticle shown in (B) (Magnification 
x 25,800). 
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Figure 43 
Electron micrograph showing a cluster of latex microparticles (0.5µm) labelled 
with colloidal gold (Mp) within a paracellular compartment of an M cell. 
Magnification x 47,120 
JIFP 
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3.5 DISCUSSION 
The rational behind using colloidal gold, either as a particulate itself or as a marker 
on the surface of latex microparticles, was to achieve unequivocal identification of 
particulates inside cells. Under the TEM, particulate gold 30-100nm was electron 
dense but was very polydisperse with respect to size. Little evidence was achieved in 
the uptake studies performed in the rabbit using these particulates. This may have 
been due to the dose administered rather than lack of identification. Colloidal gold 
markers on the surface of latex microparticles were more precise because of the 
monodispersity shown by the latex. The greatest amount of labelling was achieved 
with the Covaspheres using anti-biotin gold. A strong fluorescent signal was also 
emitted with these microparticles. In the uptake study performed with these 
microparticles only a few microparticles were apparent. These microparticles, 
however, were intercellular, indicating that the paracellular compartment is a 
component in the pathway for particulate transport from lumen to lymph. Childers et 
al. (1990) has suggested that liposomes are transported through the intercellular space 
of rat Peyer's patches, whilst Owen et al. (1986) demonstrated that Vibrio cholerae 
was transported through rabbit M cells in the intercellular spaces. Aprahamian et al. 
(1987) reported the presence of polyalkylcyanoacrylate nanoparticles (100-200nm) in 
the intercellular spaces of intestinal enterocytes. A more recent study by Damge et 
al. (1991) reported a paracellular pathway of nanoparticles after uptake over rat 
Peyer's patches. The low numbers of microparticles observed in my study could 
be 
due a low dose and the small areas analysed under TEM. 
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CHAPTER 4 
QUANTITATION OF MICROPARTICLE UPTAKE 
ACROSS THE INTESTINAL EPITHELIUM 
4.1 INTRODUCTION 
To exploit the mechanisms of uptake described (refer to previous chapter) for the 
delivery of an oral vaccine in microparticles it was important to quantify the 
microparticulate uptake across the intestinal barrier. The most contentious issue 
surrounding this phenomenon is the degree of uptake. Many workers have 
investigated this, using analytical methods to count the numbers of microparticles in 
isolated tissue sections after the oral or intraluminal administration of microparticles 
(refer to section 1.5.3. ). 
Evidence suggests that absorbed microparticles are removed from the gut wall into 
draining lymph vessels (LeFevre et al. 1978, Eldridge et al. 1990, Jani et al. 1989, 
1992, refer to section 1.5.2. ). The mucosal efferent lymphatics merge to form the 
superior mesenteric lymph duct. This duct discharges into the cysterna chyli which 
in turn becomes the thoracic duct (refer to Figure 44). 
The approach used, in this thesis, to quantify microparticle uptake across the intestine 
was to administer a dose of microparticles either orally or intraduodenally to rats, and 
cannulate the superior mesenteric and thoracic ducts and count the number of 
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Figure 44 Migratory pathway of lymph draining the intestine 
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microparticles within the draining lymph. Fluorescent latex microparticles of similar 
sizes to those used to characterise uptake in chapter 2 were employed in these studies. 
In addition, microparticles composed of poly(lactide-co-glycolide) (PLG) containing 
a fluorescent dye (rhodamine) were used to assess directly the feasibility of using an 
antigen delivery system (refer to section 1.4.4. ) for oral vaccines. 
Two methods of detection were used to count the numbers of fluorescent 
microparticles in lymph; (a) manual counting under the fluorescence microscope and 
(b) flow cytometry. 
4.2 MATERIALS AND METHODS 
Animals 
The rat was the animal model used in the quantitative uptake studies that were 
performed. 
Adult male Wistar rats (thoracic drainage) 300-400 grams 
Adult male Wistar rats (mesenteric drainage) 140-180 grams 
The animals were obtained from the Department of Biomedical Services, University 
of Nottingham. 
Microparticles 
Fluorescent polystyrene microparticles 0.15µm (Polyscience laboratories, Warrington. 
PA, U. S. A. ) 
Fluorescent polystyrene microparticles 1. Oµm (Polyscience laboratories, Warrington, 
PA, U. S. A. ) 
11-16 
Poly(DLlactide-co-glycolide) 50: 50 rhodamine microparticles 1.10µm. (Produced in 
this work, refer to Appendix 3). 
Surgical Procedures: 
1) Cannulation of the thoracic duct in the rat 
This procedure was undertaken in Germany at the University of Kiel, Department of 
Experimental Surgery under the direction of Dr. W. Sass. 
The method of cannulating the thoracic duct was adapted from that described by 
Bollman et al. (1948) and Seifert and Sass (1991 personal communication). Adult rats 
300-400 grams, which had been fasted for 24 hours, were anaesthetised. This was 
achieved by placing the animal in an ether filled bucket. When the animal was sedated 
an intraperitoneal injection of chlorohydrate (2 ml) was administered. The 
consciousness of the animal was tested by the deep tendon reflex and was monitored 
throughout the surgical procedure. The abdominal hair was shaved and an incision 
made approximately 2 cm long, exposing the abdominal cavity. Using cotton buds the 
intestine was carefully wrapped in moist cotton gauze (soaked in physiological saline 
maintained at 37°C) and laid to the right of the animal. The suprarenal abdominal 
aorta was localised and using a pair of curved anatomical forceps the connective 
tissue teased away by an opening and closing action parallel to the aorta. The thoracic 
duct (distinguished by milky white appearance of the contained lymph) was then 
teased away from the aorta and the connective tissue using the same instrument. A 
ligature was tied around the thoracic duct just posterior to the diaphragm (for 
preparation of ligatures refer to Figure 6), which resulted in the formation of a 
reservoir of lymph with the concomitant dilation of the thoracic duct. Two loose 
ligatures were prepared around the thoracic duct approximately 10 mm apart. 
Using 
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a pair of fine scissors an incision was carefully made 10 mm below the ligature. A 
cannula of perspex tubing (Portex, 0.5 mm internal diameter and 1.0 mm external 
diameter), was filled with heparin and inserted into the opening of the duct and 
pushed 5 mm into the duct using watchmakers forceps. The cannula was prepared 
with aU turn to allow a parallel lie. The cannula was then secured in place by 
tightening the two loose ligatures. The cannula was secured to the abdominal muscle 
using a suture and allowed to hang over the side of the dissecting bench. To allow 
gravitational flow, the length of the cannula was approximately 10 cm below the level 
of the rat. The abdominal cavity was closed using clips and the lymph was collected 
in Epindorf tubes attached to the end of the cannula. 
2) Cannulation of the superior mesenteric lymph duct in the rat. 
The method of cannulating the superior mesenteric lymph duct was adapted from that 
described by Bollman et al. (1948). Adult rats 170-180 grams were anaesthetised 
using an intraperitoneal injection of Nembutal (pentobarbitone sodium BP 60 mg/ml; 
0.1 ml of Nembutal/ 100gms of body weight). The level of anaesthesia was tested by 
the deep tendon reflex and constantly monitored during the surgical procedure. 
The animal was placed on an heated dissecting table (37 °C) and the abdominal cavity 
was opened by making a cruciate incision along the midline. Using cotton buds, the 
stomach and intestine were laid to the left of the animal and wrapped in gauze soaked 
in phisiological saline (37°C). The superior mesenteric lymph duct was identified by 
the milky white appearance of the contained lymph to the left of the right kidney. 
The 
cannula consisting of a 20 cm length of perspex tubing (Portex 0.5 µm internal 
diameter, 1. Oµm external diameter) was filled with heparin. Using anatomical 
forceps, a hole was pierced through the connective and fat tissue underlying 
the right 
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kidney, and the cannula taken within the tips of the forceps and drawn back through 
under the kidney so that the cannula was lying parallel to the mesenteric lymph duct. 
Using fine scissors, a small incision was made in the mesenteric lymph duct. The 
cannula was then fed into this hole and pushed 5 mm into the duct, a thin layer of 
connective tissue overlying the duct ensured the duct was rigid. When the lymph was 
flowing through the cannula it was held in place by the addition of a drop of 
cyanoacrylate adhesive at the site of insertion and the abdominal muscle. The 
abdominal cavity was then covered in moist gauze soaked in physiological saline 
(37°C). The cannula was extended below the level of the dissecting table and lymph 
collected in Eppindorf tubes. 
Microparticle detection methods 
The flow cytometric analysis was performed by Dr. P. J. Jenkins using an EPICS V 
flow cytometer (Coulter Electronics Ltd, Luton, U. K. ). 
The microscopic detection method is described in the Appendix 3 
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4.3 THE QUANTITATION OF THE ABSORPTION OF MICROPARTICLES 
INTO THE THORACIC LYMPH OF RATS 
4.3.1 Materials and Methods 
A male Wistar rat (320 gms. ) was anaesthetised and the thoracic duct was cannulated 
according to the method described (section 4.2. ). 
When the lymph was flowing from the cannula, 1.7 mis. of a suspension (0.025 gms 
microparticles made upto 4 mis with distilled water) of PLG rhodamine microparticles 
(1.10µm) were administered orally using a gastric tube. The thoracic lymph was 
collected in 15 minutes aliquots over 3 hours and stored at 4°C. The number of 
microparticles in each lymph sample was calculated using the microscopic detection 
method described in Appendix 3. 
4.3.2 Results 
The numbers of microparticles found in each lymph sample was extremely low, 
reflected in the total levels found 2.9 x 10-6% of the administered dose. The uptake 
of the microparticles into the thoracic lymph was a rapid event with maximal levels 
of microparticles found in the lymph only 15 minutes after microparticle 
administration. The temporal levels of microparticles found in the lymph can be seen 
in Figure 45. The microscopic analysis was time consuming and laborious but it 
enabled a direct observation of the microparticles. The microparticles were found to 
he intercellular with some closely associated with lymphocytes (refer to Figure 46). 
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Figure 46 
Photomicrograph showing rhodamine labelled PLG microparticles (Mp) in a 
sample of thoracic lymph. Some microparticles are closely associated with 
lymphocytes (L). Magnification x 400 
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4.4 THE QUANTITATION OF THE ABSORPTION OF MICROPARTICLES 
INTO THE MESENTERIC LYMPH OF RATS 
4.4.1 Materials and Methods 
Male Wistar rats (140-180 gms) were anaesthetised and the mesenteric lymph 
cannulated according to the method described (section 4.2. ). 5 minutes after the 
lymph was flowing from the cannula, 1 ml of either 0.15µm (approximately lx 1013) 
or 1. Oµm (approximately 1x1010) fluorescent latex microparticles were intraduodenally 
administered close to an observable Peyer's patch in groups of rats (n=5). Special 
care was taken to ensure that none of the microparticles contaminated the area where 
the cannula was inserted. A control group (n=2) were given 1 ml of saline 
intraduodenally. Lymph was collected from the cannula over a period of 90 minutes, 
in 5 minute aliquots and stored at 4°C. The number of microparticles in each sample 
was measured using the flow cytometric method. 
4.4.2 Results 
The flow cytometric analysis enabled a rapid and accurate calculation of the number 
of microparticles present in the mesenteric lymph. Microparticle absorption across the 
intestine, indicated by the numbers of microparticles found in the mesenteric lymph, 
occurred at a rapid rate but at low levels (refer to Figures 47-48 and Table 10). Both 
the 0.15µm and 1.01tm microparticles were found in the lymph 5 minutes after 
administration. Similar times for the maximal numbers were found for both sizes of 
microparticles; 35 minutes and 65 minutes for the 0.15µm and 25 minutes and 
65 
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Table 10 Times and levels of maximal absorption of 0.151tm and 
1. Oµm latex microparticles to the mesenteric lymph in rats. 
Time of maximal Maximal number of Total number of particles Theoretical volumetric 
absorption of particles absorbed absorbed to the lymph carrying capacity of total 
microparticles (% dose) (% determined by AUC). number of absorbed 
particles (µl). 
0.15µm 65 minutes 2059 50006 0.88 
particles (2 x 10-8 %) (5 x 10' %) 
1.0µm 65 minutes 2617 49964 36.9 
particles (2.6 x 10-5 %) (5 x 10' %) 
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minutes for the 1 
. 
0µm microparticles. The amount of microparticle absorption, 
expressed as a percentage of the dose was low; 5x104% for the 1 
. 
Oµm and 5x10-7% 
for the 0.15µm microparticles. 
4.5 DISCUSSION 
The techniques presented here represent a valid approach to elucidate the numbers of 
microparticles crossing the intestine. Although it is generally accepted that, after 
intestinal uptake across lymphoid tissue, microparticles are carried by the lymphatic 
vessels, no direct evidence of microparticles in the lymph has been reported; previous 
evidence being based on microparticle detection in isolated mesenteric lymph node 
and systemic tissues (LeFevre et al. 1978, Eldridge et al. 1990, Jani et al. 1989, 
1992). In contrast, the present method directly measures microparticles in flowing 
lymph derived from the intestine; the superior mesenteric duct receives lymph from 
most of the lymphatics draining the intestine while the thoracic duct receives lymph 
from peripheral tissues including the liver in addition to the intestine, 95 % of cells 
in the thoracic lymph are derived from the nodes draining the intestine. 
The results of the present studies clearly demonstrate lymphatic transport of absorbed 
inicroparticles. Additionally, the profiles for absorption can be interpreted as 
indicating a cyclic pattern. Microparticles were found in both the mesenteric and 
thoracic lymph 5 minutes after administration suggesting an extremely rapid uptake 
across the intestine. This agrees with the findings of Sass et al. (1990) who 
demonstrated the uptake of latex microparticles across rat M cells into the lymphatic 
capillaries within 10 minutes. Similarly, Pappo and Ermak (1989) reported that 
137 
microparticles crossed the follicle-associated epithelium in the rabbit within 10 
minutes. The rapid rate of uptake of microparticles into the lymph also correlates with 
our findings of microparticle uptake across the follicle associated epithelium to the 
serosa within 15 minutes of intraluminal administration in the rabbit (refer to chapter 
2). In contrast, Sanders and Ashworth (1961) reported that microparticles were found 
in the intestinal lymphatics 2-4 hours after oral administration in rats, although this 
may just have been a reflection of the times tissue was sampled. 
The extent of intestinal uptake found in the present studies was low if expressed as 
a percentage of the administered dose; 2.9x 10-6 (1.10µm) in the thoracic and 5x 10-4 
(1.01tm), 5x10-' (0.15µm) in the mesenteric lymph. This does not reflect total uptake, 
however, because no attempt was made to quantify microparticles in the systemic 
tissues. These low levels correlate with the limited amount of microparticle uptake 
found in the TEM and fluorescent studies performed in chapter 2. The PLG 
microparticles were polydisperse with respect to size (refer to Figure 49) which 
presented a problem when counting under the microscope. The strong fluorescence 
signal emitted by the rhodamine, however, made identification relatively easy. The 
manual counting method was very time consuming. In contrast, the flow cytometric 
method represented a very efficient and accurate detection method. Interestingly, 
similar temporal profiles and low levels were found using the microscopic and flow 
cytometric detection methods. Although the data from the thoracic drainage represents 
only one animal, these levels are in agreement with the levels of latex microparticle 
in thoracic lymph measured by the manual counting method in experiments conducted 
by the group led by Professor J. Seifert, Kiel, Germany (personal communication). 
The levels of microparticle uptake in the present study agree with a number of studies 
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Figure 49 
Scanning electron micrograph of PLG 
rhodamine. Magnification x 52,000 
(50: 50), microparticles containing 
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investigating uptake; LeFevre et al. (1977) reported that 0.01 % of radioiodinated 
latex microparticles (170-227nm) were taken across the intestine in mice after a single 
gavage. This estimate was calculated by measuring the radioiodinated label in the 
body tissue. The levels in the study conducted by LeFevre et al. (1977) may not be 
totally accurate, however, due to the instability of the label on the microparticles. 
Using a flow cytometric detection method, similar to the one used in our mesenteric 
studies, Ebel (1990), also found less than 0.01 % of an oral dose of fluorescent latex 
microparticles (2.651tm) in mice was taken across the intestine, estimated by the 
numbers in Peyer's patch, mesenteric lymph node and spleenic tissue. Interestingly 
the levels were found to be greater in fed mice as opposed to fasted animals, Ebel 
(1990) attributed this to a possible increase in M cell activity due to increased luminal 
contents. 
Jepson et al. (1993a) used confocal microscopy to measure the uptake of latex 
microparticles across rabbit lymphoid tissue. They found that 5x10-5% of a dose of 
fluorescent polystyrene microparticles (0.461im) was taken across the follicle 
associated epithelium. This figure was calculated by counting the amount of 
microparticles within the FAE of each Peyer's patch dome (1 x 105 microparticles per 
dome). Also in the rabbit, Pappo and Ermak (1989) reported that 5% of an 
intraluminal dose of fluorescent microparticles (600-750nm) was taken across the 
follicle associated epithelium as detected by fluorescent microscopy analysis of 
Peyer's patch tissue. This was an order of magnitude greater than the amount of 
microparticle uptake found in the murine model (Pappo and Ermak 1989). Pappo and 
Ermak reasoned that this may be a result of the greater number of M cells 
found in 
140 
the rabbit; 50% of the follicle associated epithelium in rabbits is composed of M cells 
(Pappo et al. 1988) as opposed to 5-10% in rats (Smith 1980). 
In contrast to the low levels described, much higher levels of intestinal uptake of 
microparticles has been reported; Alpar et al. (1989) claimed that 39% of an oral 
dose of latex microparticles (1.1µm) given to rats was found in blood 45 minutes after 
administration. This seems an extraordinary finding especially when no mechanism 
or route across the intestine was demonstrated. High levels of intestinal uptake was 
also described by Jani et al. (1990); in this study latex microparticles (50nm and 
100run) were fed to rats for 10 days, isolated tissue was then digested and an assay 
was used to measure the amount of latex present. Levels of microparticulate uptake 
of 34% for the 50nm and 26% for the 100nm were reported. The problem with this 
analytical method was that it did not disassociate those microparticles adhering to the 
luminal surface of the intestine from those taken across the intestine. Jani et al. 
(1990) suggested that uptake into isolated tissue would reflect a more accurate 
assessment; giving levels of 7% (50nm) and 4% (100nm) of the dose. 
The various uptake levels reported seem to fall into one of two catorgories: (a) less 
than 0.01 % and (b) 5% and over. The differing reported levels of microparticle 
uptake are probably a result of the different experimental and analytical detection 
methods employed as well as the species used in the study. 
In the present studies a greater level of uptake was found for the 1.0µm latex 
microparticles (5x 10-4% of the dose) than the 1.0µm PLG microparticles (2.9x 10 ö% 
of the dose). This is an important finding for the development of PLG microparticles 
gis an antigen delivery system. However, it is unclear whether this 
is due to the 
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different techniques and detection methods used. Jepson et al. (1993b), reported that 
PLG microparticles were taken across rabbit follicle associated epithelium at similar 
levels to those found in the present studies. Using the technique of confocal 
microscopy to count the numbers in Peyer's patches Jepson et al. (1993) found the 
levels of PLG to be an order of magnitude less than they found for latex. Jepson 
et al. (1993) suggested that this reflected the greater binding capacity of the 
polystyrene to the M cells. 
Under the fluorescence microscope, samples taken from both the thoracic and 
mesenteric lymph showed intercellular microparticles. In the thoracic lymph, 
however, a proportion of the microparticles seemed to be associated with 
lymphocytes. For pathogenic microorganisms entering the host through M cells, 
phagocytosis by macrophages in the Peyer's patch represents an important defence. 
Owen et al. (1986) demonstrated the association of Vibrio cholera with macrophages 
in the central hollow of rabbit M cells whilst, Fujimura (1986) reported that 
mycobacteria were taken up by macrophages in the follicle associated epithelium of 
rabbits. 
LeFevre et al. (1978), detected latex microparticles (2µm) in macrophages within 
Peyer's patches and mesenteric lymph nodes suggesting intracellular migration. 
LeFevre et al. suggested that a proportion may migrate as: "free microparticles" 
Eldridge et al. (1990) also suggested a migratory macrophage population containing 
microparticles originating in the dome of the Peyer's patch and later found in the 
mesenteric lymph nodes and spleen. Although all microparticles were found within 
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macrophages in the patch only those less than 5µm migrated. The association of 
microparticles with macrophages within Peyer's patch follicle domes has also been 
reported by Pappo and Ermak (1989), Sass et al. (1990) and Jepson et al. (1993). 
The results from the present studies suggest that the majority of microparticles found 
in the draining lymph are transported intercellularly but there is evidence of 
microparticles closely associated with lymphocytes. The low levels of microparticles 
found in the lymph suggest that oral delivery of therapeutic drugs in microparticles 
appears improbable but the low levels of antigen required to elicit an immune 
response indicates that the delivery of an oral vaccine by this route is indeed possible. 
For an illustrated summary of the microparticle uptake findings contained in this 
thesis refer to Figures 50 
- 
51. 
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Figure 50 
Schematic representation of microparticle 
uptake findings at the ultrastructural level 
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Figure 51 
Schematic representation of the temporal movement 
of microparticles through Peyer's patches 
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CHAPTER 5 
THE FORMULATION AND CHARACTERISATION OF 
POLY(LACTIDE-CO-GLYCOLIDE) MICROPARTICLES 
CONTAINING INFLUENZA VIRUS 
5.1 INTRODUCTION 
The work conducted in chapters 2-4 has given unequivocal evidence that the primary 
route for microparticle uptake across the intestine is the Peyer's patches (refer to 
Chapters 2-4). Evidence suggests that a disseminated mucosal immune response is 
initiated at these sites (refer to section 1.3). In order to investigate the feasibility of 
this route for the delivery of a microparticulate oral vaccine, the antigen must ideally 
be incorporated into microparticles. 
The process of incorporating an antigen into a polymer matrix is termed 
microencapsulation. Various microencapsulation techniques are currently in use 
(Morris et al. 1994). Recently, the process of solvent evaporation has been employed 
extensively to microencapsulate drugs and antigens using the poly(lactide-co- 
glycolide) (PLG) copolymers (Tice and Gilley 1985, Jeffery et al. 1991). 
As previously discussed, poly(lactide-co-glycolide) microparticles have been used as 
antigen delivery systems for both parenteral (refer to section 1.4.6) and oral 
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immunisation (refer to section 1.4.6). Poly(lactide-co-glycolide) (PLG) is non-toxic 
and has been approved by the FDA for human use. The biodegradability of PLG can 
potentially be exploited to give sustained or pulse release of antigen. 
The antigen selected for microencapsulation was influenza virus. This is an ideal 
candidate for an oral vaccine for the reasons described in section 1.7. Equine 
influenza was the type of influenza used in these studies. It is a orthomyovirus (A 
group) of which there are two subtypes A/equi-1 and A/equi-2 (Paccaud, 1970). The 
pathogenesis of equine influenza mimics that in humans with initial invasion at the 
respiratory mucosa (Gerber, 1970). Outbreaks can be rapid and severe (Wood, 1988), 
leading to considerable economic cost especially in racehorse populations. The 
common vaccine in present use in Britain is composed of inactivated whole viruses 
(variants of the two subtypes) adsorbed to alum which is administered intramuscularly 
(licensed name-PREVAC). These induce short term responses (Wood, Mumford, 
Folkers et al. 1983), requiring boosters at least every 9 months, and low protection 
(Mumford, Wood, Scott et al. 1983). 
This chapter describes the production and characterisation (size, morphology and 
antigen content) of PLG microparticles containing influenza virus, the release of 
antigen from the microparticle system and the antigenic integrity of the encapsulated 
virus. 
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5.2 PRINCIPLES OF THE SOLVENT EVAPORATION 
MICROENCAPSULATION TECHNIQUE 
The basic principle is the formation of an emulsion in which microdroplets 
(comprising of polymer, drug or antigen and solvent) referred to as the discontinuous 
phase are dispersed in a continuous phase. The solvent is then removed by 
evaporation leaving microparticles consisting of the drug or antigen dispersed within 
the polymer. 
The first step involves dissolution of the polymer in an organic solvent. The antigen 
is added in lyophilised form to the polymer solution. This dispersion is then added 
to an immiscible aqueous phase containing a surfactant such as Polyvinyl alcohol and 
mixed by stirring to form an oil-in-water emulsion. The microdroplets, (a term 
described by Tice and Gilley 1985) are stabilised by molecules of the emulsifier in 
the continuous phase forming a coating around the microparticles. The organic solvent 
is then slowly removed by evaporation necessitating the use of a solvent whose 
boiling point is lower than water. The microdroplets harden as the solvent is removed 
to form stable microparticles comprising of antigen dispersed throughout the polymer 
matrix. The microparticles are harvested by a process of centrifugation and washing 
to remove excess surfactant (refer to Figure 52). 
One problem associated with using the solvent evaporation technique is the possible 
adverse effects on the antigen due to contact with the organic solvent. The solvent 
may destroy important antigenic epitopes and affect the subsequent antigenicity' of the 
antigen. This may be avoided by first dissolving the antigen in an aqueous solution 
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Figure 52 Production of microparticles using 
oil-in-water (o/w) solvent evaporation technique 
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which is then added to the polymer solution, thereby avoiding direct contact between 
the antigen and the solvent. This results in a water-in-oil (w/o) emulsion which 
subsequently forms a water-in-oil-in-water (w/o/w) emulsion when mixed with an 
aqueous phase containing the emulsion stabiliser (refer to Figure 53). 
Microparticles of submicron size can be made by solvent evaporation. From the data 
presented in Chapters 2-4, it is evident that microparticles of approximately 1µm are 
required for optimum uptake across the Peyer's patches. 
Changing process parameters such as the size and speed of the stirrer, size of the 
mixing vessel and polymer concentration can all result in changes in microparticle 
size (Watts et al. 1990, and Jeffery et al. 1991). One of the principle factors in 
producing small or large microparticles is the magnitude of the shearing forces acting 
on the microparticle droplets; stirring at maximum speeds in a small volume increases 
the shearing forces which break down the emulsion droplets resulting in small 
microparticles. In contrast, stirring at slower speeds in a larger volume results in 
lower shearing forces allowing the formation of large microparticles. PLG 
microparticles containing the equine influenza virus were prepared using a water-in- 
oil-in-water solvent evaporation technique, in which selected process conditions were 
varied to produce microparticles of submicron and 10 micron respectively. 
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Figure 53 Production of microparticles using 
water-in-oil-in-water (w/o/w) solvent evaporation technique 
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5.3 MICROENCAPSULATION OF EQUINE INFLUENZA VIRUS LNTO 
BIODEGRADABLE PLG MICROPARTICLES 
The whole inactivated influenza virus, prague strain (A/Equine/Prague/56) (supplied 
by Behringwerke, Germany) was used for encapsulation studies. 
1) Production of submicron microparticles containing influenza: 
(a) 400 mgs poly(lactide-co-glycolide) copolymer (Boehringer, Germany) was 
added to 10 mis of Dichloromethane (HPLC grade, Fissons, Loughborough, 
U. K. ). 
(b) Approximately 5 mgs of freeze dried equine influenza were resuspended in 2- 
2.5 mis of distilled water and added to the PLG solution in a 100 ml beaker. 
(c) The mixture was stirred at 12,400 rpm for 1 minute with a Silverson 
homogeniser using a 12mm diameter stirrer head (Silverson Machines, 
Chesham, Bucks) to give a water-in-oil emulsion. 
(d) 25 mis of a 10% (w/v) solution of polyvinyl alcohol in distilled water)(87- 
89% hydrolysed 13,000-23,000 daltons, Aldrich Chemical Company, Dorset, 
U. K) was added to the mixture and stirred at 12,400 rpm for 5 minutes to 
give a water-in-oil-in-water emulsion. 
(e) The mixture was stirred overnight using a magnetic stirrer to allow the solvent 
to evaporate. 
(f) The microparticle suspension was centrifuged for 30 minutes at 15 , 000 r. p. m. 
Two further centrifugation steps were performed at 10,000r. p. m. for 15 
minutes. After each wash, the supernatant was discarded and the precipitate 
resuspended in distilled water (15 mis). 
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(g) The microparticles were freeze dried and stored in a desiccator at 25 °C. 
For the appearance of a typical batch of submicron microparticles refer to Figure 54. 
2) Production of microparticles 5 micron and over containing influenza virus: 
(a) 900 mgs polylactide-co-glycolide polymer was added to 10 mis of 
Dichloromethane. 
(b) Approximately 5 mgs of freeze dried equine influenza were resuspended in 2- 
2.5 mis of distilled water and added to the poly(lactide-co-glycolide) solution 
in a 500 ml glass beaker. 
(c) The solution was stirred at 8,100 rpm for 1 minute with a Silverson 
homogeniser using a 16mm diameter stirrer to give a water-in-oil emulsion. 
(d) 500 mis of a 0.5 % solution of polyvinyl alcohol was added to the mixture and 
stirred at 8,100 rpm for 5 minutes to give a water-in-oil-in-water emulsion. 
(e) The mixture was stirred overnight using a magnetic stirrer to allow the solvent 
to evaporate. 
(f) The microparticle suspension was centrifuged for 15 minutes at 14,000 r. p. m. 
Two further centrifugation steps were performed at 14,000 r. p. m. for 15 
minutes. After each wash, the supernatant was discarded and the precipitate 
resuspended in distilled water (15 mls). 
(g) The microparticles were then freeze dried and stored in a desiccator at 25 °C. 
For the appearance of a typical batch of microparticles greater than 
5µm refer toi 
Figure 55. 
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Figure 54 
Scanning electron micrograph of a typical batch of PLG submicron 
microparticles containing equine influenza virus. 
Figure 55 
Scanning electron micrograph of a typical batch of PLG microparticles over 5µm 
containing equine influenza virus. 
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The procedures described above was used for the production of blank PLG 
microparticles (dependent on size of microparticles required) with omission of the 
antigen, thus, the blank microparticles were formed from an oil-in-water emulsion. 
5.4 CHARACTERISATION OF PLG MICROPARTICLES CONTAINING 
THE EQUINE INFLUENZA VIRUS 
5.4.1 Morphological Analysis Using Scanning and Transmission Electron 
Microscopy 
The external morphology of the microparticles was investigated using scanning 
electron microscopy (SEM, JOEL 6400 Winsem). Both the small and large 
microparticles prepared in section 5.3. were spherical in shape and showed a smooth 
surface, with an absence of surface pores (this is important for the controlled release 
of entrapped antigen). If the current of the SEM was high, however, the PLG 
microparticles distorted and formed visible pores. For this reason the current was kept 
at 0.2 x 10-10 amps. Pores also formed if the volume of the internal aqueous phase 
(virus in water) was high (over 4 ml in production of small microparticles). This is 
possibly the result of an unstable primary emulsion (w/o) (Cohen et al. 1991). The 
use of the formulation approaches described in section 5.3 resulted in microparticles 
of either submicron or 5 micron and over (refer to Figure 54-55). The microparticles. 
however, did show a degree of heterogeneity with respect to size within batches 
(confirmed using Photon correlation spectroscopy, Malvern 2600). One possible 
reason is non-uniform mixing as the mixing vessel is manually moved with respect 
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to the stirrer head, thus, some regions of the emulsion are stirred more than others 
resulting in a heterogenous size population. 
Transmission electron microscopy was used (TEM, Phillips 300 and 410) to 
determine the interior morphology of the microparticles. This work was performed 
using a preparation of large PLG microparticles (approximately 10µm) containing 
equine influenza virus. The procedure for resin embedding of PLG microparticles is 
listed in the Appendix 3. The polymerised resin blocks containing microparticles were 
sectioned using a Reichert OMU3 ultra-microtome (refer to section 2.2. ). 
Initially semithins (11tm sections) were placed on a carbon disc overlying aluminium 
stubs, sputter coated, and viewed under the SEM. Poor contrast between the 
topography of the microparticles and surrounding resin resulted in unsatisfactory 
images when viewed under SEM. The image did, however, indicate an homogenous 
matrix (refer to Figure 56). Ultrathin sections (90nm) of the PLG microparticles were 
viewed under the TEM revealed grey spherical structures relating to the 
microparticles (refer to Figure 57). The internal matrix appeared homogenous and 
was surrounded by a dense border. This indicates that the influenza is dispersed 
throughout the whole matrix (referred to as monolithic by Tice and Cowsar 1984). 
Influenza virus could be seen on the outside of the microparticles (refer to Figure 58). 
In the absence of specific labelling of the virus, however, it was difficult to observe 
microencapsulated material. 
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Figure 56 
Scanning electron micrograph of a TEM section of PLG microparticles 
containing equine influenza virus. 
Figure 57 
Electron micrograph of sectioned PLG microparticles containing equine influenza 
virus, showing a homogenous internal matrix. Magnification x 26,150 
Figure 56 
Figure 57 
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Figure 58 
Electron micrograph of PLG microparticles (containing equine influenza virus) 
showing the equine influenza (V) on the outside. Magnification x 54,980 
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5.4.2 Determination of the Amount of Entrapped Virus in PLG Microparticles 
The amount of influenza virus entrapped in the PLG microparticles was determined 
using a bicinchoninic acid protein assay (BCA, Smith et al. 1985). The basis of the 
assay is a two step reaction (a) the reduction of Cull to Cull ions by protein in an 
alkaline environment and (b) the formation of a purple complex between the resulting 
Cu" ions and bicinchoninic acid which has an absorbance maximum at 562nm. The 
intensity of this purple complex can be related to protein concentration using a 
standard calibration curve. 
In order to measure the amount of viral material in PLG microparticles, the 
encapsulated virus was released by digesting the PLG microparticles. This was 
achieved by incubating the PLG microparticles in a solution of 0.1 M sodium 
hydroxide containing 5% SDS (p. H. 7.4) on a shaker system overnight. 
BCA assay procedure for determining the amount of influenza virus in PLG 
microparticles: 
(a) 15-25mgs of freeze dried microparticles were added to 1 ml of a solution of 
OA M NaOH/5 % SDS (performed in triplicate) and shaken at room 
temperature overnight. The assay was also performed on blank (protein-free) 
PLG microparticle. 
(h) A dilution series of influenza virus was prepared as a standard using the same 
virus used to prepare the microparticles (prague) in 0.1M/5% SDS (100µg/ml 
- 
800µg/m1) 
. 
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(c) 2 ml of BCA solution (50m1 BCA +1 ml copper sulphate) was added to 
0.1 ml of microparticle suspension and standards (all tests were performed in 
duplicate). 0.1 ml samples of 0.1M NaOH/5 % SDS digestion medium were 
also tested. 
(d) The samples were incubated in a water bath set at 60°C for 25 minutes and 
allowed to cool. 
(e) The samples were centrifuged at 4,000 r. p. m for 5 minutes to sediment the 
digested microparticles. 
(f) The supernatant was collected and the absorbance measured in a 
spectrophotometer set at wavelength 562nm. 
A standard curve was plotted from the dilution series of influenza virus and the 
amount of virus in the assay sample was determined. This was then used to calculate 
the amount of virus associated with the total microparticle sample. 
Example: 
Weight of PLG microparticle containing virus used for assay = 13.7 mg. 
Amount of virus (calculated from standard curve) = 49.051tg in 0.1 ml (volume used 
for assay). 
1 ml of digestion medium was used, therefore, 490.5µg of virus are contained in 
13.7mg of microparticles. 
total protein 
x100= % w/w. 
weight of sample 
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490.5 
e. g. x 100 = 3.58% weight of virus/weight of PLG. 
13700 
The same calculation was performed for the blank PLG microparticles and this was 
subtracted from the protein content figure to allow for any absorbance reading due 
to PLG. 
Initially the Lowry-Hess (1977) protein assay was used to measure the amount of 
virus contained in PLG microparticles. However, it was found that protein free PLG 
blanks were giving comparable absorbance readings to the virus containing PLG 
microparticles. It was apparent that some constituent used in the microparticle 
formulation process was interfering with the assay. Polyvinyl alcohol was 
subsequently found to give a strong absorbance reading indicating that PVA was 
present in the PLG microparticle preparation. Polyvinyl alcohol did not give a 
significant absorbance reading when the BCA assay was used to estimate protein 
content. 
Considerable problems were encountered when using the BCA assay to measure the 
viral content. Initially the PLG remnant was removed following digestion by 
centrifuging and the BCA assay was performed on the supernatant. However, no 
absorbance reading was obtained on analysis of the supernatant. It was later found 
that the virus was associated with the PLG sediment (refer to section 5.6). The 
protocol was subsequently adapted; removing the PLG sediment only after the BCA 
colour reaction had taken place. The level of viral entrapment varied between 0.25 
% 
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- 
3.6 % (weight of virus/weight of polymer) and was found to be dependent on the 
size of the microparticles (refer to section 5.6). 
5.5 INVESTIGATION OF THE ANTIGENIC INTEGRITY OF THE 
EQUINE INFLUENZA VIRUS AFTER MICROENCAPSULATION 
USING THE SINGLE-RADIAL-IMMUNODIFFUSION ASSAY 
5.5.1 Introduction 
Influenza is an orthomyxovirus, existing of 3 types A, B and C. They are spherical 
in shape composed of a central capsid containing ribonucleoproteins and an outer 
capsid composed of protruding spikes of either haemagglutinin or neuraminidase. The 
haemagglutinin antigen on the surface of influenza, is involved in cell attachment and 
is the main antigen to which neutralising antibodies are formed to confer immunity. 
The success of a microencapsulated vaccine against influenza depends on the antigenic 
integrity of these epitopes remaining intact during the microencapsulation process. 
During the solvent evaporation process the virus may be subjected to high shearing 
forces as well as solvent exposure (Dichloromethane). 
The single-radial-diffusion (SRD) assay was used to investigate antigen integrity. This 
assay measures the amount of haemagglutinin in influenza preparations expressed as 
micrograms of antigen activity (Wood et al. 1983). The assay is based on an antigen 
(haemagglutinin epitopes) /antibody (specific to the HA) interaction. The SRD system 
comprises of an agarose gel containing the specific antiserum to which a influenza 
virus, disrupted by treatment with detergent, is added in wells cut in the agarose. As 
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the virus diffuses out of the wells a radially produced precipitation zone is formed, 
as a result of the HA of the virus reacting with the anti-HA, the size of which 
correlates to the amount of haemagglutinin in the influenza virus preparation. The 
assay, therefore, works for influenza retaining haemagglutinin activity. Using this 
principle, an SRD test performed on influenza virus before and after 
microencapsulation would, therefore, indicate loss of haemagglutinin antigenicity. 
Experiments were performed to investigate the antigenic integrity of PLG 
microencapsulated influenza virus after production by solvent evaporation. To 
investigate the effect of time of microencapsulation, various microparticle 
preparations were incubated in PBS at 37°C and SRD tests were performed at various 
time points. The aim of the investigation was to determine whether antigen integrity 
was maintained after microencapsulation. No quantification of virus content was 
attempted. 
5.5.2 Materials and Methods 
Preparation of PLG microparticles containing equine influenza virus 
Two PLG polymers, resomer 858 (85: 15 lactide-glycolide ratio, 53kD) and resomer 
503 (50: 50,9kD) (Boehringer, Germany) were used to microencapsulate equine 
influenza, prague strain (A/Equine/Prague/56) (the virus was kindly supplied by 
NIBSC, Potters Bar, England). The microparticles were produced using the method 
described in section 5.3. for the preparation of submicron microparticles. 
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Incubation of PLG microparticles containing equine influenza virus 
Test-tubes containing 10-20 mg of freeze dried microparticles were dispersed in 3 mis 
of phosphate buffered saline (p. H. 7.4) and kept at 37°C. Tubes were removed at 
0,1 week, 6 weeks, 11 weeks and 12 weeks and stored at 
-20°C. SRD tests were 
then performed on each sample. A substantial amount of virus was surface associated 
as revealed by in vitro release studies (refer to section 5.6). Therefore, in order to 
have sufficient virus to perform the SRD test both the microparticle suspension and 
the supernatant was used for the SRD assay. 
The single-radial-immunodiffusion procedure (adapted from the method used at 
NIBSC, Potters Bar, England) was conducted at NIBSC under direction of Dr. J. 
Wood. 
Antigenic reagents: 
Influenza virus used for microencapsulation (A/Equine/Prague/56 (H7N7) 
2707µgHA/m1 NIBSC ref. H10). 
Standard influenza virus (A/Equine/Prague/56 (H7N7) 110µgHA/ml NIBSC ref. 
85/553). 
Anti-influenza virus serum: Goat anti-A/Equine/Prague/56 H. A. NIBSC ref. 84/673. 
For preparation of the reagents used in the SRD test refer to Appendix 2. 
(a) Two glass plate (12 x 12cm) was cleaned using a detergent (Decon) and dried. 
(b) Agarose was melted in a boiling water bath and dispensed into prewarmed 
glass universals in a 50°C water bath (14 ml agarose per plate). 
(c) Hot agarose was smeared on the glass plates using a tissue and allowed to dry . 
(d) A perspex mould (internal diameter 9 cm) was placed on each glass plate and 
the edges sealed with hot agarose. This was left to dry for 5 mins. 
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(e) The 84/673 antiserum was added to the agarose (7.5ul per ml agarose), gently 
rotated by hand, and poured into the mould on a level surface (14 mis per 
plate). Bubbles in the agarose were removed using a Pasteur pipette. The 
agarose was left for 10 minutes before removing the mould. 
(f) 5 ul of detergent (Zwittergent) was added to 45 ul of microparticle suspension 
in a multiwell plate and shaken for 30 minutes at room temperature. A 
standard prague sample (85/553) and a sample of the prague virus used for 
microencapsulation were used as reference samples and diluted to the same 
concentration with phosphate buffered saline (these were also disrupted with 
detergent). 
(g) A metal hole punch (5 mm diameter) was used to punch a series of wells. The 
gel in each hole was removed using a Pasteur pipette attached to a vacuum. 
(f) 20 uls of sample was introduced into the wells. 
(g) The plates were covered by a perspex lid and placed in a plastic container 
lined with moist blue roll tissue. Diffusion was allowed to take place for a 
minimum of 18 hours at room temperature. 
(h) After 18 hours the plates were washed under tap water. The plate was then 
placed on paper towels and the gel covered with filter paper (Whatman 1,15 
cm. ). Lint was then placed on top and finally a metal weight (approx. 650 
gms) for 15 minutes to tightly compress the gel to the glass plate. 
(i) The weight and lint were removed and the gel (with filter paper attached) 
dried under warm air at 37°C. When dried (approximately 2 hours), the filter 
paper was removed and the gel stained in Coomassie Blue stain for 15 
minutes. The gel was then destained in methanol-acetic acid until the blue 
precipitation zones were evident. The plates were allowed to dry and viewed 
with a magnifying lens. 
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5.5.3 Results and Discussion 
Only the standard influenza virus sample (85/553) and the week 12,503 microparticle 
sample gave a positive SRD reaction (refer to Figure 59). Of the two polymers used 
to encapsulate the virus for this study, 503 is the faster degrading. At 12 weeks the 
503 microparticle sample was clear indicating that the PLG had totally degraded 
whereas all the other microparticulate samples showed a cloudy appearance due to 
non-degraded PLG. It would appear that the presence of a PLG suspension interferes 
with the SRD reaction possibly restricting the diffusion of the influenza virus through 
the agarose gel. The colour reaction inside the wells indicates a non-specific reaction 
between the PLG suspension and the Coomassie stain. On close examination, using 
an eye lens, the ring evident in the week 12,503 sample was fainter than the 
reference standard and was slightly crenated which may indicate slight disruption of 
the HA during microencapsulation, although a level of antigenicity remains. Factors 
accounting for the faint ring could be either (a) trace remains of PLG interfering with 
the reaction or (b) the shift of pH found in the closed in vitro system in which the 
microparticles were kept; over the incubation period the pH of the external medium 
changed from 7.4 (0 weeks) to approximately 3.0 (12 weeks)(see section 5.6). The 
haemagglutonin spikes can be disrupted at this pH (Dr John Wood, NIBSC, Personal 
communication). Earlier a series of SRD tests were performed on unencapsulated 
equine influenza virus supplied by Behringwerke, Germany. A negative result was 
achieved, however, due to the high level of formalin used to inactivate the virus 
(which cross-linked the haemagglutinin spikes). For this reason virus inactivated with 
lower formalin concentrations was used in the studies described. 
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A 
B 
Figure 59 
Single-radial-inimunodiffusion plate showing precipitation zones (positive 
reaction) for A, PLG (resomer 503) microencapsulated 12 week sample and B, 
control aqueous equine influenza sample. 
167 
The results suggest that haemagglutinin activity remains after microencapsulation but 
there may be a slight loss which may be attributed to remaining PLG or the 
limitations in the in vitro system used. To routinely use the SRD test, however, 
methods to completely remove residual PLG must be sought. 
In summary, PLG microparticles of various sizes, containing equine influenza virus 
were prepared. These microparticles were both spherical and smooth, showing an 
homogenous internal matrix. The antigen integrity of the haemagglutinin spikes on 
the virus was found to remain after microencapsulation. The levels of entrapment 
indicated that these microparticles could be useful as an antigen delivery system for 
influenza virus. First, however, it was important to investigate the in vitro release of 
influenza from the PLG microparticles to determine the virus release pattern. 
5.6 INVESTIGATION OF THE IN VITRO RELEASE OF EQUINE 
INFLUENZA FROM PLG MICROPARTICLES 
5.6.1 Introduction 
The release of antigen from PLG microparticles depends on the degradation of the 
polymer and the diffusion of the antigen through the matrix. The importance of 
diffusion on release depends on the permeability of the entrapped material within the 
polymer matrix. Peptides and proteins have low permeability through the PLG 
polymer and are the principle factor in their release is the degradation of the polymer 
matrix (Tice and Cowsar 1984, and Cohen et al. 1991). 
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The rate of degradation of PLG depends on a number of factors, principally of which 
are the molecular weight of the polymer and the lactide/glycolide ratio. PLG is 
broken down by a hydrolytic cleavage of the ester bonds linking the polymer to give 
lactic and glycolic acid (Tice and Gilley 1984). High molecular weight polymers 
require more hydrolysis to break down the long chain molecules resulting in a lower 
rate of degradation compared with low molecular weight polymers (Wang et al. 
1990). The lactide to glycolide ratio in the polymer also determines the rate of 
hydrolysis and subsequently the rate of degradation since the methyl groups on the 
lactide segments in the cytoplasm tend to shield the ester groups from hydrolysis. 
Miller et al. 1977 found that a polymer composed of 100% lactide degraded in 6 
months in vivo. If the glycolide content was increased the degradation rate increased; 
a 50: 50 ratio polymer degraded in 1 week. The glycolide units in the copolymer are 
more hydrophillic than the lactide unit and, therefore, increase the amount of water 
uptake (Gilding and Reed 1979, Hollinger and Battistone 1986). Microparticles 
composed of a polymer with a higher lactide content will result in a slower rate of 
degradation (Wang et al. 1990 and Spienlehauer et al. 1989). Size factors must also 
be taken into account in that smaller microparticles present a larger surface area for 
hydrolytic attack and water uptake which will influence microparticle degradation. 
PLG microparticles of different composition (lactide/glycolide ratio) and molecular 
weight should release antigen at different rates and over varying time periods. The 
significance of this is that microparticles composed of different polymer compositions 
may be formulated to release antigen at predetermined times, giving a pulse release 
profile or continuous release. 
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To investigate the release profiles of equine influenza virus from PLG microparticles, 
an in-vitro release study was conducted using polymers of different compositions 
(lactide/glycolide ratio) and molecular weight. 
5.6.2 Materials and Methods 
Several batches of PLG microparticles containing the equine influenza virus (praque 
strain supplied by Behringwerke, Germany) were produced using the solvent 
evaporation method (refer to Table 11). Blank PLG microparticle containing no virus 
were also produced from each of the PLG polymers under investigation (Boehringer, 
Germany). 
Test-tubes containing 10-20 mg of freeze dried microparticles dispersed in 3 mis of 
phosphate buffered saline (PBS, p. H 7.4) were placed in a water bath at 37°C. The 
test-tubes were shaken periodically to keep the microparticles in suspension. At 
regular time intervals test-tubes were removed and assayed for protein content using 
a bicinchoninic acid protein assay as described in section 5.4.2. From these results 
the percentage of equine influenza released at each sample time (percentage of the 
original protein content) was calculated and plotted against time to give the 
cumulative release profiles. To investigate the morphology changes of the 
microparticles over time, samples taken from the in-vitro test-tubes were washed in 
distilled water (to remove the PBS) and viewed under a scanning electron microscope 
(JOEL 6400 Winsem). 
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Table 11 Microparticles encapsulating equine influenza virus using 
different Poly(lactide-co-glycolide) polymers. 
Batch Lactide/Glycolide %Influenza 
encapsulated 
%w/w 
Particle 
size(µm) 
6 50/50(503,9kD) 1.13 0.5 
4 50/50(505,18kD) 0.8 1.0 
8 85/15(858,53kD) 1.02 1.0 
9 50/50(858,53kD) 0.54 0.2-1.0 
10* 85/15(858,53kD) 1.0 0.2-1.0 
*NIBSC inactivated virus 
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5.6.3 Results of the In-Vitro Release Studies 
Polymer 
- 
PLG 50: 50 (lactide/glycolide) (9W) Resomer 503 
At time zero 65 % of the virus content was detected by the BCA method (refer to 
Figure 60), which indicated the presence of virus adsorbed on the surface of the 
microparticles. The amount of virus then decreased over the next 8 hours. The 50: 50 
(lactide/glycolide), low molecular weight polymer was expected to degrade rapidly 
and release encapsulated virus over a short time scale. Figure 61, shows a temporal 
release of the virus but even after 12 weeks only 70% of the original virus content 
was released. Under the SEM (refer to Figure 62), pores were apparent on the 
surface of microparticles after 2 weeks and by 12 weeks total degradation had taken 
place. Thus, 100% release of the virus was anticipated by 12 weeks. 
Polymer 
- 
50: 50 (18kD) Resomer 505 
The profile in Figure 63 shows that 55 % of the virus was released at time zero which 
indicated the disassociation of adsorbed surface virus from the microparticles. Being 
a higher molecular weight polymer the degradation rate was expected to be slower 
than the 503 resomer. Under the SEM (refer to Figure 64) surface degradation was 
not apparent until after 3 weeks. 100% of virus was detected by the BCA assay at 4 
weeks and then the amount declined thereafter. However, a controlled release of virus 
appears to be taking place over 4 weeks in vitro. 
Polymer 
- 
85: 15 (53W) Resomer 858 
The 85: 15 copolymer was expected to degrade at a lower rate than the other two 
copolymers due to the higher lactide content and high molecular weight. SEM 
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examination showed that the microparticles morphology appeared unaltered even after 
24 weeks, indicative of a very slow degradation rate (refer to Figure 65). The initial 
28-50% detected by the BCA assay of virus at time zero (refer to Figure 66-67) was 
attributed to surface associated virus. The level of release did not reach 100%. The 
difference in the profiles obtained with batch 8 and 10 could be due to the origin of 
the virus Batch 10 virus was supplied from NIBSC using a low level of formalin for 
inactivation. 
5.6.4 Discussion 
An initial "burst" release of virus was apparent for all the microparticle systems 
investigated in vitro. A similar phenomenon has been recorded by others investigating 
the in vitro release of antigen from PLG microparticles; Cohn et al. 1991 found an 
initial burst of FITC-BSA (20-60 % cumulative release dependent on the polymer 
molecular weight. Wang et al. (1990) found 70-80% of BSA was released within 1 
day from microparticles composed of 50: 50 PLG copolymer. Both groups attributed 
this initial burst of release to loosely bound surface protein. The results from the 
present studies indicate the presence of surface protein which is supported by SEM 
evidence. No detectable morphological deterioration or pore formation (which could 
account for virus release) was observed in any of the microparticles within the first 
week. The SEM evidence supported the theory that degradation decreases in PLG 
polymers with increased lactide content and higher molecular weight (degradation 
50: 50,9kD greater than 50: 50,18kD which is greater than 85: 15,53kD). 
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Only the 505 resomer in vitro system released 100% of the entrapped virus, where 
a controlled release of virus took place upto 4 weeks. The 858 microparticles did not 
show any morphological changes after 24 weeks indicating that complete release of 
virus would occur only after this period. The fact that total release was not detected 
in the 503 resomer, although SEM evidence showed complete degradation of the 
microparticles after 12 weeks, may indicate that a decrease in sensitivity of the virus 
to the BCA assay. One factor encountered in the in vitro release studies was a marked 
pH shift in the external medium (PBS) over time (refer to Table 12). This was due 
to lactic acid formation as the polymer degrades. As expected a marked pH shift was 
seen in the 503 system compared to the other polymers, indicative of greater 
degradation to monomers. In the in vitro system, each test-tube was sampled rather 
than aliquots taken and the external medium (PBS) replenished, therefore, the released 
virus was not removed from the system and may be degraded by the increasingly acid 
release medium; as previously discussed the influenza can be disrupted at pH 3-4 (Dr 
John Wood, NIBSC, Personal communication). The optimum pH for the BCA assay 
is 11.25 (Smith et. al. 1985), with an acidic sample the pH of the assay may be 
altered and diminish the sensitivity of the assay. 
The use of an in vitro system in which the external medium was changed over time 
would remove released virus and overcome the problem of pH shift. This condition 
is a result of the limitation of the in vitro system used in these experiments and would 
not necessarily occur in vivo. 
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Figure 62 
Scanning electron micrographs of PLG microparticles (50: 50, resomer 503) 
containing equine influenza virus following incubation in PBS. 
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Figure 63 Influenza release from lµm PLG (505, batch 4) microparticles 
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Figure 64 
Scanning electron micrographs of PLG microparticles (50: 50, resomer 505) 
containing equine influenza virus following incubation in PBS. 
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Figure 65 
Scanning electron micrographs of PLG microparticles (85: 15, resomer 858) 
containing equine influenza virus following incubation in PBS. 
UU Weeks 
I 
4A 
40, 
r 
4 
, 
ý4 
r 
44 
I 
r 
fe 
4 
4 Weeks 
24 Weeks 
179 
Figure 66 
100 
90 
80 
e 70 
60 
R 50 
> 40 
30- 
U 20- 
10- 
04 
0 
Influenza release from 1µm PLG (858, batch 8) microparticles 
Figure 67 
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Table 12 pH shift of the external medium of Poly (lactide-co-glycolide) 
microparticles during in-vitro studies. 
Batch Time pH 
(weeks) of external medium 
3 (resomer 505) 0 7.4 
6 4.5-5.0 
8 (resomer 858) 0 7.4 
26 6.5 
9 (resomer 503) 0 7.4 
10 3.0-4.0 
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CHAPTER 6 
IMMUNISATION STUDIES USING PLG 
MICROPARTICLES CONTAINING INFLUENZA VIRUS 
6.1 INTRODUCTION 
PLG microparticles containing equine influenza virus had been formulated and 
characterised (refer to Chapter 5). The next step in the development of an oral 
vaccine against influenza was to assess the immunological responses to these 
microparticles in vivo. Immunisation studies were conducted in mice and the 
immunological responses were assessed by measuring the levels of anti-influenza 
antibodies produced utilising a specific enzyme linked immunosorbant assay (ELISA). 
Two studies were conducted (a) a subcutaneous study (s. c) to evaluate the 
immunogenicity of the microencapsulated influenza virus in mice and (b) an oral 
study to investigate the mucosal immune response in mice after immunisation with 
equine influenza virus encapsulated within PLG microparticles. 
6.2 ENZYME LINKED IMMUNOSORBANT ASSAY (ELISA) 
For a comprehensive review of the principle of the ELISA the reader is referred to 
Kemeny, A practical guide to ELISA (1990). 
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The basis of this assay is the antibody: antigen interaction (immunoassay) in which an 
antibody or antigen linked to an enzyme is added to either an antibody or antigen 
immobilised on a solid phase. The type of solid supports vary but plastic microtitre 
plates are routinely used which are composed of a series of wells in which the 
reaction takes place. The subsequent antibody: antigen reaction results in a bound 
fraction with enzymatic activity. Addition of the enzyme substrate gives a colour 
reaction, the intensity of which is related to the amount of antibody: antigen complex. 
The plates are washed after each step to remove unbound reagents. ELISA's can be 
divided into non-competitive such as described above, and competitive where a 
mixture of enzyme labelled antigen and unlabelled antigen compete for the binding 
sites on an immobilised antibody. 
There are many formats and types of ELISA dependent on the component is being 
measured, but all work by the basic principles described above. To measure antibody 
levels in biological fluids the non-competitive sandwich ELISA is commonly 
employed. The plates are coated with a dilution of the antigen, the biological fluid is 
added and the specific antibodies bind to the plate via an antigen/ antibody complex. 
A specific secondary enzyme conjugated antibody is added which forms a 
antigen\antibody\enzyme conjugated antibody. Enzyme substrate is subsequently 
added to give a colour reaction. 
Each step of the ELISA protocol requires optimisation to ensure an efficient and 
accurate assay. This is achieved by running test ELISA using different concentrations 
of reagents (changing only one parameter each time) and finding the optimal 
conditions. Interpretation of ELISA data can be a simple "yes" or 
"no" for the 
presence of the specific antibody signified by colour development. 
For a more 
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quantitative assessment the colour intensity (optical density) of the reaction is 
measured and compared to a reference curve. The reference curve is obtained by 
performing an ELISA on a series of dilutions of antisera (or other biological fluid), 
containing an high content of the antibody being investigated, and plotting the optical 
densities against dilution to give a linear curve. 
6.3 PARENTERAL IMMUNISATION STUDIES IN MICE USING PLG 
MICROPARTICLES ENCAPSULATING EQUINE INFLUENZA VIRUS 
The objectives of this study were twofold; (a) To evoke the production of antibodies 
to the equine influenza virus entrapped within a biodegradable carrier system 
administered parenterally and (b) To compare the effect of different size carrier 
systems to the immunological response. 
6.3.1 Materials and Methods 
Animals: 
Male Balb/c mice (25g) were halothane anaesthetised and immunised subcutaneously 
with a 25G (5/8 inch) needle. 
PLG microparticles with entrapped virus: 
The microparticles were formulated and characterised according to the methods 
described in Chapter 5. 
Virus 
- 
Inactivated Influenza A/equine/prague/56 (H7N7)(supplied by Behringwerke, 
Germany) 
PLG Polymer 
- 
PLG 50: 50 (9kD) resomer 503 (Boehringer, Germany) 
Microparticles 
- 
(1µm) 2.1 % w/w entrapped virus 
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(30µm) 3.6% w/w entrapped virus 
Immunisation schedule: 
The mice were divided into four groups of 10, and were given the following by s. c. 
injection: 
Group A. PLG microparticles (1µm)(1000 HA, 17µg protein) in saline. 
Group B. Inactivated influenza (1000 HA, 17µg protein) in saline. 
Group C. Inactivated influenza (1000 HA, 17µg protein) adsorbed to Alum (2%) in 
saline. 
Group D. PLG microparticles (30µm)(1000 HA, 171tg protein) in saline. 
Immunisations were repeated after 6 weeks. 
Blood samples were collected from the tail vein of halothane anaesthetised mice at 14 
day intervals. The specific anti-influenza IgG antibody content of each serum sample 
was determined in an established ELISA and standardised against the positive control 
antiserum obtained in an hyperimmunisation study with whole influenza 
A/equine/Prague/56 (H7N7). 
Hyperimmune study 
Two mice male Balb/C 6-8 weeks old (25g) were immunised IP with inactivated 
equine influenza (A/equine/Prague/56, H7N7) in Freund's complete adjuvant (FCA) 
the administered dose contained 1,000 HA units. Two weeks after the initial 
immunisation the mice were given an IP injection of equine influenza virus (Prague 
strain H7N7) in Freund's incomplete adjuvant (FIA) containing 1,000HA units of 
protein. The mice were given a third IP immunisation of equine influenza 
in Freund's 
incomplete adjuvant containing 1,000HA units of protein four weeks after the initial 
immunisation. 
Blood was removed 1 week after the third immunisation and the serum separated. 
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ELISA for measurement of anti-influenza IgG antibodies in serum 
(a) 4Oµ1 inactivated influenza (A/Equine/Prague/56, H7N7, supplied by 
Behringwerke, Germany) was added to 20 mis of coating buffer, gently mixed 
and 200u1 dispensed into all the wells of a microtitre multiwell plate (NUNC- 
immuno plate Maxisorp F96)(0.48µg influenza per well). The plate was left 
overnight at 4'C. 
(b) The plate was emptied by flicking and washed 3 times with wash buffer using 
a microplate washer (Titertek). The plate was then tapped on sheets of blue 
towel to remove residue wash buffer. 
(c) 200 uls of blocking buffer was then added to all the wells except a blank 
column and left for 2 hours at room temperature. 
(d) Step (b) was repeated. 
(e) The serum samples and raised antisera (positive control) was diluted in wash 
buffer and 150 ul of diluted sample dispensed into the wells, and left for 2 
hours at room temperature. 
(f) Step (b) was repeated. 
(g) The secondary enzyme conjugated antibody (Mouse anti-IgG conjugated to 
horseradish peroxidase) was diluted with wash buffer (1 in 2000 dilution) and 
150u1 added to each well except the blank column. This was left 2 hours at 
room temperature. 
(h) Step (b) was repeated. 
(i) The chromogen solution (substrate) was prepared by adding 40ul of hydrogen 
peroxide to 40mg of o-Phenylenediamine (OPD), mixed, and added to 50m! s 
of a 1: 1 citrate: phosphate solution (25mis citrate, 25mis phosphate). When 
fully dissolved, 100ul was added to all wells (including blanks). The glassware 
used for the preparing the chromogen solution was scrupulously cleaned with 
dilute sulphuric acid then citrate/phosphate buffer before hand. 
(j) After 15 minutes in the dark the reaction was stopped by adding 50ul of dilute 
sulphuric acid to each well and the optical density of the colour reaction 
measured using a plate reader set at 492nm. 
For buffers refer to Appendix 2. 
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6.3.2 Results and Discussion of Parenteral Study 
For the serum IgG antibody responses obtained in the parenteral study refer to Figure 
68. For statistical evaluation a two-way analysis of variance was performed on the 
data using a Unistat statisical package (version 4.50). 
The animals were given 1,000HA of equine influenza, Prague strain which is the 
concentration used in the commercial vaccine for horses (PREVAC*- Hoechst Animal 
Health). An IgG antibody response was seen in all 4 groups. The greatest response 
was seen in the group administered with virus adsorbed to Alum. This is due to the 
adjuvant nature of Alum. Although, a raised humoral response was observed with the 
Alum formulation it is worth bearing in mind that Alum is not thought to evoke cell 
mediated responses (Warren et al. 1986). The serum IgG response in the 
microparticle groups was not greater than the virus only group. This may be 
explained by the size of the virus, being 80-100nm it may itself be perceived as a 
particulate by the macrophage system and be treated in a similar manner to small 
microparticles. In a recent study conducted by Moldoveanu et al. (1993), inactivated 
influenza virus, A/H3N2, either encapsulated in PLG microparticles or as an aqueous 
solution of virus were administered subcutaneously to mice. As in our studies the 
microencapsulated virus induced levels of virus-specific antibodies in sera comparable 
but not greater to those obtained after immunisation with the aqueous virus. 
The 
polymer used in our study is known to degrade after approximately one week 
(Miller 
et al. 1977) therefore, both the large and small microparticles would release the 
entrapped virus soon after administration. This may account 
for the similar responses 
observed in the two microparticulate groups. The results of the present study, 
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however, demonstrate an evoked immunological response in vivo to equine influenza 
entrapped within a biodegradable carrier system administered parenterally. 
6.4 ORAL IMVIUNISATION STUDIES IN MICE USING PLG 
MICROPARTICLES ENCAPSULATING EQUINE INFLUENZA VIRUS 
It was envisaged that an orally delivered microencapsulated antigen would be taken 
across the intestinal lymphoid tissue (refer to Chapters 2-4) and induce a mucosal 
immune response giving raised levels of IgA, the primary immunoglobulin produced 
at mucosal surfaces (refer to section 1.3). Utilising the common immune system an 
orally delivered microparticulate containing antigen might not only evoke a local 
response in the gut but possibly stimulate a response at more distant secretory sites. 
This was investigated by oral immunisation of equine influenza virus to mice 
encapsulated within PLG microparticles and measuring the IgA levels in saliva 
(secreted by salivary glands connected to the oral cavity). To investigate the systemic 
effect IgG levels in serum were also measured. PLG polymers of different 
compositions release antigen at different rates (refer to 5.6.1), the effect of this on 
the resultant immunological responses after oral administration was investigated. 
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6.4.1 Materials and Methods 
Animals: 
Male Balb/c mice (25g) were gastrically intubated with a curved blunt-ended oral 
dosing needle. 
PLG microparticles with entrapped virus: 
The microparticles were formulated and characterised according to the methods 
described in Chapter 5. 
Virus 
- 
Inactivated Influenza A/equine/prague/56 (H7N7)(supplied by Behringwerke, 
Germany) 
. 
Polymer 
- 
PLG 50: 50 (9kD) and PLG 85: 15 (531W) resomer 858 (Boehringer) 
Microparticles 
- 
(1µm) 91W 1.2% w/w entrapped virus 
(1µm) 53kD 1.1 % w/w entrapped virus 
Oral immunisation schedule: 
The mice were divided into three groups of 10, they were fasted 4 hours prior to 
receiving the following by gastric intubation on three consecutive days: 
Group E. Virus (10,000 HA, 53µg protein) in saline. 
Group F. PLG microparticles 11im (9kD)(10,000 HA, 53µg) in saline. 
Group G. PLG microparticles 1µm (53kD)(10,000 HA, 53µg) in saline. 
Immunisations were repeated 4 weeks later. 
Blood samples were collected from the tail vein of halothane anaesthetised mice at 7 
day intervals. Salivary samples were collected from halothane anaesthetised mice at 
7 day intervals after an intraperitoneal injection of pilocarpine. The specific anti- 
influenza IgG antibody content of each serum sample and the specific anti-influenza 
IgA antibody response of each saliva sample was determined in an established ELISA 
and standardised against a positive antiserum obtained in an hyperimmunisation study 
(refer to section 6.3.1) with whole equine influenza (Prague) virus. 
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ELISA for measurement of anti-influenza IgA antibodies in saliva 
(a) 55µl influenza (A/Equine/Prague/56, H7N7, supplied by Behringwerke. 
Germany) was added to 20 mis of coating buffer, gently mixed and 190u1 
dispensed into all the wells of a microtitre multiwell plate (NUNC-immuno 
plate Maxisorp F96)(0.47µg influenza per well). The plate was left overnight 
at 40C. 
(b) The plate was emptied by flicking and washed 3 times with wash buffer using 
a microplate washer (Titertek). The plate was then tapped on sheets of blue 
towel to remove any residue wash buffer. 
(c) 200uls of blocking buffer was then added to all the wells except column 1 
(blank column) and left for 2 hours at room temperature. 
(d) Step (b) was repeated. 
(e) The saliva samples and raised antisera (positive control) was diluted in wash 
buffer and 150ul of diluted sample dispensed into the wells and left for 2 
hours at room temperature. 
(f) Step (b) was repeated. 
(g) Sheep anti-mouse IgA was diluted with wash buffer (1 in 1000 dilution) and 
110ul added to each well except the blank column. This was left 2 hours at 
room temperature. 
(h) Step (b) was repeated. 
(g) Donkey anti-sheep IgG alkaline phosphatase conjugate (Sigma) was diluted 
with wash buffer (1 in 300 dilution) and added to each well except the blank 
column. This was left for 2 hours at room temperature. 
(h) Step (b) was repeated with an additional wash in distilled water. 
(i) The chromogen solution was prepared by dissolving 4 tablets of p-nitrophenyl 
phosphate (pNPP, Sigma) to 20 mls of diethanolamine buffer. 100uls of this 
was added to each well. 
(j) The colour reaction was allowed to develop in the dark for 15 minutes. The 
reaction was stopped by adding 50u1 of NaOH (3M) to each well. 
(k) The optical density of the colour reaction was measured at 405nm in a plate 
reader. 
For buffers refer to Appendix 2. 
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6.4.2 Results and Discussion of the Oral Study 
For the serum IgG responses obtained in the oral study refer to Figure 69. For 
statistical evaluation a two-way analysis of variance was performed on the data using 
a Unistat statisical package (version 4.50). 
The IgG antibody responses were similar in all three groups. The levels of IgG 
antibody in the serum after oral microparticulate delivery were comparable to levels 
produced after s. c. immunisation (refer to 6.3.2). This is a good result because, 
although, we are specifically trying to evoke a mucosal immune response with the 
oral administration of antigen it is advantageous to induce anti-influenza antibodies 
in the systemic circulation. These results are in contrast to those of Waldman et al. 
(1986) and Bergmann et al. (1986), who found no serum antibody (IgG) increase in 
humans to orally administered inactivated influenza virus. 
For the salivary IgA responses obtained in the oral study refer to Figure 70. Raised 
levels of IgA was seen in all the groups indicating that oral administration of 
inactivated influenza can induce a disseminated mucosal response in areas distant 
from the gut. The greater response was elicited from the group containing soluble 
virus. A number of reasons may account for this. As described earlier, the virus size 
may enable the virus to act as a particulate and itself and be taken up by the 
Peyer's 
patches in a similar manner to the microparticle formulations. There 
has been 
numerous reports of the uptake of viruses through M cells of Peyer's patches: 
reovirus (Wolf et al. 1981.1983), Poliovirus (Sicinski et a!. 1990) and HIV' 
(Amergen cat al. 1991). Various workers have reported increased IgA 
levels in 
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mucosal secretions after oral administration of an aqueous solution of inactivated 
influenza virus in humans and animals; Chen et al. (1987), Chen and Quinnan (1988) 
and Chen and Quinnan (1989) found raised levels of specific secretory IQA in 
pulmonary secretions in mice whilst in humans, Waldman et al. (1986) and Bergmann 
et al. (1986), also demonstrated increased levels of IgA in external secretions (tears. 
saliva and nasal) after immunisation with inactivated influenza virus administered in 
enteric-coated gelatin capsules. There was little difference in the IgA responses 
between the two different PLG polymers used, the 9kD rapidly degrading polymer 
and the 53kD slower degrading polymer. 
6.5 GENERAL DISCUSSION 
The immunological studies show that raised levels of serum IgG and salivary IgA 
(compared to preimmune levels) were produced to either parenterally or orally 
administered PLG microparticles containing inactivated equine influenza virus. These 
levels were comparable to those obtained after immunisation with virus in solution. 
Our finding that an aqueous solution of the virus can elicit an immune response is in 
agreement with findings of other workers (Chen et al. 1987,1988 and 1989, Waldman 
et al. 1986 and Bergman et al. 1986 and Moldoveanu et al. 1993). 
The results obtained from our studies are similar by comparison with other groups 
investigating oral immunisation with PLG microencapsulated influenza. Moldoveanu 
et al. (1993) evaluated PLG microparticles as an oral antigen delivery system with 
human influenza virus type A/H3N2. Two systemic immunisations with 
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microencapsulated virus induced levels of antibodies in sera that were comparable but 
not greater than those obtained after immunisation with virus in solution. Only by 
priming systemically with virus in solution were the levels of IgA and IgG induced 
by an oral boost of microencapsulated virus slightly higher than those induced by an 
oral boost of the virus in solution. This group however, did not investigate the effect 
of priming and boosting orally with microencapsulated virus. Importantly, using the 
oral route of immunisation in the studies presented in this thesis, raised levels of anti- 
influenza antibodies in mucosal secretions and the systemic circulation were induced. 
The IgG antibody levels in sera obtained in the oral study were comparable with those 
obtained with the parenteral study. This contrasts with the findings of Bergmann et 
al. (1986) and Waldman et al. (1986) where no serum antibodies were raised after 
oral immunisation with inactivated virus. 
The fact that the microencapsulated virus did not give greater antibody responses in 
comparison to the aqueous virus may have been due to a loss of antigen integrity 
during microencapsulation (refer to 5.5). As mentioned earlier, in the studies carried 
out by Moldoveanu et al. (1993), the greatest levels of IgA antibody and protection 
were produced after first priming with aqueous influenza virus systemically and then 
boosting orally with PLG encapsulated virus. Cox and Taubman (1984), also found 
the greatest level of IgA response to a particulate form of antigen, given orally, was 
achieved after first priming systemically with the aqueous form of the antigen. 
Our 
levels may be increased if an oral boost after priming systemically 
is performed. 
indicating this route of vaccination may provide a simple and 
inexpensive means of 
providing "booster" immunisations. 
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In the present study measurements were made of the IgA levels in saliva which 
protects the pharynx, we did not however, measure other mucosal secretions 
important in protecting against influenza invasion such as bronchial and pulmonary 
secretions. It would be important in any future studies to determine antibody levels 
in these fluids. 
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V 
CHAPTER 7 
FINAL DISCUSSION 
The aim of the work contained in this thesis was to investigate the feasibility of 
developmening an oral vaccine against influenza virus, using a microparticulate 
antigen delivery system. The work was conducted on the hypothesis that an oral 
microparticulate containing antigen would be taken into intestinal lymphoid tissue and 
induce a disseminated mucosal response. To test this hypothesis, a series of 
experiments were conducted. The objective of this section is not to reiterate the 
results and discussions presented earlier in the thesis, but to highlight the major 
findings and relate them to published work. Conclusions will be drawn as whether, 
these studies further the development of an oral vaccine for influenza and how future 
investigatory work might be directed. 
Initial work was carried out to investigate the uptake of a model microparticulate 
(latex) across the intestine. Peyer's patches were found to be the primary site of 
microparticle (size, 0.94µm and 0.11µm) uptake. This confirmed the findings of 
numerous workers using latex microparticles of a similar size range (LeFevre et al. 
1978, Pappo and Ermak 1989, Jani et al. 1989 and 1992 and Eldridge et al. 1990). 
Most evidence of uptake was achieved when microparticles were administered using 
an in situ intestinal loop. The drawback to this technique, however, is the possible 
contamination by microparticles still present in the gut lumen. This problem does not 
occur if a clearing out period is allowed after chronic feeding. Low levels of 
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microparticles were found in the chronic feeding studies conducted in this thesis. 
however, in comparison to other studies investigating microparticle uptake after 
chronic feeding (LeFevre et al. 1978, Jani et al. 1989 and 1992). This may have been 
due to the lower dose (5 % of the dose used in the study by Jan' et al. 1989) and 
shorter period of feeding used in my studies. To eliminate the problems associated 
with histological sectioning (frozen and cryostat sections) the technique of confocal 
microscopy could be used for the visualization of microparticles within tissue. This 
method does not have the inherent problem of section contamination because it optical 
sections tissue. This method has already been used to follow the disposition of 
microparticles through intestinal lymphoid tissue (James et al. 1992 and Jepson et al. 
1993a and 1993b). The implication of preferential microparticle uptake across Peyer's 
patches is that antigen contained within microparticles will be delivered to the 
intestinal lymphoid tissue, which is thought to be a site for the induction of a mucosal 
immune response (Russell and Mestecky 1988, Eldridge et al. 1990, and McGee and 
Kiyono 1993). 
Transmission electron microscopy (TEM) was used to investigate microparticle uptake 
at the ultrastructural level. In the rabbit a phagocytotic mechanism of uptake was 
found at the M cell surface. This result is confirmation of the 
finding by Sass et al. 
(1990) and Jepson et al. (1993a) using scanning electron microscopy (SEM), 
proposed a similar mechanism of phagocytosis over the 
M cells of rats and rabbits, 
respectively. The limitation of SEM, however, is 
it does not allow the identification 
of intracellular microparticles. In contrast, the work presented 
in this thesis is more 
convincing because possible microparticles within vesicles 
in the apical cytoplasm of 
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the M cell were found giving more evidence to the presented mechanism (refer to 
Figure 50). The only other account using TEM evidence to demonstrate a 
phagocytotic mechanism of microparticle uptake over follicle associated epithelium, 
is that proposed by Landsverk (1988), however, there was no evidence of uptake into 
M cells. Other workers have reported M cell uptake of microparticles (Pappo and 
Ermak 1989, James et al. 1992, Porta et al. 1992) but have not directly demonstrated 
the mechanism at the M cell surface using electron microscopic analysis. The 
importance of microparticle uptake into M cells is the entrapped antigen will escape 
lysosomal breakdown due to the reduced number of lysosomes found in M cells 
(Owen et al. 1986). It is concluded that data presented in this thesis supports the 
hypothesis that M cells are antigen sampling cells allowing the entry of luminal 
material to immunocompetent cells where a mucosal immune response can be initiated 
(Owen 1977). 
Gold labelled microparticles were used to clearly identify intracellular microparticles. 
This was the first study in which TEM had been used to detect microparticles labelled 
with colloidal gold. Microparticles were found in paracellular compartment of M 
cells; it is unlikely that the microparticles enter the cell through the tight junctions 
because, a more likely situation is that microparticles enter the paracellular 
compartment after uptake at the luminal surface and transport through the 
M cell 
cytoplasm and are discharged at the lateral plasma membrane (refer to Figure 50). 
This finding was found in a study conducted by Damage et al. (1991) who described 
a paracellular pathway of nanocapsules transport through cells. 
The consequence of 
a paracellular route is the microparticles (hence entrapped antigen) may escape 
further 
lysosomal breakdown. The advantage of using TEM is the position of the 
200 
microparticle in relation to cell organelles can be detected. The limitation is the small 
area that is viewed and the time required to analyse the whole follicle associated 
epithelium. This may be one reason for the low levels of microparticles observed in 
the TEM morphological studies. A more rapid means of investigating microparticle 
uptake over the FAE would be to use confocal microscopy (Jepson et al. 1993a and 
1993b). 
The work presented in this thesis investigated microparticle uptake in the rabbit and 
the rat and represents a direct comparison between two species. More uptake was 
found in the rabbit, which may be a reflection of the greater number of M cells found 
in the rabbit (Pappo 1988) compared to the rat (Smith et al. 1980). The feasibility of 
oral vaccines may depend on the species for which the vaccine is to be used or more 
specifically the number of M cells within the lymphoid tissue. 
Previous evidence used indirect methods to quantify microparticle uptake across the 
intestine by counting numbers in isolated tissue samples (Pappo and Ermak 1989, Jani 
et al. 1990, Ebel 1990 and Jepson et al. 1993). The advantage of the methodology 
presented in this thesis is that each and every microparticle within lymph draining the 
intestine is counted. A disadvantage with this method is it does not measure any 
microparticles transported in the portal blood and does not allow visualisation of 
microparticles within tissue. The presence of microparticles in the mesenteric and 
thoracic lymph confirmed the migratory pathway taken by microparticles crossing the 
intestine. This was the first evidence of microparticles actually within lymph. 
Previous evidence of microparticles within the lymph system were provided 
by 
histological analysis of lymphatic vessels (Jani et at. 1989 and 1992) and lymph nodes 
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(Eldridge et al. 1990). The presence of microparticles in the thoracic lymph 5 
minutes after oral delivery suggests a rapid rate of intestinal uptake suggesting that 
a greater amount of morphological evidence would have been achieved if tissue was 
taken shorter periods after microparticle administration; future investigatory studies 
into microparticle uptake across the intestine should bear this in mind. 
Qualitative assessment of microparticle uptake of histological samples whether in situ 
loop or chronic feeding indicated a low level of uptake, and this was confirmed by 
the quantitative studies of thoracic and mesenteric samples; if assessed as a percentage 
of the administered dose approximately 10-4 
- 
10-'% were detected, although this does 
not include microparticles in tissues or blood. These levels are in agreement with a 
number of workers (LeFevre et al. 1977, Ebel 1990, Jepson et al. 1993) but contrasts 
with the level of uptake described by Jani et al. (1990). The latter authors (Jani et al. 
1990) did not distinguish between microparticle absorption and microparticle adhesion 
to the gut wall which may have led to an overestimation. In a recent study by Jenkins 
et al. (1993) the flow cytometric detection method has been used to measure 
microparticles in digested tissue (adapted from a method by Ebel 1990). The level of 
microparticle uptake across the intestine did not significantly increase by 
including 
the numbers found in Peyer's patch and mesenteric lymph node tissues. 
The method 
of lymph drainage provides an efficient method to investigate 
intestinal uptake of 
microparticulates, where uptake parameters such as size of microparticulate can easily 
be investigated (Jenkins et al. 1993) without the inherent problems described for 
histological sectioning. 
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In contrast to the numerous studies that describe the role of macrophages in the 
translocation of microparticles within the Peyer's patch and their subsequent migration 
away from the patch (Lefevre et al. 1978, Pappo and Ermak 1989, Sass et al. 1990 
and Jepson et al. 1993) the majority of microparticles detected microscopically in this 
study were found to be intercellular, although some microparticles were found closely 
associated with lymphocytes. This finding is supported by previous studies at 
Nottingham (McKenzie, 1993). The possibility also exists that microparticles were 
taken up by macrophages in areas not examined in the present studies such as 
mesenteric lymph nodes. Macrophages present antigen to helper T-cells to induce T- 
cell responses (refer to section 1.1), the significance of macrophage evasion from a 
point of view of using microparticles as antigen delivery systems is reduced cell 
mediated immunity. This would be a disadvantage in the development of oral vaccines 
against viral pathogens where cell mediated immunity is important (M`Gee and 
Kiyono 1993, section 1.1), in particular, to viruses such as influenza (Wood, 1988) 
whose epitopes are prone to antigenic drift because of the broader specificity of T- 
cells (Ada, 1990). However, the adjuvant effect of microparticles as a result of 
increased delivery to antigen presenting cells (macrophages) is well documented 
(Tabata et al. 1987, Kreuter et al. 1988, O'Hagan et al. 1991 and Eldridge et al. 
1992). In addition, a recent study by O'Hagan et al. (1993) showed raised T-cell 
responses to PLG microparticles entrapping ovalbumin. 
It is difficult to draw 
conclusions on T-cell presentation from the work contained 
in this thesis because cell 
mediated responses were not investigated but future studies would need 
to address this 
important point. 
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PLG microparticles were found in thoracic lymph but no morphological studies using 
PLG were conducted to investigate the site of intestinal uptake. However, their 
presence in thoracic lymph and previous reports showing PLG microparticle uptake 
into mice Peyer's patches (Eldridge et al. 1990), and more specifically M cells in the 
FAE of rabbits (Jepson et al. 1993b) suggest that the route of uptake across the 
intestine is the lymphoid tissue. An essential extension to the morphological evidence 
of latex microparticle uptake is to investigate this phenomenon using PLG 
microparticles. 
To exploit microparticle uptake into intestinal lymphoid tissue and test the hypothesis 
that antigen taken into intestinal lymphoid tissue can induce a disseminated immune 
response (Russell and Mestecky 1987, Mestecky 1987, McGee et al. 1992) equine 
influenza was incorporated into PLG microparticles and immunological responses 
investigated. 
Equine influenza belongs to the same group of orthomyovirus that infects humans, 
group A (although the subtypes are species specific, Paccaud 1970, Wood, 1988) and 
mimics the pathogenesis in humans (Gerber, 1970). Therefore, equine influenza can 
be used as a model for the development of an oral vaccine against influenza in 
humans. 
Other workers have encapsulated Influenza (Moldoveanu et al. 1993) and 
Parainfluenza virus (Ray et al. 1993) into PLG microparticles using solvent 
evaporation although technical details were not described. 
The work in this thesis 
presents an extensive protocol for encapsulating 
influenza into microparticles of 
various sizes and is the first account of encapsulating equine 
influenza into PLG. 
Moldoveanu et al. (1993) and Ray et al. (1993) assessed the antigenicity of the 
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microencapsuled antigen by measuring antibody responses in sera of mice. The single- 
radial-immunodiffusion method presented in this thesis represents a unique, more 
convenient and rapid method to assess antigenicity of encapsulated influenza. The 
importance of this test was highlighted when it indicated the haemagglutinin epitopes 
were affected by the production processes employed by Behringwerke for their 
commercial influenza vaccine; in view of this finding Behringwerke may wish to 
assess there manufacturing procedures. 
An important finding was the change in pH as the PLG polymer degrades. The 
significance of this in relation to PLG as antigen delivery vehicles is the possible 
effect on the encapsulated antigen as the pH of the internal matrix of the 
microparticles change. This point has not been previously addressed and may limit 
the use of PLG containing high levels of lactide for encapsulating antigens affected 
by low pH. Future work will have to investigate the effect of pH on the encapsulated 
antigen. 
When PLG microparticles containing equine influenza were administered parenterally 
to mice comparable levels of serum IgG was found between the microencapsulated 
form and inactivated virus in solution. This was a similar finding to parenteral study 
conducted by Moldoveanu et al. (1993). Presently available vaccines for influenza in 
man and horses in Britain are killed inactivated virus administered parenterally which 
need to be stored at refrigeration temperatures between 2"C and 8°C (Dudgeon and 
Cutting 1991). Prior to the parenteral study the PLG microparticle preparation was 
lyophilised and stored at room temperatures. From a commercial point of view, 
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microparticle vaccines omitting the necessity for refrigeration offer an obvious 
advantage (refer to 1.2.1) 
. 
The finding that raised levels of IgA was produced in a site distant to the gut (salivary 
glands) after oral administration of PLG microencapsulated influenza and influenza 
in solution confirmed the presence of a common mucosal immune response (refer to 
section 1.3). The finding that oral administration of influenza induces a disseminated 
mucosal immune response has been reported previously in humans (Bergmann et al. 
1986 and Waldman et al. 1986) but these studies did not use microencapsulated virus. 
In my studies raised IgG serum levels were found indicating a concurrent mucosal 
and systemic immunity. This result contrasts with those of Waldman et al. (1986) and 
Bergmann et al. (1986), who found no serum antibody (IgG) increase in humans to 
orally administered inactivated influenza virus. 
The only other study investigating oral immunisation with microencapsulated 
influenza was the study conducted by Moldoveanu et al. (1993) who found raised 
levels of serum IgG and salivary IgA. However, mice were systemically primed with 
a solution of influenza before oral administration. Other workers have reported that 
systemically priming with the soluble form of the antigen prior to the administration 
of the microencapsulted form increases IgA levels in external secretions (Cox and 
Taubman 1984, and Eldridge et al. 1991). Consequently future studies should 
investigate if systemic priming is a prerequisite to oral immunisation with 
microencapsulated antigen. The results presented in this thesis, however, indicates 
that an immunisation regime using microencapsulated antigen as boosters might 
be 
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a possibility. The current influenza vaccines in humans (Kilbourne, 1988) and horses 
(Hoechst Animal Health) requires repeated boosters every 9-12 months by parenteral 
injection. Oral microencapsulated boosters offer an advance to the present vaccines 
by being more convenient and more cost effective (omitting the need for refrigeration, 
specialised equipment and personel to administer, refer to 1.2.1) 
. 
An argument against the use of sustained release vaccines is the scenario where 
administration results in to an adverse reaction in an individual. During normal 
immunisation regimes the treatment can be stopped this cannot be done in a single 
controlled release delivery system. This highlights the need for allergy testing in each 
individual before one shot vaccines can be administered. Although IgA levels in 
mucosal secretions have been found previously to correlate with protection against 
influenza (Liew et al. 1984, Moldoveanu et al. 1993), challenge experiments will 
need to be performed in order to assess the full value of the PLG influenza delivery 
system presented in this thesis. 
Future work should investigate methods of increasing the delivery of antigen across 
intestinal lymphoid tissue as means of enhancing immune responses. One possible 
way to increase the levels of microparticle uptake is to increase lymphatic absorption 
by increasing the lipophilicity of the microparticle preparation. Compounds with 
increased lipophilicity produce an increase in lymphatic transport (Charman and Stella 
1991). Targeting the apical cytoplasm of M cells is another possible method to 
increase uptake: monoclonal antibodies have been produced which are specific to 
Ni 
cells (Pappo 1989), which when conjugated to microparticles have been shown to 
enhance uptake (Pappo 1991). An interesting extension to would he to exploit the 
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avidin/biotin interaction to pretarget the M cell using a monoclonal conjugated to 
avidin (or streptavidin) and deliver a biotinylated microparticle. Formation of the 
avidin\biotin complex would result in targetting to the M cell. 
Neutra et al. (1987) found microparticles conjugated to lectins were specifically taken 
up by M cells in rabbit Peyer's patches. However, preliminary work carried out 
during this thesis investigating the uptake of latex microparticles conjugated to PHA 
(reported to bind to epithelial glycoconjugates in the intestine, Pusztai et al. 1991), 
did not show any preferential adherence or uptake across the follicle associated 
epithelium in the rat. This may have been due to structural alterations to the lectin 
binding sites during the conjugation process. Weltzin et al. (1989) found that 
secretory IgA bound specifically to M cells, Porta et al. (1992) extended this finding 
to increase M cell uptake of microparticles by coating the microparticles with IgA. 
In conclusion the work conducted in this thesis supports the contention that oral 
vaccines using biodegradable microparticulate antigen delivery systems are possible. 
An oral vaccine against influenza was investigated but due to the nature of the 
mucosal immune response the findings in this thesis can be used for the development 
of an oral vaccine against an array of pathogens. The findings included in this thesis 
have futhered the development of an oral vaccine against influenza, however, before 
this goal can be realised further investigatory studies outlined need to be conducted. 
The work included in this thesis justifies further research and I hope, will encourage 
others to join this field of study. 
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APPENDIX 2: BUFFERS AND HISTOLOGICAL FIXATIVES 
Phosphate buffer 0.2 M (pH 7.2) 
Solution A: 15.6 gms sodium dihydrogen phosphate dissolved in distilled 
water up to 500 mis. 
Solution B: 35.8 gms disodium hydrogen phosphate dissolved in distilled 
water up to 500 mls. 
Add solution A to solution B until a pH of 7.2 is reached at 20°C 
. 
Phosphate buffered saline 
Disodium hydrogen phosphate 2.13 gms. 
Sodium dihydrogen phosphate 0.23 gms. 
Sodium chloride 0.36 gms. 
Made up to 1 litre with distilled water. 
5% sucrose buffer 
0.2 M phosphate buffer (pH 7.2) 500 mis. 
Sucrose 50 gms. 
Made up to 1 litre with distilled water. 
10% sucrose buffer 
0.2 M phosphate buffer (pH 7.2) 500 mis. 
Sucrose 100 gms. 
Made up to 1 litre with distilled water. 
Prewash 
Sodium barbital 
Sodium acetate. 3H20 
Sodium chloride 
Potassium chloride 
Calcium chloride. 2H20 
Magnesium chloride. 6H20 
5.88 gms 
2.88 gms (or 2.33 gms ofanhydrous) 
5.5 gms 
0.3 gms 
0.2 gms 
0.05 gms 
Dissolve into approximately 400 mis of distilled water. Then measure out 
220-230 cm3 of 0.1 M hydrochloric acid and use this to reduce the pH of the prewash 
to 7.2. When at 7.2 make up to 1 litre with distilled water and store at 4"C. Just 
before use, to 500 mls of the prewash solution add 15 g ficoll and 0.5 gm procaine 
hydrochloride. When dissolved filter the solution. 
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Embedding medium (full strength araldite) 
Araldite CY212 (epoxy resin) 100 ml. 
Dodecenyl succinic anhydride (DDSA) 100 ml. 
The solutions are mixed thoroughly together. 
One drop of accelerator (Benzyldimethylamine (BDMA)) per ml of araldite is 
added. 
1% toluidine blue 
1g of toluidine blue is added to 100 ml of 0.05 M phosphate buffer (pH 7.2). 
Epoxy resin removal stock solutions 
A Potassium hydroxide 0.5 % in absolute methyl alcohol. 
B Pioric acid 10% in acetone. 
C Potassium hydroxide (30%) 1.5 mis. 
Alcohol (80%) 40 mis. 
Primary fixative (TEM) 3% glutaraldehyde in 0.1 M phosphate buffer (pH 7.2) 
0.2 M phosphate buffer (pH 7.2) 500 mis. 
Glutaraldehyde (25 % EM grade) 120 mis. 
Made up to 1 litre with distilled water. 
Secondary fixative (TEM) 1% osmium tetroxide in Millonig's buffer 
1g of 0204 is added to Millonig's buffer made up of: 
Sodium dihydrogen phosphate 75 ml (2.26%) 
Sodium hydroxide 15 ml (2.52%) 
Glucose 10 ml (5.4 %) 
Divided into aliquots and stored at 0°C. 
4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.2) 
0.2 M phosphate buffer (pH 7.2) 500 mis. 
10% paraformaldehyde 400 mis. 
Made up to 1 litre with distilled water. 
ELISA buffers 
Coating buffer: 0.1M Bicarbonate p. H 9.6 500 mis. 
Sodium carbonate 
Sodium Bicarbonate 
2.12 gms 
2.52 gms 
Made upto 500 mis with double distilled water. 
Wash buffer: 
0.15M PBS + 0.05% Tween 20 v/v. p. H 7.4. 
Blocking buffer: 
0.15M PBS + 0.3 % Tween 20 v/v +1% dried milk. 
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Developing buffer for IgA ELISA: Diethanolamine p. H 9.8. 
101 mg of Magnessium chloride 6H20 dissolved in 800 mis double distilled 
water. 
Add 97 mis of Diethanolamine to the magnessium chloride solution. Make 
upto 1 Ltr. with double distilled water. 
Reagents for the single-radial-immunodiffusion (SRD) assay 
Dulbeccos PBSA 
NaCl 100 gms 
KC1 2.5 gms 
Na2HPO4 14.4 gms 
Dist Water 10 litere 
10% sodium azide solution 50 mis 
p. H 7.4 
Agarose 
Seakem MEM 10 gms 
(Marine Colloids Inc 
Rockland 
USA) 
PBSA 1 litre 
10% sodium azide solution 10 mis 
a) Add agarose to PBSA at 4° and mix well 
b) Dissolve and melt agarose in PBSA over boiling 
water bath while stirring 
c) If necessary, adjust volume to 1 litre with warm 
(60°C) water 
d) Add NaN3 solution 
e) Decant into 20-25 mls amounts 
Zwittergent 3-14 detergent l gm 
(Calbiochem-Behring Corp 
La Jolla, CA 92037 
USA) 
Distilled water 9 mis 
Destain solution 
Acetic acid 
200 mis 
Methanol 1 litre 
Distilled water 1 
litre 
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Stain 
Coomassie Brilliant 
Blue G 250 1.5 gms (Serva Feinbiochemica Heidelberg) 
Destain solution 500 gms Dissolve stain and filter through Whatmans Grade 113V 
filter paper. 
APPENDIX 3: METHODS 
Paraffin wax tissue processing 
Tissues for paraffin wax embedding were fixed in 4% glutaraldehyde for 24 hours. 
The water was removed from the tissue using graded alcohols (70,90,100,100%) 
1 hour in each. The tissue was then placed in a 50: 50 chloroform: alcohol solution for 
3 hours then replaced by chloroform and left overnight. With the tissue in a glass jar, 
melted paraffin wax was added from a paraffin wax dispenser (Electrothermal). The 
unstoppered glass jar was then placed under vacuum (Hearson) for 5 minutes. The 
paraffin wax was replaced with fresh and the tissue placed under vacuum for a further 
30 minutes. This was repeated again with the tissue left under vacuum for 1 hour. 
This process eliminates the chloroform while the paraffin wax infiltrates the tissue. 
Prolonged treatment in molten paraffin wax causes shrinkage and hardening of the 
tissue, therefore the tissue should be left no longer than is necessary. The tissue was 
then put into a plastic mould containing warm paraffin wax. Using warm forceps the 
tissue was orientated in the bottom of the mould in the correct plane for sectioning. 
For Peyer's patch material the epithelium must lie flat to the bottom of the mould so 
all the FAE strata will be seen in the finished slide. The paraffin wax was allowed 
to set at room temperature for 24 hours. The paraffin wax blocks are removed from 
the moulds and trimmed using a single edge razor blade to remove excess paraffin 
wax around the tissue. A warm knife was used to melt the paraffin wax block onto 
a wooden base. The block is sectioned on a rotary microtome (Spenser '820'). 
The section's thickness was set using a feed mechanism (7 µm). It is important to 
ensure the upper and lower edges of the paraffin wax blocks are parallel to the 
knife 
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edge if ribbon sections are to be cut. Using a camel hair brush to support the leading 
edge of the ribbon section, they were removed from the microtome and placed in a 
paraffin wax section mounting bath (Electrothermal) set at 55-50°C. When the 
sections flatten out they were carefully picked up using glass slides. 
The sections were then flattened by exerting pressure using damp filter paper 
(Whatman No. 1). The slides were then put on a slide dryer (Spenser) set at 60°C for 
1-2 minutes or until the wax melts. They were left overnight on a slide dryer set at 
34°C to remove moisture from the slides. 
Staining of paraffin wax sections 
The sections were stained using haematoxylin and eosin dyes. The haematoxylin 
(Harris formula) stain nuclei blue whilst eosin counterstains cytoplasm red. Before 
staining all the paraffin wax was removed and the section brought down to water. 
With the sections in a metal slide rack, they were placed in xylene for 3 minutes then 
graded alcohols (100,90,70,50%) for 1 minute each. The slides were then washed 
under tap water. The sections were then placed in a solution of Harris haematoxylin 
for 2 minutes and then washed in tap water. This was regressive stain in that 
overstaining of the nuclei can be discolourised to remove excess colour with dilute 
acid alcohol. A solution of 0.5% hydrochloric acid in 70% alcohol was employed for 
this reason for 10-20 seconds. The sections were then washed in tap water and the 
sections viewed under the light microscope for nuclei staining. If adequately stained 
the sections were then placed in a1% solution of eosin for 30 seconds. Excess dye 
stain was removed using 50% alcohol. The sections were then dehydrated in graded 
alcohol (50,70,90,100%) for 1 minute each and a final incubation with xylene for 
3 minutes. The sections were then mounted using DPX mounts and are viewed using 
a light microscope. 
Iron test on TEM sections 
(i) Epoxy resin removal from tissue sections 
Semi-thin sections (1 µm) on glass slides were placed in a coplin jar containing a 
solution of 1: 2: 2 potassium hydroxide/acetone/benzene for 5 minutes. 
The slides were 
then rinsed in a solution of equal parts acetone/benzene for 1 minute and repeated. 
A further rinse in a solution of equal parts picric acid/acetone/benzene for 
? minutes 
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was followed by a solution of equal parts picric acid/acetone for 2 minutes. Further 
incubation with graded alcohols (100,100,95,95,80,80%) for 1 minute each was 
carried out. The tissue sections were bleached for 3-5 minutes in a solution of 
potassium hydroxide/alcohol (80%). A rinse in 80% alcohol was followed by a final 
wash in distilled water. 
(ii) Perls' Prussian Blue reaction for ferric ion (Perls, 1867) 
The ferric ion, which is released from proteins by treatment with dilute hydrochloric 
acid, reacts with dilute potassium ferrocyanide to precipitate insoluble blue compound 
ferric ferrocyanide (Prussian blue). A solution containing 2% potassium ferrocyanide, 
2% hydrochloric acid (prepared fresh before use) was added to the tissue sections for 
10-20 minutes, after which the solution was washed off with water. The tissue 
sections were then observed under the light microscope. 
Preparation of submicron PLG microparticles containing rhodamine 
(a) 300mg of poly(lactide-co-glycolide) polymer was added to 5mls Dichloromethane 
(HPLC grade). 
(b) 5 mgs of rhodamine dye was added to 2ml of distilled water. 
(c) The polymer solution was added dropwise to the rhodamine solution, and the 
mixture stirred at 12,400 rpm with a Silverson homogeniser using a 12mm diameter 
stirrer head for 2 minutes, to give a water-in-oil (w/o) emulsion. 
(d) 20 mis 10% w/v polyvinylalcohol in distilled water (PVA) was added to the 
mixture and stirred at 12,400 rpm for 5 minutes. 
(e) The mixture was stirred overnight using a magnetic stirrer to allow the solvent to 
evaporate. 
(f) The microparticle suspension was centrifuged for 45 minutes at 10,000 r. p. m. 
The 
supernatant was discarded and the microparticle suspension was redispersed 
in 
distilled water (15mis). This step was repeated two times for 20 minutes. 
(f) The microparticles were freeze dried and stored in a desiccator at 25°C. 
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Microscopic counting method to count the number of rhodamine fluorescent 
microparticles in lymph 
A5 ul aliquot of lymph was placed on a glass slide. A coverslip was placed over the 
sample and sealed using nail varnish gloss to prevent drying. Each slide was viewed 
under a fluorescent microscope set for rhodamine fluorescence (excitation maximum 
553nm, emission maximum 619nm). A grid on the microscope stage was used so the 
total area of the slide was viewed and the total numbers of microparticles in the 
sample was counted. The number of microparticles in a microparticle suspension was 
calculated using a Neubauer chamber viewed under the microscope. 
PLGA microparticles embedding for TEM analysis 
(a) Approximately 5 mg of a freeze dried preparation was resuspended in 2 mis of 
distilled water and spun in a bench centrifuge at 10,000 r. p. m. for 30 minutes to form 
a pellet. 
(b) The pellet was fixed in 1 ml of 2.5 % gluteraldehyde in 0.1 M sodium cacodylate 
buffer for 1 hour. 
(c) The pellet was fixed for 1 hour in 1% osmium tetraxide for 1 hour. 
(d) The pellet was washed three times in 0.1 M sodium cocodylate in 6% sucrose for 
45 minutes. 
(e) The pellet was washed three times in distilled water for 45 mins. 
(f) The pellet was placed in 2% uranyl acetate for 30 minutes. 
(g) Dehydration was performed by placing the pellet in graded alcohols (40%, 60%, 
80%, 100%, 100%, 100%) for 20 minutes in each. 
(h) The pellet was left o/n in a 3: 1 ethanol: resin (Epon resin) mixture. 
(g) The pellet was left in a 1: 1 ethanol : resin mixture for 8 hours. 
(h) The pellet was left in resin for 1 day. 
The pellet was resuspended during each step and then pelleted 
by being spun for 2 
minutes at 10,000 r. p. m using a bench centrifuge. 
(g) The pellets were then cast into Epindorfs containing epon resin and placed in a 
60°C oven for 48 hours. 
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PLG microparticle preparation for SEM analysis 
(a) Freeze dried preparations were suspended in distilled water and a drop of the 
solution pipetted onto an aluminium stub and air dried overnight. 
(b) The samples were then coated with gold using a sputter coater (EMSCOPE 500) 
at a coating current of 15mA for 2 minutes. 
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